Javascript doit fonctionner ! Activez-le et rechargez cette page.
Le Rézo de JeuxDeMots
• Types de relations
• Types de noeuds
• Consolider
le terme
  Options  
             

  Filtrage type relations : +   - (ex: 4, 12, 18, 36, 444, 555, 777)
  Filtrage valeur :          min   max
  Filtrage type noeuds :   +   - (ex: 4, 6, 8, 9, 10, 12, 18, 36, 444, 555, 777)

  Présentation de sortie :   (ex: -rien-, cloud, nicecloud)
 

'LANL'
(id=401293834 ; fe=LANL ; type=1 ; niveau=200 ; luminosité=14 ; somme entrante=80 creation date=2025-04-19 touchdate=2025-11-29 01:30:10.000)
≈ 1084 relations sortantes

  1. LANL -- r_associated #0: 11 / 1 -> médecine
    n1=LANL | n2=médecine | rel=r_associated | relid=0 | w=11
  2. LANL -- r_associated #0: 10 / 0.909 -> aiguë
    n1=LANL | n2=aiguë | rel=r_associated | relid=0 | w=10
  3. LANL -- r_associated #0: 10 / 0.909 -> bois
    n1=LANL | n2=bois | rel=r_associated | relid=0 | w=10
  4. LANL -- r_associated #0: 10 / 0.909 -> classification FAB
    n1=LANL | n2=classification FAB | rel=r_associated | relid=0 | w=10
  5. LANL -- r_associated #0: 10 / 0.909 -> corps d'Auer
    n1=LANL | n2=corps d'Auer | rel=r_associated | relid=0 | w=10
  6. LANL -- r_associated #0: 10 / 0.909 -> en:abdominal tumors (immunodeficiency-associated form)
    n1=LANL | n2=en:abdominal tumors (immunodeficiency-associated form) | rel=r_associated | relid=0 | w=10
  7. LANL -- r_associated #0: 10 / 0.909 -> en:abi1 gene
    n1=LANL | n2=en:abi1 gene | rel=r_associated | relid=0 | w=10
  8. LANL -- r_associated #0: 10 / 0.909 -> en:abi1 wt allele
    n1=LANL | n2=en:abi1 wt allele | rel=r_associated | relid=0 | w=10
  9. LANL -- r_associated #0: 10 / 0.909 -> en:abl2 gene
    n1=LANL | n2=en:abl2 gene | rel=r_associated | relid=0 | w=10
  10. LANL -- r_associated #0: 10 / 0.909 -> en:abl2 wt allele
    n1=LANL | n2=en:abl2 wt allele | rel=r_associated | relid=0 | w=10
  11. LANL -- r_associated #0: 10 / 0.909 -> en:accelerated neoplasm growth
    n1=LANL | n2=en:accelerated neoplasm growth | rel=r_associated | relid=0 | w=10
  12. LANL -- r_associated #0: 10 / 0.909 -> en:acinar cell neoplasm
    n1=LANL | n2=en:acinar cell neoplasm | rel=r_associated | relid=0 | w=10
  13. LANL -- r_associated #0: 10 / 0.909 -> en:acoustic schwannoma
    n1=LANL | n2=en:acoustic schwannoma | rel=r_associated | relid=0 | w=10
  14. LANL -- r_associated #0: 10 / 0.909 -> en:acute
    n1=LANL | n2=en:acute | rel=r_associated | relid=0 | w=10
  15. LANL -- r_associated #0: 10 / 0.909 -> en:acute basophilic leukemia
    n1=LANL | n2=en:acute basophilic leukemia | rel=r_associated | relid=0 | w=10
  16. LANL -- r_associated #0: 10 / 0.909 -> en:acute biphenotypic leukemia
    n1=LANL | n2=en:acute biphenotypic leukemia | rel=r_associated | relid=0 | w=10
  17. LANL -- r_associated #0: 10 / 0.909 -> en:acute disease
    n1=LANL | n2=en:acute disease | rel=r_associated | relid=0 | w=10
  18. LANL -- r_associated #0: 10 / 0.909 -> en:acute eosinophilic leukemia
    n1=LANL | n2=en:acute eosinophilic leukemia | rel=r_associated | relid=0 | w=10
  19. LANL -- r_associated #0: 10 / 0.909 -> en:acute erythroid leukemia
    n1=LANL | n2=en:acute erythroid leukemia | rel=r_associated | relid=0 | w=10
  20. LANL -- r_associated #0: 10 / 0.909 -> en:acute erythroleukemia (fab type m6)
    n1=LANL | n2=en:acute erythroleukemia (fab type m6) | rel=r_associated | relid=0 | w=10
  21. LANL -- r_associated #0: 10 / 0.909 -> en:acute leukaemia unclassifiable
    n1=LANL | n2=en:acute leukaemia unclassifiable | rel=r_associated | relid=0 | w=10
  22. LANL -- r_associated #0: 10 / 0.909 -> en:acute leukemia
    n1=LANL | n2=en:acute leukemia | rel=r_associated | relid=0 | w=10
  23. LANL -- r_associated #0: 10 / 0.909 -> en:acute leukemia in remission
    n1=LANL | n2=en:acute leukemia in remission | rel=r_associated | relid=0 | w=10
  24. LANL -- r_associated #0: 10 / 0.909 -> en:acute leukemia of ambiguous lineage
    n1=LANL | n2=en:acute leukemia of ambiguous lineage | rel=r_associated | relid=0 | w=10
  25. LANL -- r_associated #0: 10 / 0.909 -> en:acute leukemia of unspecified cell type not having achieved remission
    n1=LANL | n2=en:acute leukemia of unspecified cell type not having achieved remission | rel=r_associated | relid=0 | w=10
  26. LANL -- r_associated #0: 10 / 0.909 -> en:acute leukemia of unspecified cell type without mention of remission
    n1=LANL | n2=en:acute leukemia of unspecified cell type without mention of remission | rel=r_associated | relid=0 | w=10
  27. LANL -- r_associated #0: 10 / 0.909 -> en:acute leukemia of unspecified cell type, in relapse
    n1=LANL | n2=en:acute leukemia of unspecified cell type, in relapse | rel=r_associated | relid=0 | w=10
  28. LANL -- r_associated #0: 10 / 0.909 -> en:acute leukemia of unspecified cell type, without mention of having achieved remission
    n1=LANL | n2=en:acute leukemia of unspecified cell type, without mention of having achieved remission | rel=r_associated | relid=0 | w=10
  29. LANL -- r_associated #0: 10 / 0.909 -> en:acute lymphoblastic leukemia
    n1=LANL | n2=en:acute lymphoblastic leukemia | rel=r_associated | relid=0 | w=10
  30. LANL -- r_associated #0: 10 / 0.909 -> en:acute lymphoblastic leukemia - category
    n1=LANL | n2=en:acute lymphoblastic leukemia - category | rel=r_associated | relid=0 | w=10
  31. LANL -- r_associated #0: 10 / 0.909 -> en:acute lymphoblastic leukemia (in 1 patient)
    n1=LANL | n2=en:acute lymphoblastic leukemia (in 1 patient) | rel=r_associated | relid=0 | w=10
  32. LANL -- r_associated #0: 10 / 0.909 -> en:acute megakaryoblastic leukemia
    n1=LANL | n2=en:acute megakaryoblastic leukemia | rel=r_associated | relid=0 | w=10
  33. LANL -- r_associated #0: 10 / 0.909 -> en:acute monoblastic leukemia
    n1=LANL | n2=en:acute monoblastic leukemia | rel=r_associated | relid=0 | w=10
  34. LANL -- r_associated #0: 10 / 0.909 -> en:acute monoblastic leukemia (fab type m5)
    n1=LANL | n2=en:acute monoblastic leukemia (fab type m5) | rel=r_associated | relid=0 | w=10
  35. LANL -- r_associated #0: 10 / 0.909 -> en:acute monoblastic leukemia without differentiation (fab type m5a)
    n1=LANL | n2=en:acute monoblastic leukemia without differentiation (fab type m5a) | rel=r_associated | relid=0 | w=10
  36. LANL -- r_associated #0: 10 / 0.909 -> en:acute monocytic leukemia
    n1=LANL | n2=en:acute monocytic leukemia | rel=r_associated | relid=0 | w=10
  37. LANL -- r_associated #0: 10 / 0.909 -> en:acute monocytic leukemia in remission
    n1=LANL | n2=en:acute monocytic leukemia in remission | rel=r_associated | relid=0 | w=10
  38. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloblastic leukaemia
    n1=LANL | n2=en:acute myeloblastic leukaemia | rel=r_associated | relid=0 | w=10
  39. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloblastic leukemia
    n1=LANL | n2=en:acute myeloblastic leukemia | rel=r_associated | relid=0 | w=10
  40. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloblastic leukemia (without a fab classification) nos
    n1=LANL | n2=en:acute myeloblastic leukemia (without a fab classification) nos | rel=r_associated | relid=0 | w=10
  41. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloblastic leukemia 1/eto
    n1=LANL | n2=en:acute myeloblastic leukemia 1/eto | rel=r_associated | relid=0 | w=10
  42. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloblastic leukemia with t(8;21)
    n1=LANL | n2=en:acute myeloblastic leukemia with t(8;21) | rel=r_associated | relid=0 | w=10
  43. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloblastic leukemia, in relapse
    n1=LANL | n2=en:acute myeloblastic leukemia, in relapse | rel=r_associated | relid=0 | w=10
  44. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloblastic leukemia, not having achieved remission
    n1=LANL | n2=en:acute myeloblastic leukemia, not having achieved remission | rel=r_associated | relid=0 | w=10
  45. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloid leukaemia progression
    n1=LANL | n2=en:acute myeloid leukaemia progression | rel=r_associated | relid=0 | w=10
  46. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloid leukaemia recurrent
    n1=LANL | n2=en:acute myeloid leukaemia recurrent | rel=r_associated | relid=0 | w=10
  47. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloid leukemia
    n1=LANL | n2=en:acute myeloid leukemia | rel=r_associated | relid=0 | w=10
  48. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloid leukemia (aml-m2)
    n1=LANL | n2=en:acute myeloid leukemia (aml-m2) | rel=r_associated | relid=0 | w=10
  49. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13); rbm15-mkl1
    n1=LANL | n2=en:acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13); rbm15-mkl1 | rel=r_associated | relid=0 | w=10
  50. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloid leukemia and related precursor neoplams
    n1=LANL | n2=en:acute myeloid leukemia and related precursor neoplams | rel=r_associated | relid=0 | w=10
  51. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloid leukemia in remission
    n1=LANL | n2=en:acute myeloid leukemia in remission | rel=r_associated | relid=0 | w=10
  52. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloid leukemia not otherwise specified
    n1=LANL | n2=en:acute myeloid leukemia not otherwise specified | rel=r_associated | relid=0 | w=10
  53. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloid leukemia pathway
    n1=LANL | n2=en:acute myeloid leukemia pathway | rel=r_associated | relid=0 | w=10
  54. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); cbfb-myh11
    n1=LANL | n2=en:acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); cbfb-myh11 | rel=r_associated | relid=0 | w=10
  55. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloid leukemia with inv(3)(q21;q26.2) or t(13.3)(q21;q26.2); rpn1-evi1
    n1=LANL | n2=en:acute myeloid leukemia with inv(3)(q21;q26.2) or t(13.3)(q21;q26.2); rpn1-evi1 | rel=r_associated | relid=0 | w=10
  56. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloid leukemia with maturation
    n1=LANL | n2=en:acute myeloid leukemia with maturation | rel=r_associated | relid=0 | w=10
  57. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloid leukemia with minimal differentiation
    n1=LANL | n2=en:acute myeloid leukemia with minimal differentiation | rel=r_associated | relid=0 | w=10
  58. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloid leukemia with multilineage dysplasia
    n1=LANL | n2=en:acute myeloid leukemia with multilineage dysplasia | rel=r_associated | relid=0 | w=10
  59. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloid leukemia with mutated cebpa
    n1=LANL | n2=en:acute myeloid leukemia with mutated cebpa | rel=r_associated | relid=0 | w=10
  60. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloid leukemia with mutated npm1
    n1=LANL | n2=en:acute myeloid leukemia with mutated npm1 | rel=r_associated | relid=0 | w=10
  61. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloid leukemia with myelodysplasia-related changes
    n1=LANL | n2=en:acute myeloid leukemia with myelodysplasia-related changes | rel=r_associated | relid=0 | w=10
  62. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloid leukemia with t(6;9)(p23;q34); dek-nup214
    n1=LANL | n2=en:acute myeloid leukemia with t(6;9)(p23;q34); dek-nup214 | rel=r_associated | relid=0 | w=10
  63. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloid leukemia with t(8;21)(q22;q22); runx1-runx1t1
    n1=LANL | n2=en:acute myeloid leukemia with t(8;21)(q22;q22); runx1-runx1t1 | rel=r_associated | relid=0 | w=10
  64. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloid leukemia with t(9;11)(p22;q23); mllt3-mll
    n1=LANL | n2=en:acute myeloid leukemia with t(9;11)(p22;q23); mllt3-mll | rel=r_associated | relid=0 | w=10
  65. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloid leukemia without maturation
    n1=LANL | n2=en:acute myeloid leukemia without maturation | rel=r_associated | relid=0 | w=10
  66. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloid leukemia without mention of remission
    n1=LANL | n2=en:acute myeloid leukemia without mention of remission | rel=r_associated | relid=0 | w=10
  67. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloid leukemia, in relapse
    n1=LANL | n2=en:acute myeloid leukemia, in relapse | rel=r_associated | relid=0 | w=10
  68. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloid leukemia, special type
    n1=LANL | n2=en:acute myeloid leukemia, special type | rel=r_associated | relid=0 | w=10
  69. LANL -- r_associated #0: 10 / 0.909 -> en:acute myeloid leukemia, without mention of having achieved remission
    n1=LANL | n2=en:acute myeloid leukemia, without mention of having achieved remission | rel=r_associated | relid=0 | w=10
  70. LANL -- r_associated #0: 10 / 0.909 -> en:acute myelomonocytic leukemia
    n1=LANL | n2=en:acute myelomonocytic leukemia | rel=r_associated | relid=0 | w=10
  71. LANL -- r_associated #0: 10 / 0.909 -> en:acute panmyelosis with myelofibrosis
    n1=LANL | n2=en:acute panmyelosis with myelofibrosis | rel=r_associated | relid=0 | w=10
  72. LANL -- r_associated #0: 10 / 0.909 -> en:acute promyelocytic leukemia with t(15;17)(q22;q12); pml-rara
    n1=LANL | n2=en:acute promyelocytic leukemia with t(15;17)(q22;q12); pml-rara | rel=r_associated | relid=0 | w=10
  73. LANL -- r_associated #0: 10 / 0.909 -> en:acute promyelocytic leukemia, t(15;17)(q22;q11-12)
    n1=LANL | n2=en:acute promyelocytic leukemia, t(15;17)(q22;q11-12) | rel=r_associated | relid=0 | w=10
  74. LANL -- r_associated #0: 10 / 0.909 -> en:acute undifferentiated leukemia
    n1=LANL | n2=en:acute undifferentiated leukemia | rel=r_associated | relid=0 | w=10
  75. LANL -- r_associated #0: 10 / 0.909 -> en:adenocarcinoma
    n1=LANL | n2=en:adenocarcinoma | rel=r_associated | relid=0 | w=10
  76. LANL -- r_associated #0: 10 / 0.909 -> en:adenocarcinoma (some)
    n1=LANL | n2=en:adenocarcinoma (some) | rel=r_associated | relid=0 | w=10
  77. LANL -- r_associated #0: 10 / 0.909 -> en:adenoid cystic carcinoma
    n1=LANL | n2=en:adenoid cystic carcinoma | rel=r_associated | relid=0 | w=10
  78. LANL -- r_associated #0: 10 / 0.909 -> en:adenoma and/or adenocarcinoma
    n1=LANL | n2=en:adenoma and/or adenocarcinoma | rel=r_associated | relid=0 | w=10
  79. LANL -- r_associated #0: 10 / 0.909 -> en:adipocytic tumors (all subtypes)
    n1=LANL | n2=en:adipocytic tumors (all subtypes) | rel=r_associated | relid=0 | w=10
  80. LANL -- r_associated #0: 10 / 0.909 -> en:adnexal and/or skin appendage neoplasm
    n1=LANL | n2=en:adnexal and/or skin appendage neoplasm | rel=r_associated | relid=0 | w=10
  81. LANL -- r_associated #0: 10 / 0.909 -> en:adrenal cortex carcinoma
    n1=LANL | n2=en:adrenal cortex carcinoma | rel=r_associated | relid=0 | w=10
  82. LANL -- r_associated #0: 10 / 0.909 -> en:adrenal gland pheochromocytoma
    n1=LANL | n2=en:adrenal gland pheochromocytoma | rel=r_associated | relid=0 | w=10
  83. LANL -- r_associated #0: 10 / 0.909 -> en:adrenal glands are most common site
    n1=LANL | n2=en:adrenal glands are most common site | rel=r_associated | relid=0 | w=10
  84. LANL -- r_associated #0: 10 / 0.909 -> en:adult acute myeloid leukemia
    n1=LANL | n2=en:adult acute myeloid leukemia | rel=r_associated | relid=0 | w=10
  85. LANL -- r_associated #0: 10 / 0.909 -> en:advanced malignant neoplasm
    n1=LANL | n2=en:advanced malignant neoplasm | rel=r_associated | relid=0 | w=10
  86. LANL -- r_associated #0: 10 / 0.909 -> en:aggravated acute myeloid leukemia
    n1=LANL | n2=en:aggravated acute myeloid leukemia | rel=r_associated | relid=0 | w=10
  87. LANL -- r_associated #0: 10 / 0.909 -> en:aggravated malignant neoplasm
    n1=LANL | n2=en:aggravated malignant neoplasm | rel=r_associated | relid=0 | w=10
  88. LANL -- r_associated #0: 10 / 0.909 -> en:aids related neoplasm/cancer
    n1=LANL | n2=en:aids related neoplasm/cancer | rel=r_associated | relid=0 | w=10
  89. LANL -- r_associated #0: 10 / 0.909 -> en:aids-related malignant neoplasm
    n1=LANL | n2=en:aids-related malignant neoplasm | rel=r_associated | relid=0 | w=10
  90. LANL -- r_associated #0: 10 / 0.909 -> en:air sac
    n1=LANL | n2=en:air sac | rel=r_associated | relid=0 | w=10
  91. LANL -- r_associated #0: 10 / 0.909 -> en:aleukemic leukemia
    n1=LANL | n2=en:aleukemic leukemia | rel=r_associated | relid=0 | w=10
  92. LANL -- r_associated #0: 10 / 0.909 -> en:aleukemic myeloid leukemia
    n1=LANL | n2=en:aleukemic myeloid leukemia | rel=r_associated | relid=0 | w=10
  93. LANL -- r_associated #0: 10 / 0.909 -> en:alveolar cell carcinoma (some)
    n1=LANL | n2=en:alveolar cell carcinoma (some) | rel=r_associated | relid=0 | w=10
  94. LANL -- r_associated #0: 10 / 0.909 -> en:aml progression
    n1=LANL | n2=en:aml progression | rel=r_associated | relid=0 | w=10
  95. LANL -- r_associated #0: 10 / 0.909 -> en:amlcr2 gene
    n1=LANL | n2=en:amlcr2 gene | rel=r_associated | relid=0 | w=10
  96. LANL -- r_associated #0: 10 / 0.909 -> en:ampulla of vater adenocarcinoma
    n1=LANL | n2=en:ampulla of vater adenocarcinoma | rel=r_associated | relid=0 | w=10
  97. LANL -- r_associated #0: 10 / 0.909 -> en:anal carcinoma
    n1=LANL | n2=en:anal carcinoma | rel=r_associated | relid=0 | w=10
  98. LANL -- r_associated #0: 10 / 0.909 -> en:anaplastic malignant neoplasm
    n1=LANL | n2=en:anaplastic malignant neoplasm | rel=r_associated | relid=0 | w=10
  99. LANL -- r_associated #0: 10 / 0.909 -> en:anatomic structures
    n1=LANL | n2=en:anatomic structures | rel=r_associated | relid=0 | w=10
  100. LANL -- r_associated #0: 10 / 0.909 -> en:anemia
    n1=LANL | n2=en:anemia | rel=r_associated | relid=0 | w=10
  101. LANL -- r_associated #0: 10 / 0.909 -> en:aneurysm
    n1=LANL | n2=en:aneurysm | rel=r_associated | relid=0 | w=10
  102. LANL -- r_associated #0: 10 / 0.909 -> en:angina
    n1=LANL | n2=en:angina | rel=r_associated | relid=0 | w=10
  103. LANL -- r_associated #0: 10 / 0.909 -> en:angiolipoma
    n1=LANL | n2=en:angiolipoma | rel=r_associated | relid=0 | w=10
  104. LANL -- r_associated #0: 10 / 0.909 -> en:angioplasty
    n1=LANL | n2=en:angioplasty | rel=r_associated | relid=0 | w=10
  105. LANL -- r_associated #0: 10 / 0.909 -> en:annexin a8
    n1=LANL | n2=en:annexin a8 | rel=r_associated | relid=0 | w=10
  106. LANL -- r_associated #0: 10 / 0.909 -> en:anticoagulant agent
    n1=LANL | n2=en:anticoagulant agent | rel=r_associated | relid=0 | w=10
  107. LANL -- r_associated #0: 10 / 0.909 -> en:antihypertensive agent
    n1=LANL | n2=en:antihypertensive agent | rel=r_associated | relid=0 | w=10
  108. LANL -- r_associated #0: 10 / 0.909 -> en:aortic aneurysm
    n1=LANL | n2=en:aortic aneurysm | rel=r_associated | relid=0 | w=10
  109. LANL -- r_associated #0: 10 / 0.909 -> en:aplastic anemia
    n1=LANL | n2=en:aplastic anemia | rel=r_associated | relid=0 | w=10
  110. LANL -- r_associated #0: 10 / 0.909 -> en:approximately 10% of cases are paraneoplastic
    n1=LANL | n2=en:approximately 10% of cases are paraneoplastic | rel=r_associated | relid=0 | w=10
  111. LANL -- r_associated #0: 10 / 0.909 -> en:arnt gene
    n1=LANL | n2=en:arnt gene | rel=r_associated | relid=0 | w=10
  112. LANL -- r_associated #0: 10 / 0.909 -> en:arnt wt allele
    n1=LANL | n2=en:arnt wt allele | rel=r_associated | relid=0 | w=10
  113. LANL -- r_associated #0: 10 / 0.909 -> en:arrhythmia
    n1=LANL | n2=en:arrhythmia | rel=r_associated | relid=0 | w=10
  114. LANL -- r_associated #0: 10 / 0.909 -> en:arteriovenous hemangioma
    n1=LANL | n2=en:arteriovenous hemangioma | rel=r_associated | relid=0 | w=10
  115. LANL -- r_associated #0: 10 / 0.909 -> en:aspects of mortality statistics
    n1=LANL | n2=en:aspects of mortality statistics | rel=r_associated | relid=0 | w=10
  116. LANL -- r_associated #0: 10 / 0.909 -> en:aspects of radionuclide imaging
    n1=LANL | n2=en:aspects of radionuclide imaging | rel=r_associated | relid=0 | w=10
  117. LANL -- r_associated #0: 10 / 0.909 -> en:associated with other malignancies
    n1=LANL | n2=en:associated with other malignancies | rel=r_associated | relid=0 | w=10
  118. LANL -- r_associated #0: 10 / 0.909 -> en:astrocytoma
    n1=LANL | n2=en:astrocytoma | rel=r_associated | relid=0 | w=10
  119. LANL -- r_associated #0: 10 / 0.909 -> en:atherosclerosis
    n1=LANL | n2=en:atherosclerosis | rel=r_associated | relid=0 | w=10
  120. LANL -- r_associated #0: 10 / 0.909 -> en:atrial fibrillation
    n1=LANL | n2=en:atrial fibrillation | rel=r_associated | relid=0 | w=10
  121. LANL -- r_associated #0: 10 / 0.909 -> en:atypical chronic myeloid leukemia, bcr-abl1 negative
    n1=LANL | n2=en:atypical chronic myeloid leukemia, bcr-abl1 negative | rel=r_associated | relid=0 | w=10
  122. LANL -- r_associated #0: 10 / 0.909 -> en:b-cell lymphomas
    n1=LANL | n2=en:b-cell lymphomas | rel=r_associated | relid=0 | w=10
  123. LANL -- r_associated #0: 10 / 0.909 -> en:b-cell non-hodgkin lymphoma
    n1=LANL | n2=en:b-cell non-hodgkin lymphoma | rel=r_associated | relid=0 | w=10
  124. LANL -- r_associated #0: 10 / 0.909 -> en:basal cell neoplasm
    n1=LANL | n2=en:basal cell neoplasm | rel=r_associated | relid=0 | w=10
  125. LANL -- r_associated #0: 10 / 0.909 -> en:basal cell nevus
    n1=LANL | n2=en:basal cell nevus | rel=r_associated | relid=0 | w=10
  126. LANL -- r_associated #0: 10 / 0.909 -> en:basocellular neoplasms
    n1=LANL | n2=en:basocellular neoplasms | rel=r_associated | relid=0 | w=10
  127. LANL -- r_associated #0: 10 / 0.909 -> en:basocellular neoplasms develop after second decade
    n1=LANL | n2=en:basocellular neoplasms develop after second decade | rel=r_associated | relid=0 | w=10
  128. LANL -- r_associated #0: 10 / 0.909 -> en:behcet syndrome
    n1=LANL | n2=en:behcet syndrome | rel=r_associated | relid=0 | w=10
  129. LANL -- r_associated #0: 10 / 0.909 -> en:bence jones proteins increased
    n1=LANL | n2=en:bence jones proteins increased | rel=r_associated | relid=0 | w=10
  130. LANL -- r_associated #0: 10 / 0.909 -> en:benign digestive system neoplasm
    n1=LANL | n2=en:benign digestive system neoplasm | rel=r_associated | relid=0 | w=10
  131. LANL -- r_associated #0: 10 / 0.909 -> en:benign endocrine neoplasm
    n1=LANL | n2=en:benign endocrine neoplasm | rel=r_associated | relid=0 | w=10
  132. LANL -- r_associated #0: 10 / 0.909 -> en:benign epithelial neoplasm
    n1=LANL | n2=en:benign epithelial neoplasm | rel=r_associated | relid=0 | w=10
  133. LANL -- r_associated #0: 10 / 0.909 -> en:benign female reproductive system neoplasm
    n1=LANL | n2=en:benign female reproductive system neoplasm | rel=r_associated | relid=0 | w=10
  134. LANL -- r_associated #0: 10 / 0.909 -> en:benign genitourinary tract neoplasm
    n1=LANL | n2=en:benign genitourinary tract neoplasm | rel=r_associated | relid=0 | w=10
  135. LANL -- r_associated #0: 10 / 0.909 -> en:benign male reproductive system neoplasm
    n1=LANL | n2=en:benign male reproductive system neoplasm | rel=r_associated | relid=0 | w=10
  136. LANL -- r_associated #0: 10 / 0.909 -> en:benign neoplasm
    n1=LANL | n2=en:benign neoplasm | rel=r_associated | relid=0 | w=10
  137. LANL -- r_associated #0: 10 / 0.909 -> en:benign nervous system neoplasm
    n1=LANL | n2=en:benign nervous system neoplasm | rel=r_associated | relid=0 | w=10
  138. LANL -- r_associated #0: 10 / 0.909 -> en:benign skin neoplasm
    n1=LANL | n2=en:benign skin neoplasm | rel=r_associated | relid=0 | w=10
  139. LANL -- r_associated #0: 10 / 0.909 -> en:benign soft tissue neoplasm
    n1=LANL | n2=en:benign soft tissue neoplasm | rel=r_associated | relid=0 | w=10
  140. LANL -- r_associated #0: 10 / 0.909 -> en:benign teratoma
    n1=LANL | n2=en:benign teratoma | rel=r_associated | relid=0 | w=10
  141. LANL -- r_associated #0: 10 / 0.909 -> en:benign tumors of the eye, heart, and lungs
    n1=LANL | n2=en:benign tumors of the eye, heart, and lungs | rel=r_associated | relid=0 | w=10
  142. LANL -- r_associated #0: 10 / 0.909 -> en:bilateral malignant neoplasm
    n1=LANL | n2=en:bilateral malignant neoplasm | rel=r_associated | relid=0 | w=10
  143. LANL -- r_associated #0: 10 / 0.909 -> en:bile duct carcinoma
    n1=LANL | n2=en:bile duct carcinoma | rel=r_associated | relid=0 | w=10
  144. LANL -- r_associated #0: 10 / 0.909 -> en:biliary tract neoplasm
    n1=LANL | n2=en:biliary tract neoplasm | rel=r_associated | relid=0 | w=10
  145. LANL -- r_associated #0: 10 / 0.909 -> en:biological polymorphism
    n1=LANL | n2=en:biological polymorphism | rel=r_associated | relid=0 | w=10
  146. LANL -- r_associated #0: 10 / 0.909 -> en:biopsy
    n1=LANL | n2=en:biopsy | rel=r_associated | relid=0 | w=10
  147. LANL -- r_associated #0: 10 / 0.909 -> en:bladder carcinoma
    n1=LANL | n2=en:bladder carcinoma | rel=r_associated | relid=0 | w=10
  148. LANL -- r_associated #0: 10 / 0.909 -> en:bladder neoplasm
    n1=LANL | n2=en:bladder neoplasm | rel=r_associated | relid=0 | w=10
  149. LANL -- r_associated #0: 10 / 0.909 -> en:bladder urothelial carcinoma
    n1=LANL | n2=en:bladder urothelial carcinoma | rel=r_associated | relid=0 | w=10
  150. LANL -- r_associated #0: 10 / 0.909 -> en:blastic plasmacytoid dendritic cell neoplasm
    n1=LANL | n2=en:blastic plasmacytoid dendritic cell neoplasm | rel=r_associated | relid=0 | w=10
  151. LANL -- r_associated #0: 10 / 0.909 -> en:bleeding diathesis
    n1=LANL | n2=en:bleeding diathesis | rel=r_associated | relid=0 | w=10
  152. LANL -- r_associated #0: 10 / 0.909 -> en:blood
    n1=LANL | n2=en:blood | rel=r_associated | relid=0 | w=10
  153. LANL -- r_associated #0: 10 / 0.909 -> en:blood clot
    n1=LANL | n2=en:blood clot | rel=r_associated | relid=0 | w=10
  154. LANL -- r_associated #0: 10 / 0.909 -> en:blood or lymphatic cancer
    n1=LANL | n2=en:blood or lymphatic cancer | rel=r_associated | relid=0 | w=10
  155. LANL -- r_associated #0: 10 / 0.909 -> en:blood platelet disorders
    n1=LANL | n2=en:blood platelet disorders | rel=r_associated | relid=0 | w=10
  156. LANL -- r_associated #0: 10 / 0.909 -> en:blood transfusion and donation
    n1=LANL | n2=en:blood transfusion and donation | rel=r_associated | relid=0 | w=10
  157. LANL -- r_associated #0: 10 / 0.909 -> en:blood vessel neoplasm
    n1=LANL | n2=en:blood vessel neoplasm | rel=r_associated | relid=0 | w=10
  158. LANL -- r_associated #0: 10 / 0.909 -> en:blood, heart and circulation
    n1=LANL | n2=en:blood, heart and circulation | rel=r_associated | relid=0 | w=10
  159. LANL -- r_associated #0: 10 / 0.909 -> en:body constitution
    n1=LANL | n2=en:body constitution | rel=r_associated | relid=0 | w=10
  160. LANL -- r_associated #0: 10 / 0.909 -> en:body system/site cancer
    n1=LANL | n2=en:body system/site cancer | rel=r_associated | relid=0 | w=10
  161. LANL -- r_associated #0: 10 / 0.909 -> en:bone marrow
    n1=LANL | n2=en:bone marrow | rel=r_associated | relid=0 | w=10
  162. LANL -- r_associated #0: 10 / 0.909 -> en:bone marrow stem cell
    n1=LANL | n2=en:bone marrow stem cell | rel=r_associated | relid=0 | w=10
  163. LANL -- r_associated #0: 10 / 0.909 -> en:bone neoplasm
    n1=LANL | n2=en:bone neoplasm | rel=r_associated | relid=0 | w=10
  164. LANL -- r_associated #0: 10 / 0.909 -> en:bone sarcoma
    n1=LANL | n2=en:bone sarcoma | rel=r_associated | relid=0 | w=10
  165. LANL -- r_associated #0: 10 / 0.909 -> en:bone-forming neoplasm
    n1=LANL | n2=en:bone-forming neoplasm | rel=r_associated | relid=0 | w=10
  166. LANL -- r_associated #0: 10 / 0.909 -> en:brain aneurysm
    n1=LANL | n2=en:brain aneurysm | rel=r_associated | relid=0 | w=10
  167. LANL -- r_associated #0: 10 / 0.909 -> en:brain morphology
    n1=LANL | n2=en:brain morphology | rel=r_associated | relid=0 | w=10
  168. LANL -- r_associated #0: 10 / 0.909 -> en:brain neoplasm
    n1=LANL | n2=en:brain neoplasm | rel=r_associated | relid=0 | w=10
  169. LANL -- r_associated #0: 10 / 0.909 -> en:breast cancer (rare)
    n1=LANL | n2=en:breast cancer (rare) | rel=r_associated | relid=0 | w=10
  170. LANL -- r_associated #0: 10 / 0.909 -> en:breast cancer, early-onset (in some patients)
    n1=LANL | n2=en:breast cancer, early-onset (in some patients) | rel=r_associated | relid=0 | w=10
  171. LANL -- r_associated #0: 10 / 0.909 -> en:breast cancer, lobular
    n1=LANL | n2=en:breast cancer, lobular | rel=r_associated | relid=0 | w=10
  172. LANL -- r_associated #0: 10 / 0.909 -> en:breast carcinoma
    n1=LANL | n2=en:breast carcinoma | rel=r_associated | relid=0 | w=10
  173. LANL -- r_associated #0: 10 / 0.909 -> en:breast neoplasm
    n1=LANL | n2=en:breast neoplasm | rel=r_associated | relid=0 | w=10
  174. LANL -- r_associated #0: 10 / 0.909 -> en:breast neoplasms benign (incl nipple)
    n1=LANL | n2=en:breast neoplasms benign (incl nipple) | rel=r_associated | relid=0 | w=10
  175. LANL -- r_associated #0: 10 / 0.909 -> en:breast neoplasms malignant and unspecified (incl nipple)
    n1=LANL | n2=en:breast neoplasms malignant and unspecified (incl nipple) | rel=r_associated | relid=0 | w=10
  176. LANL -- r_associated #0: 10 / 0.909 -> en:bronchogenic carcinoma (some)
    n1=LANL | n2=en:bronchogenic carcinoma (some) | rel=r_associated | relid=0 | w=10
  177. LANL -- r_associated #0: 10 / 0.909 -> en:burkitt leukemia
    n1=LANL | n2=en:burkitt leukemia | rel=r_associated | relid=0 | w=10
  178. LANL -- r_associated #0: 10 / 0.909 -> en:burkitt lymphoma (b-cell lymphoma)
    n1=LANL | n2=en:burkitt lymphoma (b-cell lymphoma) | rel=r_associated | relid=0 | w=10
  179. LANL -- r_associated #0: 10 / 0.909 -> en:cancer alternative therapies
    n1=LANL | n2=en:cancer alternative therapies | rel=r_associated | relid=0 | w=10
  180. LANL -- r_associated #0: 10 / 0.909 -> en:cancer of nose
    n1=LANL | n2=en:cancer of nose | rel=r_associated | relid=0 | w=10
  181. LANL -- r_associated #0: 10 / 0.909 -> en:cancer--living with cancer
    n1=LANL | n2=en:cancer--living with cancer | rel=r_associated | relid=0 | w=10
  182. LANL -- r_associated #0: 10 / 0.909 -> en:cancer-related condition
    n1=LANL | n2=en:cancer-related condition | rel=r_associated | relid=0 | w=10
  183. LANL -- r_associated #0: 10 / 0.909 -> en:carcinogenesis
    n1=LANL | n2=en:carcinogenesis | rel=r_associated | relid=0 | w=10
  184. LANL -- r_associated #0: 10 / 0.909 -> en:carcinoid tumor
    n1=LANL | n2=en:carcinoid tumor | rel=r_associated | relid=0 | w=10
  185. LANL -- r_associated #0: 10 / 0.909 -> en:carcinoma
    n1=LANL | n2=en:carcinoma | rel=r_associated | relid=0 | w=10
  186. LANL -- r_associated #0: 10 / 0.909 -> en:carcinoma in situ
    n1=LANL | n2=en:carcinoma in situ | rel=r_associated | relid=0 | w=10
  187. LANL -- r_associated #0: 10 / 0.909 -> en:carcinosarcoma of skin
    n1=LANL | n2=en:carcinosarcoma of skin | rel=r_associated | relid=0 | w=10
  188. LANL -- r_associated #0: 10 / 0.909 -> en:cardiac arrest
    n1=LANL | n2=en:cardiac arrest | rel=r_associated | relid=0 | w=10
  189. LANL -- r_associated #0: 10 / 0.909 -> en:cardiac rehabilitation
    n1=LANL | n2=en:cardiac rehabilitation | rel=r_associated | relid=0 | w=10
  190. LANL -- r_associated #0: 10 / 0.909 -> en:cardiac resuscitation
    n1=LANL | n2=en:cardiac resuscitation | rel=r_associated | relid=0 | w=10
  191. LANL -- r_associated #0: 10 / 0.909 -> en:cardiac surgery procedures
    n1=LANL | n2=en:cardiac surgery procedures | rel=r_associated | relid=0 | w=10
  192. LANL -- r_associated #0: 10 / 0.909 -> en:cardiomyopathy
    n1=LANL | n2=en:cardiomyopathy | rel=r_associated | relid=0 | w=10
  193. LANL -- r_associated #0: 10 / 0.909 -> en:cardiovascular neoplasm
    n1=LANL | n2=en:cardiovascular neoplasm | rel=r_associated | relid=0 | w=10
  194. LANL -- r_associated #0: 10 / 0.909 -> en:carotid artery disorder
    n1=LANL | n2=en:carotid artery disorder | rel=r_associated | relid=0 | w=10
  195. LANL -- r_associated #0: 10 / 0.909 -> en:carotid body paraganglioma
    n1=LANL | n2=en:carotid body paraganglioma | rel=r_associated | relid=0 | w=10
  196. LANL -- r_associated #0: 10 / 0.909 -> en:carotid body tumors (most common location)
    n1=LANL | n2=en:carotid body tumors (most common location) | rel=r_associated | relid=0 | w=10
  197. LANL -- r_associated #0: 10 / 0.909 -> en:carotid body tumors (most common)
    n1=LANL | n2=en:carotid body tumors (most common) | rel=r_associated | relid=0 | w=10
  198. LANL -- r_associated #0: 10 / 0.909 -> en:cartilage-forming neoplasm
    n1=LANL | n2=en:cartilage-forming neoplasm | rel=r_associated | relid=0 | w=10
  199. LANL -- r_associated #0: 10 / 0.909 -> en:cellular morphology
    n1=LANL | n2=en:cellular morphology | rel=r_associated | relid=0 | w=10
  200. LANL -- r_associated #0: 10 / 0.909 -> en:central nervous system embryonal neoplasm
    n1=LANL | n2=en:central nervous system embryonal neoplasm | rel=r_associated | relid=0 | w=10
  201. LANL -- r_associated #0: 10 / 0.909 -> en:central nervous system leukemia
    n1=LANL | n2=en:central nervous system leukemia | rel=r_associated | relid=0 | w=10
  202. LANL -- r_associated #0: 10 / 0.909 -> en:central nervous system neoplasm
    n1=LANL | n2=en:central nervous system neoplasm | rel=r_associated | relid=0 | w=10
  203. LANL -- r_associated #0: 10 / 0.909 -> en:cerebrovascular accident
    n1=LANL | n2=en:cerebrovascular accident | rel=r_associated | relid=0 | w=10
  204. LANL -- r_associated #0: 10 / 0.909 -> en:cervical cancer
    n1=LANL | n2=en:cervical cancer | rel=r_associated | relid=0 | w=10
  205. LANL -- r_associated #0: 10 / 0.909 -> en:cervical cancer (rare)
    n1=LANL | n2=en:cervical cancer (rare) | rel=r_associated | relid=0 | w=10
  206. LANL -- r_associated #0: 10 / 0.909 -> en:cervical cancer screening
    n1=LANL | n2=en:cervical cancer screening | rel=r_associated | relid=0 | w=10
  207. LANL -- r_associated #0: 10 / 0.909 -> en:cervical carcinoma
    n1=LANL | n2=en:cervical carcinoma | rel=r_associated | relid=0 | w=10
  208. LANL -- r_associated #0: 10 / 0.909 -> en:cervical neoplasm
    n1=LANL | n2=en:cervical neoplasm | rel=r_associated | relid=0 | w=10
  209. LANL -- r_associated #0: 10 / 0.909 -> en:chemically induced
    n1=LANL | n2=en:chemically induced | rel=r_associated | relid=0 | w=10
  210. LANL -- r_associated #0: 10 / 0.909 -> en:chemotherapy
    n1=LANL | n2=en:chemotherapy | rel=r_associated | relid=0 | w=10
  211. LANL -- r_associated #0: 10 / 0.909 -> en:chemotherapy-related leukemia
    n1=LANL | n2=en:chemotherapy-related leukemia | rel=r_associated | relid=0 | w=10
  212. LANL -- r_associated #0: 10 / 0.909 -> en:chest pain
    n1=LANL | n2=en:chest pain | rel=r_associated | relid=0 | w=10
  213. LANL -- r_associated #0: 10 / 0.909 -> en:childhood acute myeloid leukemia/other myeloid malignancies
    n1=LANL | n2=en:childhood acute myeloid leukemia/other myeloid malignancies | rel=r_associated | relid=0 | w=10
  214. LANL -- r_associated #0: 10 / 0.909 -> en:childhood brain neoplasm
    n1=LANL | n2=en:childhood brain neoplasm | rel=r_associated | relid=0 | w=10
  215. LANL -- r_associated #0: 10 / 0.909 -> en:childhood leukemia
    n1=LANL | n2=en:childhood leukemia | rel=r_associated | relid=0 | w=10
  216. LANL -- r_associated #0: 10 / 0.909 -> en:childhood malignant neoplasm
    n1=LANL | n2=en:childhood malignant neoplasm | rel=r_associated | relid=0 | w=10
  217. LANL -- r_associated #0: 10 / 0.909 -> en:cholesterol
    n1=LANL | n2=en:cholesterol | rel=r_associated | relid=0 | w=10
  218. LANL -- r_associated #0: 10 / 0.909 -> en:chondrogenic neoplasm
    n1=LANL | n2=en:chondrogenic neoplasm | rel=r_associated | relid=0 | w=10
  219. LANL -- r_associated #0: 10 / 0.909 -> en:chordoma
    n1=LANL | n2=en:chordoma | rel=r_associated | relid=0 | w=10
  220. LANL -- r_associated #0: 10 / 0.909 -> en:choriocarcinoma
    n1=LANL | n2=en:choriocarcinoma | rel=r_associated | relid=0 | w=10
  221. LANL -- r_associated #0: 10 / 0.909 -> en:choroid plexus carcinoma
    n1=LANL | n2=en:choroid plexus carcinoma | rel=r_associated | relid=0 | w=10
  222. LANL -- r_associated #0: 10 / 0.909 -> en:chromaffin cell neoplasm
    n1=LANL | n2=en:chromaffin cell neoplasm | rel=r_associated | relid=0 | w=10
  223. LANL -- r_associated #0: 10 / 0.909 -> en:chronic clinical course
    n1=LANL | n2=en:chronic clinical course | rel=r_associated | relid=0 | w=10
  224. LANL -- r_associated #0: 10 / 0.909 -> en:chronic eosinophilic leukemia, not otherwise specified
    n1=LANL | n2=en:chronic eosinophilic leukemia, not otherwise specified | rel=r_associated | relid=0 | w=10
  225. LANL -- r_associated #0: 10 / 0.909 -> en:chronic leukemia
    n1=LANL | n2=en:chronic leukemia | rel=r_associated | relid=0 | w=10
  226. LANL -- r_associated #0: 10 / 0.909 -> en:chronic lymphocytic leukemia
    n1=LANL | n2=en:chronic lymphocytic leukemia | rel=r_associated | relid=0 | w=10
  227. LANL -- r_associated #0: 10 / 0.909 -> en:chronic lymphocytic leukemia, b-cell, susceptibility to
    n1=LANL | n2=en:chronic lymphocytic leukemia, b-cell, susceptibility to | rel=r_associated | relid=0 | w=10
  228. LANL -- r_associated #0: 10 / 0.909 -> en:chronic monocytic leukemia
    n1=LANL | n2=en:chronic monocytic leukemia | rel=r_associated | relid=0 | w=10
  229. LANL -- r_associated #0: 10 / 0.909 -> en:chronic myelogenous leukemia, bcr-abl1 positive
    n1=LANL | n2=en:chronic myelogenous leukemia, bcr-abl1 positive | rel=r_associated | relid=0 | w=10
  230. LANL -- r_associated #0: 10 / 0.909 -> en:chronic myeloid leukemia - category
    n1=LANL | n2=en:chronic myeloid leukemia - category | rel=r_associated | relid=0 | w=10
  231. LANL -- r_associated #0: 10 / 0.909 -> en:chronic myeloid leukemia, bcr/abl-positive
    n1=LANL | n2=en:chronic myeloid leukemia, bcr/abl-positive | rel=r_associated | relid=0 | w=10
  232. LANL -- r_associated #0: 10 / 0.909 -> en:chronic myelomonocytic leukemia
    n1=LANL | n2=en:chronic myelomonocytic leukemia | rel=r_associated | relid=0 | w=10
  233. LANL -- r_associated #0: 10 / 0.909 -> en:clear cell acanthoma
    n1=LANL | n2=en:clear cell acanthoma | rel=r_associated | relid=0 | w=10
  234. LANL -- r_associated #0: 10 / 0.909 -> en:clear cell neoplasm
    n1=LANL | n2=en:clear cell neoplasm | rel=r_associated | relid=0 | w=10
  235. LANL -- r_associated #0: 10 / 0.909 -> en:clear cell renal cell carcinoma
    n1=LANL | n2=en:clear cell renal cell carcinoma | rel=r_associated | relid=0 | w=10
  236. LANL -- r_associated #0: 10 / 0.909 -> en:colon adenocarcinoma
    n1=LANL | n2=en:colon adenocarcinoma | rel=r_associated | relid=0 | w=10
  237. LANL -- r_associated #0: 10 / 0.909 -> en:colon carcinoma
    n1=LANL | n2=en:colon carcinoma | rel=r_associated | relid=0 | w=10
  238. LANL -- r_associated #0: 10 / 0.909 -> en:colon polyp
    n1=LANL | n2=en:colon polyp | rel=r_associated | relid=0 | w=10
  239. LANL -- r_associated #0: 10 / 0.909 -> en:colorectal cancer (in some patients)
    n1=LANL | n2=en:colorectal cancer (in some patients) | rel=r_associated | relid=0 | w=10
  240. LANL -- r_associated #0: 10 / 0.909 -> en:colorectal cancer, early onset
    n1=LANL | n2=en:colorectal cancer, early onset | rel=r_associated | relid=0 | w=10
  241. LANL -- r_associated #0: 10 / 0.909 -> en:colorectal carcinoma
    n1=LANL | n2=en:colorectal carcinoma | rel=r_associated | relid=0 | w=10
  242. LANL -- r_associated #0: 10 / 0.909 -> en:complex epithelial neoplasm
    n1=LANL | n2=en:complex epithelial neoplasm | rel=r_associated | relid=0 | w=10
  243. LANL -- r_associated #0: 10 / 0.909 -> en:complex mixed and stromal neoplasms
    n1=LANL | n2=en:complex mixed and stromal neoplasms | rel=r_associated | relid=0 | w=10
  244. LANL -- r_associated #0: 10 / 0.909 -> en:complex mixed and/or stromal neoplasm
    n1=LANL | n2=en:complex mixed and/or stromal neoplasm | rel=r_associated | relid=0 | w=10
  245. LANL -- r_associated #0: 10 / 0.909 -> en:complication aspects
    n1=LANL | n2=en:complication aspects | rel=r_associated | relid=0 | w=10
  246. LANL -- r_associated #0: 10 / 0.909 -> en:compound eye
    n1=LANL | n2=en:compound eye | rel=r_associated | relid=0 | w=10
  247. LANL -- r_associated #0: 10 / 0.909 -> en:compound leukemias
    n1=LANL | n2=en:compound leukemias | rel=r_associated | relid=0 | w=10
  248. LANL -- r_associated #0: 10 / 0.909 -> en:congenital mesh qualifier
    n1=LANL | n2=en:congenital mesh qualifier | rel=r_associated | relid=0 | w=10
  249. LANL -- r_associated #0: 10 / 0.909 -> en:core binding factor acute myeloid leukemia
    n1=LANL | n2=en:core binding factor acute myeloid leukemia | rel=r_associated | relid=0 | w=10
  250. LANL -- r_associated #0: 10 / 0.909 -> en:coronary artery bypass surgery
    n1=LANL | n2=en:coronary artery bypass surgery | rel=r_associated | relid=0 | w=10
  251. LANL -- r_associated #0: 10 / 0.909 -> en:coronary artery disease
    n1=LANL | n2=en:coronary artery disease | rel=r_associated | relid=0 | w=10
  252. LANL -- r_associated #0: 10 / 0.909 -> en:craniopharyngioma
    n1=LANL | n2=en:craniopharyngioma | rel=r_associated | relid=0 | w=10
  253. LANL -- r_associated #0: 10 / 0.909 -> en:ctrp terminology
    n1=LANL | n2=en:ctrp terminology | rel=r_associated | relid=0 | w=10
  254. LANL -- r_associated #0: 10 / 0.909 -> en:cutaneous leiomyosarcoma (less common)
    n1=LANL | n2=en:cutaneous leiomyosarcoma (less common) | rel=r_associated | relid=0 | w=10
  255. LANL -- r_associated #0: 10 / 0.909 -> en:cutaneous melanoma
    n1=LANL | n2=en:cutaneous melanoma | rel=r_associated | relid=0 | w=10
  256. LANL -- r_associated #0: 10 / 0.909 -> en:cylindromas may show malignant transformation
    n1=LANL | n2=en:cylindromas may show malignant transformation | rel=r_associated | relid=0 | w=10
  257. LANL -- r_associated #0: 10 / 0.909 -> en:cyst
    n1=LANL | n2=en:cyst | rel=r_associated | relid=0 | w=10
  258. LANL -- r_associated #0: 10 / 0.909 -> en:cystadenoma
    n1=LANL | n2=en:cystadenoma | rel=r_associated | relid=0 | w=10
  259. LANL -- r_associated #0: 10 / 0.909 -> en:cystic, mucinous and/or serous neoplasm
    n1=LANL | n2=en:cystic, mucinous and/or serous neoplasm | rel=r_associated | relid=0 | w=10
  260. LANL -- r_associated #0: 10 / 0.909 -> en:cytogenetically normal acute myeloid leukemia
    n1=LANL | n2=en:cytogenetically normal acute myeloid leukemia | rel=r_associated | relid=0 | w=10
  261. LANL -- r_associated #0: 10 / 0.909 -> en:dck gene
    n1=LANL | n2=en:dck gene | rel=r_associated | relid=0 | w=10
  262. LANL -- r_associated #0: 10 / 0.909 -> en:dck wt allele
    n1=LANL | n2=en:dck wt allele | rel=r_associated | relid=0 | w=10
  263. LANL -- r_associated #0: 10 / 0.909 -> en:deep vein thrombosis
    n1=LANL | n2=en:deep vein thrombosis | rel=r_associated | relid=0 | w=10
  264. LANL -- r_associated #0: 10 / 0.909 -> en:desmoid-type fibromatosis
    n1=LANL | n2=en:desmoid-type fibromatosis | rel=r_associated | relid=0 | w=10
  265. LANL -- r_associated #0: 10 / 0.909 -> en:desmoplastic small cell tumor
    n1=LANL | n2=en:desmoplastic small cell tumor | rel=r_associated | relid=0 | w=10
  266. LANL -- r_associated #0: 10 / 0.909 -> en:development of tumors in adulthood
    n1=LANL | n2=en:development of tumors in adulthood | rel=r_associated | relid=0 | w=10
  267. LANL -- r_associated #0: 10 / 0.909 -> en:diabetic foot
    n1=LANL | n2=en:diabetic foot | rel=r_associated | relid=0 | w=10
  268. LANL -- r_associated #0: 10 / 0.909 -> en:diabetic heart disease
    n1=LANL | n2=en:diabetic heart disease | rel=r_associated | relid=0 | w=10
  269. LANL -- r_associated #0: 10 / 0.909 -> en:diagnosis aspect
    n1=LANL | n2=en:diagnosis aspect | rel=r_associated | relid=0 | w=10
  270. LANL -- r_associated #0: 10 / 0.909 -> en:dietary approaches to stop hypertension diet
    n1=LANL | n2=en:dietary approaches to stop hypertension diet | rel=r_associated | relid=0 | w=10
  271. LANL -- r_associated #0: 10 / 0.909 -> en:digestive system carcinoma
    n1=LANL | n2=en:digestive system carcinoma | rel=r_associated | relid=0 | w=10
  272. LANL -- r_associated #0: 10 / 0.909 -> en:digestive system neoplasm
    n1=LANL | n2=en:digestive system neoplasm | rel=r_associated | relid=0 | w=10
  273. LANL -- r_associated #0: 10 / 0.909 -> en:digestive system neoplasms
    n1=LANL | n2=en:digestive system neoplasms | rel=r_associated | relid=0 | w=10
  274. LANL -- r_associated #0: 10 / 0.909 -> en:disorder of pericardium
    n1=LANL | n2=en:disorder of pericardium | rel=r_associated | relid=0 | w=10
  275. LANL -- r_associated #0: 10 / 0.909 -> en:disseminated malignant neoplasm
    n1=LANL | n2=en:disseminated malignant neoplasm | rel=r_associated | relid=0 | w=10
  276. LANL -- r_associated #0: 10 / 0.909 -> en:disseminated malignant neoplasm, unspecified
    n1=LANL | n2=en:disseminated malignant neoplasm, unspecified | rel=r_associated | relid=0 | w=10
  277. LANL -- r_associated #0: 10 / 0.909 -> en:dohle bodies and leukemia
    n1=LANL | n2=en:dohle bodies and leukemia | rel=r_associated | relid=0 | w=10
  278. LANL -- r_associated #0: 10 / 0.909 -> en:ductal and lobular neoplasms
    n1=LANL | n2=en:ductal and lobular neoplasms | rel=r_associated | relid=0 | w=10
  279. LANL -- r_associated #0: 10 / 0.909 -> en:ductal breast carcinoma
    n1=LANL | n2=en:ductal breast carcinoma | rel=r_associated | relid=0 | w=10
  280. LANL -- r_associated #0: 10 / 0.909 -> en:ductal, lobular and/or medullary neoplasm
    n1=LANL | n2=en:ductal, lobular and/or medullary neoplasm | rel=r_associated | relid=0 | w=10
  281. LANL -- r_associated #0: 10 / 0.909 -> en:duodenal carcinoid
    n1=LANL | n2=en:duodenal carcinoid | rel=r_associated | relid=0 | w=10
  282. LANL -- r_associated #0: 10 / 0.909 -> en:duodenal carcinoma
    n1=LANL | n2=en:duodenal carcinoma | rel=r_associated | relid=0 | w=10
  283. LANL -- r_associated #0: 10 / 0.909 -> en:dysgerminoma
    n1=LANL | n2=en:dysgerminoma | rel=r_associated | relid=0 | w=10
  284. LANL -- r_associated #0: 10 / 0.909 -> en:dysplasia with neoplasia
    n1=LANL | n2=en:dysplasia with neoplasia | rel=r_associated | relid=0 | w=10
  285. LANL -- r_associated #0: 10 / 0.909 -> en:early-onset hepatocellular carcinoma
    n1=LANL | n2=en:early-onset hepatocellular carcinoma | rel=r_associated | relid=0 | w=10
  286. LANL -- r_associated #0: 10 / 0.909 -> en:ebv-induced b-cell lymphoma
    n1=LANL | n2=en:ebv-induced b-cell lymphoma | rel=r_associated | relid=0 | w=10
  287. LANL -- r_associated #0: 10 / 0.909 -> en:edema
    n1=LANL | n2=en:edema | rel=r_associated | relid=0 | w=10
  288. LANL -- r_associated #0: 10 / 0.909 -> en:egg shell
    n1=LANL | n2=en:egg shell | rel=r_associated | relid=0 | w=10
  289. LANL -- r_associated #0: 10 / 0.909 -> en:electric organ
    n1=LANL | n2=en:electric organ | rel=r_associated | relid=0 | w=10
  290. LANL -- r_associated #0: 10 / 0.909 -> en:emberger syndrome
    n1=LANL | n2=en:emberger syndrome | rel=r_associated | relid=0 | w=10
  291. LANL -- r_associated #0: 10 / 0.909 -> en:embryologic
    n1=LANL | n2=en:embryologic | rel=r_associated | relid=0 | w=10
  292. LANL -- r_associated #0: 10 / 0.909 -> en:embryonal carcinoma
    n1=LANL | n2=en:embryonal carcinoma | rel=r_associated | relid=0 | w=10
  293. LANL -- r_associated #0: 10 / 0.909 -> en:embryonal neoplasm
    n1=LANL | n2=en:embryonal neoplasm | rel=r_associated | relid=0 | w=10
  294. LANL -- r_associated #0: 10 / 0.909 -> en:end stage cancer
    n1=LANL | n2=en:end stage cancer | rel=r_associated | relid=0 | w=10
  295. LANL -- r_associated #0: 10 / 0.909 -> en:endocarditis
    n1=LANL | n2=en:endocarditis | rel=r_associated | relid=0 | w=10
  296. LANL -- r_associated #0: 10 / 0.909 -> en:endocrine neoplasms malignant and unspecified
    n1=LANL | n2=en:endocrine neoplasms malignant and unspecified | rel=r_associated | relid=0 | w=10
  297. LANL -- r_associated #0: 10 / 0.909 -> en:endocrine system cancer
    n1=LANL | n2=en:endocrine system cancer | rel=r_associated | relid=0 | w=10
  298. LANL -- r_associated #0: 10 / 0.909 -> en:endolymphatic sac tumor
    n1=LANL | n2=en:endolymphatic sac tumor | rel=r_associated | relid=0 | w=10
  299. LANL -- r_associated #0: 10 / 0.909 -> en:endometrial adenocarcinoma
    n1=LANL | n2=en:endometrial adenocarcinoma | rel=r_associated | relid=0 | w=10
  300. LANL -- r_associated #0: 10 / 0.909 -> en:endometrial carcinoma
    n1=LANL | n2=en:endometrial carcinoma | rel=r_associated | relid=0 | w=10
  301. LANL -- r_associated #0: 10 / 0.909 -> en:endometrial neoplasm
    n1=LANL | n2=en:endometrial neoplasm | rel=r_associated | relid=0 | w=10
  302. LANL -- r_associated #0: 10 / 0.909 -> en:enteropathy-associated t-cell lymphoma
    n1=LANL | n2=en:enteropathy-associated t-cell lymphoma | rel=r_associated | relid=0 | w=10
  303. LANL -- r_associated #0: 10 / 0.909 -> en:environment related neoplasm/cancer
    n1=LANL | n2=en:environment related neoplasm/cancer | rel=r_associated | relid=0 | w=10
  304. LANL -- r_associated #0: 10 / 0.909 -> en:environment-related malignant neoplasm
    n1=LANL | n2=en:environment-related malignant neoplasm | rel=r_associated | relid=0 | w=10
  305. LANL -- r_associated #0: 10 / 0.909 -> en:enzootic bovine leukosis
    n1=LANL | n2=en:enzootic bovine leukosis | rel=r_associated | relid=0 | w=10
  306. LANL -- r_associated #0: 10 / 0.909 -> en:enzymology
    n1=LANL | n2=en:enzymology | rel=r_associated | relid=0 | w=10
  307. LANL -- r_associated #0: 10 / 0.909 -> en:eosinophilic disorder
    n1=LANL | n2=en:eosinophilic disorder | rel=r_associated | relid=0 | w=10
  308. LANL -- r_associated #0: 10 / 0.909 -> en:ependymoma
    n1=LANL | n2=en:ependymoma | rel=r_associated | relid=0 | w=10
  309. LANL -- r_associated #0: 10 / 0.909 -> en:epidemiologic
    n1=LANL | n2=en:epidemiologic | rel=r_associated | relid=0 | w=10
  310. LANL -- r_associated #0: 10 / 0.909 -> en:epithelial neoplasm
    n1=LANL | n2=en:epithelial neoplasm | rel=r_associated | relid=0 | w=10
  311. LANL -- r_associated #0: 10 / 0.909 -> en:eps15 gene
    n1=LANL | n2=en:eps15 gene | rel=r_associated | relid=0 | w=10
  312. LANL -- r_associated #0: 10 / 0.909 -> en:eps15 wt allele
    n1=LANL | n2=en:eps15 wt allele | rel=r_associated | relid=0 | w=10
  313. LANL -- r_associated #0: 10 / 0.909 -> en:erythraemic myelosis (in remission)
    n1=LANL | n2=en:erythraemic myelosis (in remission) | rel=r_associated | relid=0 | w=10
  314. LANL -- r_associated #0: 10 / 0.909 -> en:erythroleukemia, familial
    n1=LANL | n2=en:erythroleukemia, familial | rel=r_associated | relid=0 | w=10
  315. LANL -- r_associated #0: 10 / 0.909 -> en:esophageal carcinoma
    n1=LANL | n2=en:esophageal carcinoma | rel=r_associated | relid=0 | w=10
  316. LANL -- r_associated #0: 10 / 0.909 -> en:ethnologic
    n1=LANL | n2=en:ethnologic | rel=r_associated | relid=0 | w=10
  317. LANL -- r_associated #0: 10 / 0.909 -> en:etiology aspects
    n1=LANL | n2=en:etiology aspects | rel=r_associated | relid=0 | w=10
  318. LANL -- r_associated #0: 10 / 0.909 -> en:ewing sarcoma
    n1=LANL | n2=en:ewing sarcoma | rel=r_associated | relid=0 | w=10
  319. LANL -- r_associated #0: 10 / 0.909 -> en:exposure as collected domain
    n1=LANL | n2=en:exposure as collected domain | rel=r_associated | relid=0 | w=10
  320. LANL -- r_associated #0: 10 / 0.909 -> en:extra-adrenal paraganglioma
    n1=LANL | n2=en:extra-adrenal paraganglioma | rel=r_associated | relid=0 | w=10
  321. LANL -- r_associated #0: 10 / 0.909 -> en:extra-adrenal sympathetic paraganglioma
    n1=LANL | n2=en:extra-adrenal sympathetic paraganglioma | rel=r_associated | relid=0 | w=10
  322. LANL -- r_associated #0: 10 / 0.909 -> en:eye neoplasm
    n1=LANL | n2=en:eye neoplasm | rel=r_associated | relid=0 | w=10
  323. LANL -- r_associated #0: 10 / 0.909 -> en:familial acute myeloid leukemia
    n1=LANL | n2=en:familial acute myeloid leukemia | rel=r_associated | relid=0 | w=10
  324. LANL -- r_associated #0: 10 / 0.909 -> en:familial acute myeloid leukemia with mutated cebpa
    n1=LANL | n2=en:familial acute myeloid leukemia with mutated cebpa | rel=r_associated | relid=0 | w=10
  325. LANL -- r_associated #0: 10 / 0.909 -> en:fibroblastic/myofibroblastic tumors (all subtypes)
    n1=LANL | n2=en:fibroblastic/myofibroblastic tumors (all subtypes) | rel=r_associated | relid=0 | w=10
  326. LANL -- r_associated #0: 10 / 0.909 -> en:fibroelastoma
    n1=LANL | n2=en:fibroelastoma | rel=r_associated | relid=0 | w=10
  327. LANL -- r_associated #0: 10 / 0.909 -> en:fibroepithelial neoplasm
    n1=LANL | n2=en:fibroepithelial neoplasm | rel=r_associated | relid=0 | w=10
  328. LANL -- r_associated #0: 10 / 0.909 -> en:fibrohistiocytic neoplasm
    n1=LANL | n2=en:fibrohistiocytic neoplasm | rel=r_associated | relid=0 | w=10
  329. LANL -- r_associated #0: 10 / 0.909 -> en:fibromatous neoplasm
    n1=LANL | n2=en:fibromatous neoplasm | rel=r_associated | relid=0 | w=10
  330. LANL -- r_associated #0: 10 / 0.909 -> en:fibrosarcoma
    n1=LANL | n2=en:fibrosarcoma | rel=r_associated | relid=0 | w=10
  331. LANL -- r_associated #0: 10 / 0.909 -> en:fibrous connective tissue neoplasm
    n1=LANL | n2=en:fibrous connective tissue neoplasm | rel=r_associated | relid=0 | w=10
  332. LANL -- r_associated #0: 10 / 0.909 -> en:follicular lymphoma
    n1=LANL | n2=en:follicular lymphoma | rel=r_associated | relid=0 | w=10
  333. LANL -- r_associated #0: 10 / 0.909 -> en:follicular neoplasm
    n1=LANL | n2=en:follicular neoplasm | rel=r_associated | relid=0 | w=10
  334. LANL -- r_associated #0: 10 / 0.909 -> en:frequent skin cancer
    n1=LANL | n2=en:frequent skin cancer | rel=r_associated | relid=0 | w=10
  335. LANL -- r_associated #0: 10 / 0.909 -> en:gallbladder carcinoma
    n1=LANL | n2=en:gallbladder carcinoma | rel=r_associated | relid=0 | w=10
  336. LANL -- r_associated #0: 10 / 0.909 -> en:ganglioneuroblastoma
    n1=LANL | n2=en:ganglioneuroblastoma | rel=r_associated | relid=0 | w=10
  337. LANL -- r_associated #0: 10 / 0.909 -> en:ganglioneuroma
    n1=LANL | n2=en:ganglioneuroma | rel=r_associated | relid=0 | w=10
  338. LANL -- r_associated #0: 10 / 0.909 -> en:gangrene
    n1=LANL | n2=en:gangrene | rel=r_associated | relid=0 | w=10
  339. LANL -- r_associated #0: 10 / 0.909 -> en:gastric adenocarcinoma
    n1=LANL | n2=en:gastric adenocarcinoma | rel=r_associated | relid=0 | w=10
  340. LANL -- r_associated #0: 10 / 0.909 -> en:gastric cancer, diffuse type, poorly differentiated, high-grade submucosal lesions
    n1=LANL | n2=en:gastric cancer, diffuse type, poorly differentiated, high-grade submucosal lesions | rel=r_associated | relid=0 | w=10
  341. LANL -- r_associated #0: 10 / 0.909 -> en:gastric carcinoma
    n1=LANL | n2=en:gastric carcinoma | rel=r_associated | relid=0 | w=10
  342. LANL -- r_associated #0: 10 / 0.909 -> en:gastrointestinal neoplasms malignant and unspecified
    n1=LANL | n2=en:gastrointestinal neoplasms malignant and unspecified | rel=r_associated | relid=0 | w=10
  343. LANL -- r_associated #0: 10 / 0.909 -> en:gastrointestinal stromal tumors (less common)
    n1=LANL | n2=en:gastrointestinal stromal tumors (less common) | rel=r_associated | relid=0 | w=10
  344. LANL -- r_associated #0: 10 / 0.909 -> en:gene mutation-related cancer
    n1=LANL | n2=en:gene mutation-related cancer | rel=r_associated | relid=0 | w=10
  345. LANL -- r_associated #0: 10 / 0.909 -> en:genetic aspects
    n1=LANL | n2=en:genetic aspects | rel=r_associated | relid=0 | w=10
  346. LANL -- r_associated #0: 10 / 0.909 -> en:genital cancer
    n1=LANL | n2=en:genital cancer | rel=r_associated | relid=0 | w=10
  347. LANL -- r_associated #0: 10 / 0.909 -> en:genitourinary neoplasms
    n1=LANL | n2=en:genitourinary neoplasms | rel=r_associated | relid=0 | w=10
  348. LANL -- r_associated #0: 10 / 0.909 -> en:germ cell and gonadal stromal cell neoplasms (all subtypes)
    n1=LANL | n2=en:germ cell and gonadal stromal cell neoplasms (all subtypes) | rel=r_associated | relid=0 | w=10
  349. LANL -- r_associated #0: 10 / 0.909 -> en:germ cell tumor
    n1=LANL | n2=en:germ cell tumor | rel=r_associated | relid=0 | w=10
  350. LANL -- r_associated #0: 10 / 0.909 -> en:gestational trophoblastic tumor
    n1=LANL | n2=en:gestational trophoblastic tumor | rel=r_associated | relid=0 | w=10
  351. LANL -- r_associated #0: 10 / 0.909 -> en:giant cell astrocytoma
    n1=LANL | n2=en:giant cell astrocytoma | rel=r_associated | relid=0 | w=10
  352. LANL -- r_associated #0: 10 / 0.909 -> en:giant cell lesion of small bones
    n1=LANL | n2=en:giant cell lesion of small bones | rel=r_associated | relid=0 | w=10
  353. LANL -- r_associated #0: 10 / 0.909 -> en:giant cell tumor
    n1=LANL | n2=en:giant cell tumor | rel=r_associated | relid=0 | w=10
  354. LANL -- r_associated #0: 10 / 0.909 -> en:glioblastoma
    n1=LANL | n2=en:glioblastoma | rel=r_associated | relid=0 | w=10
  355. LANL -- r_associated #0: 10 / 0.909 -> en:glioma
    n1=LANL | n2=en:glioma | rel=r_associated | relid=0 | w=10
  356. LANL -- r_associated #0: 10 / 0.909 -> en:glomus tympanicum paraganglioma
    n1=LANL | n2=en:glomus tympanicum paraganglioma | rel=r_associated | relid=0 | w=10
  357. LANL -- r_associated #0: 10 / 0.909 -> en:gonadoblastoma
    n1=LANL | n2=en:gonadoblastoma | rel=r_associated | relid=0 | w=10
  358. LANL -- r_associated #0: 10 / 0.909 -> en:granular cell tumor and/or alveolar soft part sarcoma
    n1=LANL | n2=en:granular cell tumor and/or alveolar soft part sarcoma | rel=r_associated | relid=0 | w=10
  359. LANL -- r_associated #0: 10 / 0.909 -> en:granular cell tumors and alveolar soft part sarcomas
    n1=LANL | n2=en:granular cell tumors and alveolar soft part sarcomas | rel=r_associated | relid=0 | w=10
  360. LANL -- r_associated #0: 10 / 0.909 -> en:growth hormone-producing pituitary gland neoplasm
    n1=LANL | n2=en:growth hormone-producing pituitary gland neoplasm | rel=r_associated | relid=0 | w=10
  361. LANL -- r_associated #0: 10 / 0.909 -> en:haematopoietic neoplasms (excl leukaemias and lymphomas)
    n1=LANL | n2=en:haematopoietic neoplasms (excl leukaemias and lymphomas) | rel=r_associated | relid=0 | w=10
  362. LANL -- r_associated #0: 10 / 0.909 -> en:hairy cell leukemia
    n1=LANL | n2=en:hairy cell leukemia | rel=r_associated | relid=0 | w=10
  363. LANL -- r_associated #0: 10 / 0.909 -> en:hamartoma
    n1=LANL | n2=en:hamartoma | rel=r_associated | relid=0 | w=10
  364. LANL -- r_associated #0: 10 / 0.909 -> en:head and neck paraganglioma
    n1=LANL | n2=en:head and neck paraganglioma | rel=r_associated | relid=0 | w=10
  365. LANL -- r_associated #0: 10 / 0.909 -> en:head or neck cancer
    n1=LANL | n2=en:head or neck cancer | rel=r_associated | relid=0 | w=10
  366. LANL -- r_associated #0: 10 / 0.909 -> en:heart dimension/size
    n1=LANL | n2=en:heart dimension/size | rel=r_associated | relid=0 | w=10
  367. LANL -- r_associated #0: 10 / 0.909 -> en:heart disease in women
    n1=LANL | n2=en:heart disease in women | rel=r_associated | relid=0 | w=10
  368. LANL -- r_associated #0: 10 / 0.909 -> en:heart diseases--prevention
    n1=LANL | n2=en:heart diseases--prevention | rel=r_associated | relid=0 | w=10
  369. LANL -- r_associated #0: 10 / 0.909 -> en:heart disorder
    n1=LANL | n2=en:heart disorder | rel=r_associated | relid=0 | w=10
  370. LANL -- r_associated #0: 10 / 0.909 -> en:heart failure
    n1=LANL | n2=en:heart failure | rel=r_associated | relid=0 | w=10
  371. LANL -- r_associated #0: 10 / 0.909 -> en:heart malformation
    n1=LANL | n2=en:heart malformation | rel=r_associated | relid=0 | w=10
  372. LANL -- r_associated #0: 10 / 0.909 -> en:heart transplantation
    n1=LANL | n2=en:heart transplantation | rel=r_associated | relid=0 | w=10
  373. LANL -- r_associated #0: 10 / 0.909 -> en:hemangioblastoma, sporadic cerebellar (e.g., 193300.0007)
    n1=LANL | n2=en:hemangioblastoma, sporadic cerebellar (e.g., 193300.0007) | rel=r_associated | relid=0 | w=10
  374. LANL -- r_associated #0: 10 / 0.909 -> en:hematologic and lymphocytic disorder
    n1=LANL | n2=en:hematologic and lymphocytic disorder | rel=r_associated | relid=0 | w=10
  375. LANL -- r_associated #0: 10 / 0.909 -> en:hematopoietic and lymphatic system
    n1=LANL | n2=en:hematopoietic and lymphatic system | rel=r_associated | relid=0 | w=10
  376. LANL -- r_associated #0: 10 / 0.909 -> en:hematopoietic and lymphoid cell
    n1=LANL | n2=en:hematopoietic and lymphoid cell | rel=r_associated | relid=0 | w=10
  377. LANL -- r_associated #0: 10 / 0.909 -> en:hematopoietic and lymphoid cell neoplasm
    n1=LANL | n2=en:hematopoietic and lymphoid cell neoplasm | rel=r_associated | relid=0 | w=10
  378. LANL -- r_associated #0: 10 / 0.909 -> en:hematopoietic and lymphoid tissue
    n1=LANL | n2=en:hematopoietic and lymphoid tissue | rel=r_associated | relid=0 | w=10
  379. LANL -- r_associated #0: 10 / 0.909 -> en:hematopoietic neoplasm/leukemia
    n1=LANL | n2=en:hematopoietic neoplasm/leukemia | rel=r_associated | relid=0 | w=10
  380. LANL -- r_associated #0: 10 / 0.909 -> en:hematopoietic tissue
    n1=LANL | n2=en:hematopoietic tissue | rel=r_associated | relid=0 | w=10
  381. LANL -- r_associated #0: 10 / 0.909 -> en:hemophagocytic lymphohistiocytosis
    n1=LANL | n2=en:hemophagocytic lymphohistiocytosis | rel=r_associated | relid=0 | w=10
  382. LANL -- r_associated #0: 10 / 0.909 -> en:hemophagocytic lymphohistiocytosis (in some patients)
    n1=LANL | n2=en:hemophagocytic lymphohistiocytosis (in some patients) | rel=r_associated | relid=0 | w=10
  383. LANL -- r_associated #0: 10 / 0.909 -> en:hemophilia
    n1=LANL | n2=en:hemophilia | rel=r_associated | relid=0 | w=10
  384. LANL -- r_associated #0: 10 / 0.909 -> en:hemorrhage
    n1=LANL | n2=en:hemorrhage | rel=r_associated | relid=0 | w=10
  385. LANL -- r_associated #0: 10 / 0.909 -> en:hemorrhagic cerebrovascular accident
    n1=LANL | n2=en:hemorrhagic cerebrovascular accident | rel=r_associated | relid=0 | w=10
  386. LANL -- r_associated #0: 10 / 0.909 -> en:hepatic and biliary neoplasms benign
    n1=LANL | n2=en:hepatic and biliary neoplasms benign | rel=r_associated | relid=0 | w=10
  387. LANL -- r_associated #0: 10 / 0.909 -> en:hepatobiliary neoplasms malignant and unspecified
    n1=LANL | n2=en:hepatobiliary neoplasms malignant and unspecified | rel=r_associated | relid=0 | w=10
  388. LANL -- r_associated #0: 10 / 0.909 -> en:hepatoblastoma
    n1=LANL | n2=en:hepatoblastoma | rel=r_associated | relid=0 | w=10
  389. LANL -- r_associated #0: 10 / 0.909 -> en:hepatocellular carcinoma
    n1=LANL | n2=en:hepatocellular carcinoma | rel=r_associated | relid=0 | w=10
  390. LANL -- r_associated #0: 10 / 0.909 -> en:hereditary malignant neoplasm
    n1=LANL | n2=en:hereditary malignant neoplasm | rel=r_associated | relid=0 | w=10
  391. LANL -- r_associated #0: 10 / 0.909 -> en:hereditary neoplastic syndrome
    n1=LANL | n2=en:hereditary neoplastic syndrome | rel=r_associated | relid=0 | w=10
  392. LANL -- r_associated #0: 10 / 0.909 -> en:historical aspects qualifier
    n1=LANL | n2=en:historical aspects qualifier | rel=r_associated | relid=0 | w=10
  393. LANL -- r_associated #0: 10 / 0.909 -> en:history of acute myeloid leukemia
    n1=LANL | n2=en:history of acute myeloid leukemia | rel=r_associated | relid=0 | w=10
  394. LANL -- r_associated #0: 10 / 0.909 -> en:hodgkin lymphoma
    n1=LANL | n2=en:hodgkin lymphoma | rel=r_associated | relid=0 | w=10
  395. LANL -- r_associated #0: 10 / 0.909 -> en:homeobox protein hox-a9
    n1=LANL | n2=en:homeobox protein hox-a9 | rel=r_associated | relid=0 | w=10
  396. LANL -- r_associated #0: 10 / 0.909 -> en:hormone related neoplasm/cancer
    n1=LANL | n2=en:hormone related neoplasm/cancer | rel=r_associated | relid=0 | w=10
  397. LANL -- r_associated #0: 10 / 0.909 -> en:host-tumor interaction
    n1=LANL | n2=en:host-tumor interaction | rel=r_associated | relid=0 | w=10
  398. LANL -- r_associated #0: 10 / 0.909 -> en:hoxa9 gene
    n1=LANL | n2=en:hoxa9 gene | rel=r_associated | relid=0 | w=10
  399. LANL -- r_associated #0: 10 / 0.909 -> en:hoxa9 wt allele
    n1=LANL | n2=en:hoxa9 wt allele | rel=r_associated | relid=0 | w=10
  400. LANL -- r_associated #0: 10 / 0.909 -> en:hypersensitivity to chemotherapy
    n1=LANL | n2=en:hypersensitivity to chemotherapy | rel=r_associated | relid=0 | w=10
  401. LANL -- r_associated #0: 10 / 0.909 -> en:hypertension
    n1=LANL | n2=en:hypertension | rel=r_associated | relid=0 | w=10
  402. LANL -- r_associated #0: 10 / 0.909 -> en:hypotension
    n1=LANL | n2=en:hypotension | rel=r_associated | relid=0 | w=10
  403. LANL -- r_associated #0: 10 / 0.909 -> en:hypothalamic neoplasm
    n1=LANL | n2=en:hypothalamic neoplasm | rel=r_associated | relid=0 | w=10
  404. LANL -- r_associated #0: 10 / 0.909 -> en:ileal, cecal, ovarian, and breast tumors, occasionally (endemic form)
    n1=LANL | n2=en:ileal, cecal, ovarian, and breast tumors, occasionally (endemic form) | rel=r_associated | relid=0 | w=10
  405. LANL -- r_associated #0: 10 / 0.909 -> en:imaginal discs
    n1=LANL | n2=en:imaginal discs | rel=r_associated | relid=0 | w=10
  406. LANL -- r_associated #0: 10 / 0.909 -> en:immunodeficiency-related malignant neoplasm
    n1=LANL | n2=en:immunodeficiency-related malignant neoplasm | rel=r_associated | relid=0 | w=10
  407. LANL -- r_associated #0: 10 / 0.909 -> en:immunology aspects
    n1=LANL | n2=en:immunology aspects | rel=r_associated | relid=0 | w=10
  408. LANL -- r_associated #0: 10 / 0.909 -> en:immunoproliferative disorders
    n1=LANL | n2=en:immunoproliferative disorders | rel=r_associated | relid=0 | w=10
  409. LANL -- r_associated #0: 10 / 0.909 -> en:in blood
    n1=LANL | n2=en:in blood | rel=r_associated | relid=0 | w=10
  410. LANL -- r_associated #0: 10 / 0.909 -> en:in cerebrospinal fluid
    n1=LANL | n2=en:in cerebrospinal fluid | rel=r_associated | relid=0 | w=10
  411. LANL -- r_associated #0: 10 / 0.909 -> en:in situ neoplasm (morphology)
    n1=LANL | n2=en:in situ neoplasm (morphology) | rel=r_associated | relid=0 | w=10
  412. LANL -- r_associated #0: 10 / 0.909 -> en:in urine
    n1=LANL | n2=en:in urine | rel=r_associated | relid=0 | w=10
  413. LANL -- r_associated #0: 10 / 0.909 -> en:increased hepatocellular carcinoma risk
    n1=LANL | n2=en:increased hepatocellular carcinoma risk | rel=r_associated | relid=0 | w=10
  414. LANL -- r_associated #0: 10 / 0.909 -> en:increased incidence of hepatocellular carcinoma
    n1=LANL | n2=en:increased incidence of hepatocellular carcinoma | rel=r_associated | relid=0 | w=10
  415. LANL -- r_associated #0: 10 / 0.909 -> en:increased incidence of rectosigmoid cancer
    n1=LANL | n2=en:increased incidence of rectosigmoid cancer | rel=r_associated | relid=0 | w=10
  416. LANL -- r_associated #0: 10 / 0.909 -> en:increased malignancy risk, especially lymphoma and skin neoplasm
    n1=LANL | n2=en:increased malignancy risk, especially lymphoma and skin neoplasm | rel=r_associated | relid=0 | w=10
  417. LANL -- r_associated #0: 10 / 0.909 -> en:increased risk for cancer
    n1=LANL | n2=en:increased risk for cancer | rel=r_associated | relid=0 | w=10
  418. LANL -- r_associated #0: 10 / 0.909 -> en:increased risk for embryonal tumors
    n1=LANL | n2=en:increased risk for embryonal tumors | rel=r_associated | relid=0 | w=10
  419. LANL -- r_associated #0: 10 / 0.909 -> en:increased risk for hematologic cancer, particularly acute myeloid leukemia
    n1=LANL | n2=en:increased risk for hematologic cancer, particularly acute myeloid leukemia | rel=r_associated | relid=0 | w=10
  420. LANL -- r_associated #0: 10 / 0.909 -> en:increased risk for lymphoma hodgkin disease
    n1=LANL | n2=en:increased risk for lymphoma hodgkin disease | rel=r_associated | relid=0 | w=10
  421. LANL -- r_associated #0: 10 / 0.909 -> en:increased risk for monoclonal gammopathy
    n1=LANL | n2=en:increased risk for monoclonal gammopathy | rel=r_associated | relid=0 | w=10
  422. LANL -- r_associated #0: 10 / 0.909 -> en:increased risk for multiple myeloma
    n1=LANL | n2=en:increased risk for multiple myeloma | rel=r_associated | relid=0 | w=10
  423. LANL -- r_associated #0: 10 / 0.909 -> en:increased risk for wilms tumor
    n1=LANL | n2=en:increased risk for wilms tumor | rel=r_associated | relid=0 | w=10
  424. LANL -- r_associated #0: 10 / 0.909 -> en:increased risk in heterozygotes
    n1=LANL | n2=en:increased risk in heterozygotes | rel=r_associated | relid=0 | w=10
  425. LANL -- r_associated #0: 10 / 0.909 -> en:increased risk of breast cancer in women
    n1=LANL | n2=en:increased risk of breast cancer in women | rel=r_associated | relid=0 | w=10
  426. LANL -- r_associated #0: 10 / 0.909 -> en:increased risk of chondrosarcoma
    n1=LANL | n2=en:increased risk of chondrosarcoma | rel=r_associated | relid=0 | w=10
  427. LANL -- r_associated #0: 10 / 0.909 -> en:increased risk of chondrosarcoma (mean age of onset 31 years)
    n1=LANL | n2=en:increased risk of chondrosarcoma (mean age of onset 31 years) | rel=r_associated | relid=0 | w=10
  428. LANL -- r_associated #0: 10 / 0.909 -> en:increased risk of gastrointestinal cancer
    n1=LANL | n2=en:increased risk of gastrointestinal cancer | rel=r_associated | relid=0 | w=10
  429. LANL -- r_associated #0: 10 / 0.909 -> en:increased risk of hematologic malignancy (1 patient)
    n1=LANL | n2=en:increased risk of hematologic malignancy (1 patient) | rel=r_associated | relid=0 | w=10
  430. LANL -- r_associated #0: 10 / 0.909 -> en:increased risk of leukemia
    n1=LANL | n2=en:increased risk of leukemia | rel=r_associated | relid=0 | w=10
  431. LANL -- r_associated #0: 10 / 0.909 -> en:increased risk of malignancy
    n1=LANL | n2=en:increased risk of malignancy | rel=r_associated | relid=0 | w=10
  432. LANL -- r_associated #0: 10 / 0.909 -> en:increased risk of malignancy (classic feature)
    n1=LANL | n2=en:increased risk of malignancy (classic feature) | rel=r_associated | relid=0 | w=10
  433. LANL -- r_associated #0: 10 / 0.909 -> en:increased risk of malignant lymphoma
    n1=LANL | n2=en:increased risk of malignant lymphoma | rel=r_associated | relid=0 | w=10
  434. LANL -- r_associated #0: 10 / 0.909 -> en:increased risk of medulloblastoma (rare)
    n1=LANL | n2=en:increased risk of medulloblastoma (rare) | rel=r_associated | relid=0 | w=10
  435. LANL -- r_associated #0: 10 / 0.909 -> en:increased risk of meningioma
    n1=LANL | n2=en:increased risk of meningioma | rel=r_associated | relid=0 | w=10
  436. LANL -- r_associated #0: 10 / 0.909 -> en:increased risk of myelodysplastic syndrome or leukemia (in some patients)
    n1=LANL | n2=en:increased risk of myelodysplastic syndrome or leukemia (in some patients) | rel=r_associated | relid=0 | w=10
  437. LANL -- r_associated #0: 10 / 0.909 -> en:increased risk of myelodysplastic syndromes
    n1=LANL | n2=en:increased risk of myelodysplastic syndromes | rel=r_associated | relid=0 | w=10
  438. LANL -- r_associated #0: 10 / 0.909 -> en:increased risk of pancreatic cancer
    n1=LANL | n2=en:increased risk of pancreatic cancer | rel=r_associated | relid=0 | w=10
  439. LANL -- r_associated #0: 10 / 0.909 -> en:increased risk of testicular cancer
    n1=LANL | n2=en:increased risk of testicular cancer | rel=r_associated | relid=0 | w=10
  440. LANL -- r_associated #0: 10 / 0.909 -> en:increased risk of tumor formation, especially of the head
    n1=LANL | n2=en:increased risk of tumor formation, especially of the head | rel=r_associated | relid=0 | w=10
  441. LANL -- r_associated #0: 10 / 0.909 -> en:increased susceptibility to b-cell lymphoma
    n1=LANL | n2=en:increased susceptibility to b-cell lymphoma | rel=r_associated | relid=0 | w=10
  442. LANL -- r_associated #0: 10 / 0.909 -> en:increased susceptibility to cancer
    n1=LANL | n2=en:increased susceptibility to cancer | rel=r_associated | relid=0 | w=10
  443. LANL -- r_associated #0: 10 / 0.909 -> en:increased susceptibility to carcinomas, especially cancers related to cutaneous viral infections
    n1=LANL | n2=en:increased susceptibility to carcinomas, especially cancers related to cutaneous viral infections | rel=r_associated | relid=0 | w=10
  444. LANL -- r_associated #0: 10 / 0.909 -> en:increased susceptibility to hematologic malignancies
    n1=LANL | n2=en:increased susceptibility to hematologic malignancies | rel=r_associated | relid=0 | w=10
  445. LANL -- r_associated #0: 10 / 0.909 -> en:increased susceptibility to large granular lymphocytic t-cell leukemia
    n1=LANL | n2=en:increased susceptibility to large granular lymphocytic t-cell leukemia | rel=r_associated | relid=0 | w=10
  446. LANL -- r_associated #0: 10 / 0.909 -> en:index tumor
    n1=LANL | n2=en:index tumor | rel=r_associated | relid=0 | w=10
  447. LANL -- r_associated #0: 10 / 0.909 -> en:interferon regulatory factor 1
    n1=LANL | n2=en:interferon regulatory factor 1 | rel=r_associated | relid=0 | w=10
  448. LANL -- r_associated #0: 10 / 0.909 -> en:intra-abdominal cancer advanced
    n1=LANL | n2=en:intra-abdominal cancer advanced | rel=r_associated | relid=0 | w=10
  449. LANL -- r_associated #0: 10 / 0.909 -> en:invasive malignant neoplasm
    n1=LANL | n2=en:invasive malignant neoplasm | rel=r_associated | relid=0 | w=10
  450. LANL -- r_associated #0: 10 / 0.909 -> en:invertebrate cuticle
    n1=LANL | n2=en:invertebrate cuticle | rel=r_associated | relid=0 | w=10
  451. LANL -- r_associated #0: 10 / 0.909 -> en:ischemic cerebrovascular accident
    n1=LANL | n2=en:ischemic cerebrovascular accident | rel=r_associated | relid=0 | w=10
  452. LANL -- r_associated #0: 10 / 0.909 -> en:islet cell tumor
    n1=LANL | n2=en:islet cell tumor | rel=r_associated | relid=0 | w=10
  453. LANL -- r_associated #0: 10 / 0.909 -> en:jaw and kidney tumor (endemic form)
    n1=LANL | n2=en:jaw and kidney tumor (endemic form) | rel=r_associated | relid=0 | w=10
  454. LANL -- r_associated #0: 10 / 0.909 -> en:jugulotympanic paraganglioma
    n1=LANL | n2=en:jugulotympanic paraganglioma | rel=r_associated | relid=0 | w=10
  455. LANL -- r_associated #0: 10 / 0.909 -> en:juvenile myelomonocytic leukemia
    n1=LANL | n2=en:juvenile myelomonocytic leukemia | rel=r_associated | relid=0 | w=10
  456. LANL -- r_associated #0: 10 / 0.909 -> en:juvenile ovarian granulosa cell tumor
    n1=LANL | n2=en:juvenile ovarian granulosa cell tumor | rel=r_associated | relid=0 | w=10
  457. LANL -- r_associated #0: 10 / 0.909 -> en:kaposi sarcoma
    n1=LANL | n2=en:kaposi sarcoma | rel=r_associated | relid=0 | w=10
  458. LANL -- r_associated #0: 10 / 0.909 -> en:kaposi sarcoma (1 patient)
    n1=LANL | n2=en:kaposi sarcoma (1 patient) | rel=r_associated | relid=0 | w=10
  459. LANL -- r_associated #0: 10 / 0.909 -> en:kawasaki disease
    n1=LANL | n2=en:kawasaki disease | rel=r_associated | relid=0 | w=10
  460. LANL -- r_associated #0: 10 / 0.909 -> en:kidney wilms tumor
    n1=LANL | n2=en:kidney wilms tumor | rel=r_associated | relid=0 | w=10
  461. LANL -- r_associated #0: 10 / 0.909 -> en:kit, asp816tyr
    n1=LANL | n2=en:kit, asp816tyr | rel=r_associated | relid=0 | w=10
  462. LANL -- r_associated #0: 10 / 0.909 -> en:laryngeal carcinoma
    n1=LANL | n2=en:laryngeal carcinoma | rel=r_associated | relid=0 | w=10
  463. LANL -- r_associated #0: 10 / 0.909 -> en:laryngeal neoplasm
    n1=LANL | n2=en:laryngeal neoplasm | rel=r_associated | relid=0 | w=10
  464. LANL -- r_associated #0: 10 / 0.909 -> en:le test abnormality
    n1=LANL | n2=en:le test abnormality | rel=r_associated | relid=0 | w=10
  465. LANL -- r_associated #0: 10 / 0.909 -> en:leukaemia secondary
    n1=LANL | n2=en:leukaemia secondary | rel=r_associated | relid=0 | w=10
  466. LANL -- r_associated #0: 10 / 0.909 -> en:leukaemias acute nec
    n1=LANL | n2=en:leukaemias acute nec | rel=r_associated | relid=0 | w=10
  467. LANL -- r_associated #0: 10 / 0.909 -> en:leukaemias chronic nec
    n1=LANL | n2=en:leukaemias chronic nec | rel=r_associated | relid=0 | w=10
  468. LANL -- r_associated #0: 10 / 0.909 -> en:leukaemias lymphocytic nec
    n1=LANL | n2=en:leukaemias lymphocytic nec | rel=r_associated | relid=0 | w=10
  469. LANL -- r_associated #0: 10 / 0.909 -> en:leukaemias myeloid nec in mdr
    n1=LANL | n2=en:leukaemias myeloid nec in mdr | rel=r_associated | relid=0 | w=10
  470. LANL -- r_associated #0: 10 / 0.909 -> en:leukaemias nec
    n1=LANL | n2=en:leukaemias nec | rel=r_associated | relid=0 | w=10
  471. LANL -- r_associated #0: 10 / 0.909 -> en:leukemia
    n1=LANL | n2=en:leukemia | rel=r_associated | relid=0 | w=10
  472. LANL -- r_associated #0: 10 / 0.909 -> en:leukemia (both all and aml)
    n1=LANL | n2=en:leukemia (both all and aml) | rel=r_associated | relid=0 | w=10
  473. LANL -- r_associated #0: 10 / 0.909 -> en:leukemia cutis
    n1=LANL | n2=en:leukemia cutis | rel=r_associated | relid=0 | w=10
  474. LANL -- r_associated #0: 10 / 0.909 -> en:leukemia in remission
    n1=LANL | n2=en:leukemia in remission | rel=r_associated | relid=0 | w=10
  475. LANL -- r_associated #0: 10 / 0.909 -> en:leukemia, acute myelocytic, with polyposis coli and colon cancer
    n1=LANL | n2=en:leukemia, acute myelocytic, with polyposis coli and colon cancer | rel=r_associated | relid=0 | w=10
  476. LANL -- r_associated #0: 10 / 0.909 -> en:leukemia, experimental
    n1=LANL | n2=en:leukemia, experimental | rel=r_associated | relid=0 | w=10
  477. LANL -- r_associated #0: 10 / 0.909 -> en:leukemia, feline
    n1=LANL | n2=en:leukemia, feline | rel=r_associated | relid=0 | w=10
  478. LANL -- r_associated #0: 10 / 0.909 -> en:leukemia, unspecified not having achieved remission
    n1=LANL | n2=en:leukemia, unspecified not having achieved remission | rel=r_associated | relid=0 | w=10
  479. LANL -- r_associated #0: 10 / 0.909 -> en:leukemic cell
    n1=LANL | n2=en:leukemic cell | rel=r_associated | relid=0 | w=10
  480. LANL -- r_associated #0: 10 / 0.909 -> en:leukemic infiltration of skin in acute myeloid leukemia
    n1=LANL | n2=en:leukemic infiltration of skin in acute myeloid leukemia | rel=r_associated | relid=0 | w=10
  481. LANL -- r_associated #0: 10 / 0.909 -> en:leukemic infiltration of skin in myeloid leukemia
    n1=LANL | n2=en:leukemic infiltration of skin in myeloid leukemia | rel=r_associated | relid=0 | w=10
  482. LANL -- r_associated #0: 10 / 0.909 -> en:leukemid
    n1=LANL | n2=en:leukemid | rel=r_associated | relid=0 | w=10
  483. LANL -- r_associated #0: 10 / 0.909 -> en:leukocyte abnormalities, general and nec
    n1=LANL | n2=en:leukocyte abnormalities, general and nec | rel=r_associated | relid=0 | w=10
  484. LANL -- r_associated #0: 10 / 0.909 -> en:lip and oral cavity carcinoma
    n1=LANL | n2=en:lip and oral cavity carcinoma | rel=r_associated | relid=0 | w=10
  485. LANL -- r_associated #0: 10 / 0.909 -> en:lipoma
    n1=LANL | n2=en:lipoma | rel=r_associated | relid=0 | w=10
  486. LANL -- r_associated #0: 10 / 0.909 -> en:lipomatous neoplasm
    n1=LANL | n2=en:lipomatous neoplasm | rel=r_associated | relid=0 | w=10
  487. LANL -- r_associated #0: 10 / 0.909 -> en:liver carcinoma
    n1=LANL | n2=en:liver carcinoma | rel=r_associated | relid=0 | w=10
  488. LANL -- r_associated #0: 10 / 0.909 -> en:liver neoplasms
    n1=LANL | n2=en:liver neoplasms | rel=r_associated | relid=0 | w=10
  489. LANL -- r_associated #0: 10 / 0.909 -> en:localized malignant neoplasm
    n1=LANL | n2=en:localized malignant neoplasm | rel=r_associated | relid=0 | w=10
  490. LANL -- r_associated #0: 10 / 0.909 -> en:low grade fibromyxoid sarcoma
    n1=LANL | n2=en:low grade fibromyxoid sarcoma | rel=r_associated | relid=0 | w=10
  491. LANL -- r_associated #0: 10 / 0.909 -> en:low incidence of plexiform neurofibromas
    n1=LANL | n2=en:low incidence of plexiform neurofibromas | rel=r_associated | relid=0 | w=10
  492. LANL -- r_associated #0: 10 / 0.909 -> en:low-grade neuroendocrine carcinoma (submandibular glands, salivary glands, maxillary sinus, nasal cavity)
    n1=LANL | n2=en:low-grade neuroendocrine carcinoma (submandibular glands, salivary glands, maxillary sinus, nasal cavity) | rel=r_associated | relid=0 | w=10
  493. LANL -- r_associated #0: 10 / 0.909 -> en:lund
    n1=LANL | n2=en:lund | rel=r_associated | relid=0 | w=10
  494. LANL -- r_associated #0: 10 / 0.909 -> en:lung
    n1=LANL | n2=en:lung | rel=r_associated | relid=0 | w=10
  495. LANL -- r_associated #0: 10 / 0.909 -> en:lung adenocarcinoma
    n1=LANL | n2=en:lung adenocarcinoma | rel=r_associated | relid=0 | w=10
  496. LANL -- r_associated #0: 10 / 0.909 -> en:lung carcinoma
    n1=LANL | n2=en:lung carcinoma | rel=r_associated | relid=0 | w=10
  497. LANL -- r_associated #0: 10 / 0.909 -> en:lymphatic vessel neoplasm
    n1=LANL | n2=en:lymphatic vessel neoplasm | rel=r_associated | relid=0 | w=10
  498. LANL -- r_associated #0: 10 / 0.909 -> en:lymphedema
    n1=LANL | n2=en:lymphedema | rel=r_associated | relid=0 | w=10
  499. LANL -- r_associated #0: 10 / 0.909 -> en:lymphocyte
    n1=LANL | n2=en:lymphocyte | rel=r_associated | relid=0 | w=10
  500. LANL -- r_associated #0: 10 / 0.909 -> en:lymphoid leukemia
    n1=LANL | n2=en:lymphoid leukemia | rel=r_associated | relid=0 | w=10
  501. LANL -- r_associated #0: 10 / 0.909 -> en:lymphoma
    n1=LANL | n2=en:lymphoma | rel=r_associated | relid=0 | w=10
  502. LANL -- r_associated #0: 10 / 0.909 -> en:lymphoma (in some patients)
    n1=LANL | n2=en:lymphoma (in some patients) | rel=r_associated | relid=0 | w=10
  503. LANL -- r_associated #0: 10 / 0.909 -> en:lymphomas nec
    n1=LANL | n2=en:lymphomas nec | rel=r_associated | relid=0 | w=10
  504. LANL -- r_associated #0: 10 / 0.909 -> en:lymphoproliferative disorder
    n1=LANL | n2=en:lymphoproliferative disorder | rel=r_associated | relid=0 | w=10
  505. LANL -- r_associated #0: 10 / 0.909 -> en:lymphoproliferative disorder (in some patients)
    n1=LANL | n2=en:lymphoproliferative disorder (in some patients) | rel=r_associated | relid=0 | w=10
  506. LANL -- r_associated #0: 10 / 0.909 -> en:lymphosarcoma
    n1=LANL | n2=en:lymphosarcoma | rel=r_associated | relid=0 | w=10
  507. LANL -- r_associated #0: 10 / 0.909 -> en:m5b acute differentiated monocytic leukemia
    n1=LANL | n2=en:m5b acute differentiated monocytic leukemia | rel=r_associated | relid=0 | w=10
  508. LANL -- r_associated #0: 10 / 0.909 -> en:malaria
    n1=LANL | n2=en:malaria | rel=r_associated | relid=0 | w=10
  509. LANL -- r_associated #0: 10 / 0.909 -> en:male breast carcinoma
    n1=LANL | n2=en:male breast carcinoma | rel=r_associated | relid=0 | w=10
  510. LANL -- r_associated #0: 10 / 0.909 -> en:male germ cell tumors (gct), 2 subtypes -
    n1=LANL | n2=en:male germ cell tumors (gct), 2 subtypes - | rel=r_associated | relid=0 | w=10
  511. LANL -- r_associated #0: 10 / 0.909 -> en:malignancy (34%)
    n1=LANL | n2=en:malignancy (34%) | rel=r_associated | relid=0 | w=10
  512. LANL -- r_associated #0: 10 / 0.909 -> en:malignancy in approximately 10%
    n1=LANL | n2=en:malignancy in approximately 10% | rel=r_associated | relid=0 | w=10
  513. LANL -- r_associated #0: 10 / 0.909 -> en:malignant (primary) neoplasm, unspecified
    n1=LANL | n2=en:malignant (primary) neoplasm, unspecified | rel=r_associated | relid=0 | w=10
  514. LANL -- r_associated #0: 10 / 0.909 -> en:malignant adrenal gland neoplasm
    n1=LANL | n2=en:malignant adrenal gland neoplasm | rel=r_associated | relid=0 | w=10
  515. LANL -- r_associated #0: 10 / 0.909 -> en:malignant bladder neoplasm
    n1=LANL | n2=en:malignant bladder neoplasm | rel=r_associated | relid=0 | w=10
  516. LANL -- r_associated #0: 10 / 0.909 -> en:malignant bone neoplasm
    n1=LANL | n2=en:malignant bone neoplasm | rel=r_associated | relid=0 | w=10
  517. LANL -- r_associated #0: 10 / 0.909 -> en:malignant breast neoplasm
    n1=LANL | n2=en:malignant breast neoplasm | rel=r_associated | relid=0 | w=10
  518. LANL -- r_associated #0: 10 / 0.909 -> en:malignant cell
    n1=LANL | n2=en:malignant cell | rel=r_associated | relid=0 | w=10
  519. LANL -- r_associated #0: 10 / 0.909 -> en:malignant central nervous system neoplasm
    n1=LANL | n2=en:malignant central nervous system neoplasm | rel=r_associated | relid=0 | w=10
  520. LANL -- r_associated #0: 10 / 0.909 -> en:malignant digestive system neoplasm
    n1=LANL | n2=en:malignant digestive system neoplasm | rel=r_associated | relid=0 | w=10
  521. LANL -- r_associated #0: 10 / 0.909 -> en:malignant endocrine neoplasm
    n1=LANL | n2=en:malignant endocrine neoplasm | rel=r_associated | relid=0 | w=10
  522. LANL -- r_associated #0: 10 / 0.909 -> en:malignant epithelial neoplasms (all subtypes)
    n1=LANL | n2=en:malignant epithelial neoplasms (all subtypes) | rel=r_associated | relid=0 | w=10
  523. LANL -- r_associated #0: 10 / 0.909 -> en:malignant esophageal neoplasm
    n1=LANL | n2=en:malignant esophageal neoplasm | rel=r_associated | relid=0 | w=10
  524. LANL -- r_associated #0: 10 / 0.909 -> en:malignant eye neoplasm
    n1=LANL | n2=en:malignant eye neoplasm | rel=r_associated | relid=0 | w=10
  525. LANL -- r_associated #0: 10 / 0.909 -> en:malignant fibromatous neoplasm
    n1=LANL | n2=en:malignant fibromatous neoplasm | rel=r_associated | relid=0 | w=10
  526. LANL -- r_associated #0: 10 / 0.909 -> en:malignant fibrous histiocytoma (in about 35% of patients)
    n1=LANL | n2=en:malignant fibrous histiocytoma (in about 35% of patients) | rel=r_associated | relid=0 | w=10
  527. LANL -- r_associated #0: 10 / 0.909 -> en:malignant gastric neoplasm
    n1=LANL | n2=en:malignant gastric neoplasm | rel=r_associated | relid=0 | w=10
  528. LANL -- r_associated #0: 10 / 0.909 -> en:malignant genitourinary tract tumor
    n1=LANL | n2=en:malignant genitourinary tract tumor | rel=r_associated | relid=0 | w=10
  529. LANL -- r_associated #0: 10 / 0.909 -> en:malignant giant cell neoplasm
    n1=LANL | n2=en:malignant giant cell neoplasm | rel=r_associated | relid=0 | w=10
  530. LANL -- r_associated #0: 10 / 0.909 -> en:malignant head and neck neoplasm
    n1=LANL | n2=en:malignant head and neck neoplasm | rel=r_associated | relid=0 | w=10
  531. LANL -- r_associated #0: 10 / 0.909 -> en:malignant intestinal neoplasm
    n1=LANL | n2=en:malignant intestinal neoplasm | rel=r_associated | relid=0 | w=10
  532. LANL -- r_associated #0: 10 / 0.909 -> en:malignant kidney neoplasm
    n1=LANL | n2=en:malignant kidney neoplasm | rel=r_associated | relid=0 | w=10
  533. LANL -- r_associated #0: 10 / 0.909 -> en:malignant lipomatous neoplasm
    n1=LANL | n2=en:malignant lipomatous neoplasm | rel=r_associated | relid=0 | w=10
  534. LANL -- r_associated #0: 10 / 0.909 -> en:malignant lung neoplasm
    n1=LANL | n2=en:malignant lung neoplasm | rel=r_associated | relid=0 | w=10
  535. LANL -- r_associated #0: 10 / 0.909 -> en:malignant muscle neoplasm
    n1=LANL | n2=en:malignant muscle neoplasm | rel=r_associated | relid=0 | w=10
  536. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm
    n1=LANL | n2=en:malignant neoplasm | rel=r_associated | relid=0 | w=10
  537. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm (morphology)
    n1=LANL | n2=en:malignant neoplasm (morphology) | rel=r_associated | relid=0 | w=10
  538. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm after immunosuppressive therapy
    n1=LANL | n2=en:malignant neoplasm after immunosuppressive therapy | rel=r_associated | relid=0 | w=10
  539. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm associated with aids
    n1=LANL | n2=en:malignant neoplasm associated with aids | rel=r_associated | relid=0 | w=10
  540. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm associated with transplant organ
    n1=LANL | n2=en:malignant neoplasm associated with transplant organ | rel=r_associated | relid=0 | w=10
  541. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm by grade
    n1=LANL | n2=en:malignant neoplasm by grade | rel=r_associated | relid=0 | w=10
  542. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm growth accelerated
    n1=LANL | n2=en:malignant neoplasm growth accelerated | rel=r_associated | relid=0 | w=10
  543. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm musculoskeletal
    n1=LANL | n2=en:malignant neoplasm musculoskeletal | rel=r_associated | relid=0 | w=10
  544. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm of abdomen
    n1=LANL | n2=en:malignant neoplasm of abdomen | rel=r_associated | relid=0 | w=10
  545. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm of anorectum
    n1=LANL | n2=en:malignant neoplasm of anorectum | rel=r_associated | relid=0 | w=10
  546. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm of bone, connective tissue, skin and breast
    n1=LANL | n2=en:malignant neoplasm of bone, connective tissue, skin and breast | rel=r_associated | relid=0 | w=10
  547. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm of connective tissue
    n1=LANL | n2=en:malignant neoplasm of connective tissue | rel=r_associated | relid=0 | w=10
  548. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm of digestive organs and peritoneum
    n1=LANL | n2=en:malignant neoplasm of digestive organs and peritoneum | rel=r_associated | relid=0 | w=10
  549. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm of gartner's duct
    n1=LANL | n2=en:malignant neoplasm of gartner's duct | rel=r_associated | relid=0 | w=10
  550. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm of genitourinary organ
    n1=LANL | n2=en:malignant neoplasm of genitourinary organ | rel=r_associated | relid=0 | w=10
  551. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm of lip, oral cavity and pharynx
    n1=LANL | n2=en:malignant neoplasm of lip, oral cavity and pharynx | rel=r_associated | relid=0 | w=10
  552. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm of liver
    n1=LANL | n2=en:malignant neoplasm of liver | rel=r_associated | relid=0 | w=10
  553. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm of lower limb
    n1=LANL | n2=en:malignant neoplasm of lower limb | rel=r_associated | relid=0 | w=10
  554. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm of multiple primary sites
    n1=LANL | n2=en:malignant neoplasm of multiple primary sites | rel=r_associated | relid=0 | w=10
  555. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm of other and ill-defined sites: other ill-defined sites
    n1=LANL | n2=en:malignant neoplasm of other and ill-defined sites: other ill-defined sites | rel=r_associated | relid=0 | w=10
  556. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm of other and unspecified sites
    n1=LANL | n2=en:malignant neoplasm of other and unspecified sites | rel=r_associated | relid=0 | w=10
  557. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm of other specified sites
    n1=LANL | n2=en:malignant neoplasm of other specified sites | rel=r_associated | relid=0 | w=10
  558. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm of pelvis
    n1=LANL | n2=en:malignant neoplasm of pelvis | rel=r_associated | relid=0 | w=10
  559. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm of respiratory system
    n1=LANL | n2=en:malignant neoplasm of respiratory system | rel=r_associated | relid=0 | w=10
  560. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm of skeletal system
    n1=LANL | n2=en:malignant neoplasm of skeletal system | rel=r_associated | relid=0 | w=10
  561. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm of thoracic vertebral column
    n1=LANL | n2=en:malignant neoplasm of thoracic vertebral column | rel=r_associated | relid=0 | w=10
  562. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm of upper limb nos
    n1=LANL | n2=en:malignant neoplasm of upper limb nos | rel=r_associated | relid=0 | w=10
  563. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm, primary site unknown, so stated
    n1=LANL | n2=en:malignant neoplasm, primary site unknown, so stated | rel=r_associated | relid=0 | w=10
  564. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasm, uncertain whether primary or metastatic
    n1=LANL | n2=en:malignant neoplasm, uncertain whether primary or metastatic | rel=r_associated | relid=0 | w=10
  565. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasms of ill-defined, secondary and unspecified sites
    n1=LANL | n2=en:malignant neoplasms of ill-defined, secondary and unspecified sites | rel=r_associated | relid=0 | w=10
  566. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasms of respiratory and intrathoracic organs
    n1=LANL | n2=en:malignant neoplasms of respiratory and intrathoracic organs | rel=r_associated | relid=0 | w=10
  567. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue
    n1=LANL | n2=en:malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue | rel=r_associated | relid=0 | w=10
  568. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic and related tissue
    n1=LANL | n2=en:malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic and related tissue | rel=r_associated | relid=0 | w=10
  569. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplastic disease co-occurrent with human immunodeficiency virus infection
    n1=LANL | n2=en:malignant neoplastic disease co-occurrent with human immunodeficiency virus infection | rel=r_associated | relid=0 | w=10
  570. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplastic disease in mother complicating childbirth
    n1=LANL | n2=en:malignant neoplastic disease in mother complicating childbirth | rel=r_associated | relid=0 | w=10
  571. LANL -- r_associated #0: 10 / 0.909 -> en:malignant neoplastic disease in pregnancy
    n1=LANL | n2=en:malignant neoplastic disease in pregnancy | rel=r_associated | relid=0 | w=10
  572. LANL -- r_associated #0: 10 / 0.909 -> en:malignant nervous system neoplasm
    n1=LANL | n2=en:malignant nervous system neoplasm | rel=r_associated | relid=0 | w=10
  573. LANL -- r_associated #0: 10 / 0.909 -> en:malignant ovarian neoplasm
    n1=LANL | n2=en:malignant ovarian neoplasm | rel=r_associated | relid=0 | w=10
  574. LANL -- r_associated #0: 10 / 0.909 -> en:malignant pancreatic neoplasm
    n1=LANL | n2=en:malignant pancreatic neoplasm | rel=r_associated | relid=0 | w=10
  575. LANL -- r_associated #0: 10 / 0.909 -> en:malignant peripheral nerve sheath tumor
    n1=LANL | n2=en:malignant peripheral nerve sheath tumor | rel=r_associated | relid=0 | w=10
  576. LANL -- r_associated #0: 10 / 0.909 -> en:malignant peripheral nerve sheath tumors (21%)
    n1=LANL | n2=en:malignant peripheral nerve sheath tumors (21%) | rel=r_associated | relid=0 | w=10
  577. LANL -- r_associated #0: 10 / 0.909 -> en:malignant pharyngeal neoplasm
    n1=LANL | n2=en:malignant pharyngeal neoplasm | rel=r_associated | relid=0 | w=10
  578. LANL -- r_associated #0: 10 / 0.909 -> en:malignant salivary gland neoplasm
    n1=LANL | n2=en:malignant salivary gland neoplasm | rel=r_associated | relid=0 | w=10
  579. LANL -- r_associated #0: 10 / 0.909 -> en:malignant sex cord-stromal tumor
    n1=LANL | n2=en:malignant sex cord-stromal tumor | rel=r_associated | relid=0 | w=10
  580. LANL -- r_associated #0: 10 / 0.909 -> en:malignant skin appendage neoplasm
    n1=LANL | n2=en:malignant skin appendage neoplasm | rel=r_associated | relid=0 | w=10
  581. LANL -- r_associated #0: 10 / 0.909 -> en:malignant skin neoplasm
    n1=LANL | n2=en:malignant skin neoplasm | rel=r_associated | relid=0 | w=10
  582. LANL -- r_associated #0: 10 / 0.909 -> en:malignant soft tissue neoplasm
    n1=LANL | n2=en:malignant soft tissue neoplasm | rel=r_associated | relid=0 | w=10
  583. LANL -- r_associated #0: 10 / 0.909 -> en:malignant solid tumor
    n1=LANL | n2=en:malignant solid tumor | rel=r_associated | relid=0 | w=10
  584. LANL -- r_associated #0: 10 / 0.909 -> en:malignant spindle cell neoplasm
    n1=LANL | n2=en:malignant spindle cell neoplasm | rel=r_associated | relid=0 | w=10
  585. LANL -- r_associated #0: 10 / 0.909 -> en:malignant testicular neoplasm
    n1=LANL | n2=en:malignant testicular neoplasm | rel=r_associated | relid=0 | w=10
  586. LANL -- r_associated #0: 10 / 0.909 -> en:malignant thoracic neoplasm
    n1=LANL | n2=en:malignant thoracic neoplasm | rel=r_associated | relid=0 | w=10
  587. LANL -- r_associated #0: 10 / 0.909 -> en:malignant thymus neoplasm
    n1=LANL | n2=en:malignant thymus neoplasm | rel=r_associated | relid=0 | w=10
  588. LANL -- r_associated #0: 10 / 0.909 -> en:malignant thyroid gland neoplasm
    n1=LANL | n2=en:malignant thyroid gland neoplasm | rel=r_associated | relid=0 | w=10
  589. LANL -- r_associated #0: 10 / 0.909 -> en:malignant tumor involving an organ by direct extension from bladder
    n1=LANL | n2=en:malignant tumor involving an organ by direct extension from bladder | rel=r_associated | relid=0 | w=10
  590. LANL -- r_associated #0: 10 / 0.909 -> en:malignant tumor involving an organ by direct extension from endometrium
    n1=LANL | n2=en:malignant tumor involving an organ by direct extension from endometrium | rel=r_associated | relid=0 | w=10
  591. LANL -- r_associated #0: 10 / 0.909 -> en:malignant tumor involving an organ by direct extension from fallopian tube
    n1=LANL | n2=en:malignant tumor involving an organ by direct extension from fallopian tube | rel=r_associated | relid=0 | w=10
  592. LANL -- r_associated #0: 10 / 0.909 -> en:malignant tumor involving an organ by direct extension from ovary
    n1=LANL | n2=en:malignant tumor involving an organ by direct extension from ovary | rel=r_associated | relid=0 | w=10
  593. LANL -- r_associated #0: 10 / 0.909 -> en:malignant tumor involving an organ by direct extension from prostate
    n1=LANL | n2=en:malignant tumor involving an organ by direct extension from prostate | rel=r_associated | relid=0 | w=10
  594. LANL -- r_associated #0: 10 / 0.909 -> en:malignant tumor involving an organ by direct extension from uterine cervix
    n1=LANL | n2=en:malignant tumor involving an organ by direct extension from uterine cervix | rel=r_associated | relid=0 | w=10
  595. LANL -- r_associated #0: 10 / 0.909 -> en:malignant tumor involving an organ by direct extension from uterus
    n1=LANL | n2=en:malignant tumor involving an organ by direct extension from uterus | rel=r_associated | relid=0 | w=10
  596. LANL -- r_associated #0: 10 / 0.909 -> en:malignant tumor involving an organ by direct extension from vagina
    n1=LANL | n2=en:malignant tumor involving an organ by direct extension from vagina | rel=r_associated | relid=0 | w=10
  597. LANL -- r_associated #0: 10 / 0.909 -> en:malignant tumor involving vasa deferentia by direct extension from prostate
    n1=LANL | n2=en:malignant tumor involving vasa deferentia by direct extension from prostate | rel=r_associated | relid=0 | w=10
  598. LANL -- r_associated #0: 10 / 0.909 -> en:malignant tumor of lymphoid hemopoietic and related tissue
    n1=LANL | n2=en:malignant tumor of lymphoid hemopoietic and related tissue | rel=r_associated | relid=0 | w=10
  599. LANL -- r_associated #0: 10 / 0.909 -> en:malignant tumor of nerve sheath origin
    n1=LANL | n2=en:malignant tumor of nerve sheath origin | rel=r_associated | relid=0 | w=10
  600. LANL -- r_associated #0: 10 / 0.909 -> en:malignant tumor of unknown origin or ill-defined site
    n1=LANL | n2=en:malignant tumor of unknown origin or ill-defined site | rel=r_associated | relid=0 | w=10
  601. LANL -- r_associated #0: 10 / 0.909 -> en:malignant tumor, clear cell type
    n1=LANL | n2=en:malignant tumor, clear cell type | rel=r_associated | relid=0 | w=10
  602. LANL -- r_associated #0: 10 / 0.909 -> en:malignant tumor, small cell type
    n1=LANL | n2=en:malignant tumor, small cell type | rel=r_associated | relid=0 | w=10
  603. LANL -- r_associated #0: 10 / 0.909 -> en:malignant urinary system neoplasm
    n1=LANL | n2=en:malignant urinary system neoplasm | rel=r_associated | relid=0 | w=10
  604. LANL -- r_associated #0: 10 / 0.909 -> en:malignant uterine neoplasm
    n1=LANL | n2=en:malignant uterine neoplasm | rel=r_associated | relid=0 | w=10
  605. LANL -- r_associated #0: 10 / 0.909 -> en:malignant vaginal neoplasm
    n1=LANL | n2=en:malignant vaginal neoplasm | rel=r_associated | relid=0 | w=10
  606. LANL -- r_associated #0: 10 / 0.909 -> en:malignant vulvar neoplasm
    n1=LANL | n2=en:malignant vulvar neoplasm | rel=r_associated | relid=0 | w=10
  607. LANL -- r_associated #0: 10 / 0.909 -> en:malignant white blood cell disorder
    n1=LANL | n2=en:malignant white blood cell disorder | rel=r_associated | relid=0 | w=10
  608. LANL -- r_associated #0: 10 / 0.909 -> en:mammary ductal fibroadenoma
    n1=LANL | n2=en:mammary ductal fibroadenoma | rel=r_associated | relid=0 | w=10
  609. LANL -- r_associated #0: 10 / 0.909 -> en:mast cell leukemia
    n1=LANL | n2=en:mast cell leukemia | rel=r_associated | relid=0 | w=10
  610. LANL -- r_associated #0: 10 / 0.909 -> en:mast cell neoplasm
    n1=LANL | n2=en:mast cell neoplasm | rel=r_associated | relid=0 | w=10
  611. LANL -- r_associated #0: 10 / 0.909 -> en:mature b-cell neoplasms (all subtypes)
    n1=LANL | n2=en:mature b-cell neoplasms (all subtypes) | rel=r_associated | relid=0 | w=10
  612. LANL -- r_associated #0: 10 / 0.909 -> en:mature t- and nk-cell neoplasms (all subtypes)
    n1=LANL | n2=en:mature t- and nk-cell neoplasms (all subtypes) | rel=r_associated | relid=0 | w=10
  613. LANL -- r_associated #0: 10 / 0.909 -> en:medicine
    n1=LANL | n2=en:medicine | rel=r_associated | relid=0 | w=10
  614. LANL -- r_associated #0: 10 / 0.909 -> en:medulloblastoma
    n1=LANL | n2=en:medulloblastoma | rel=r_associated | relid=0 | w=10
  615. LANL -- r_associated #0: 10 / 0.909 -> en:megakaryocytic leukemia in remission
    n1=LANL | n2=en:megakaryocytic leukemia in remission | rel=r_associated | relid=0 | w=10
  616. LANL -- r_associated #0: 10 / 0.909 -> en:melanocytic neoplasm
    n1=LANL | n2=en:melanocytic neoplasm | rel=r_associated | relid=0 | w=10
  617. LANL -- r_associated #0: 10 / 0.909 -> en:melanoma
    n1=LANL | n2=en:melanoma | rel=r_associated | relid=0 | w=10
  618. LANL -- r_associated #0: 10 / 0.909 -> en:meningioma
    n1=LANL | n2=en:meningioma | rel=r_associated | relid=0 | w=10
  619. LANL -- r_associated #0: 10 / 0.909 -> en:mesonephric neoplasm
    n1=LANL | n2=en:mesonephric neoplasm | rel=r_associated | relid=0 | w=10
  620. LANL -- r_associated #0: 10 / 0.909 -> en:mesothelial neoplasm
    n1=LANL | n2=en:mesothelial neoplasm | rel=r_associated | relid=0 | w=10
  621. LANL -- r_associated #0: 10 / 0.909 -> en:mesothelioma
    n1=LANL | n2=en:mesothelioma | rel=r_associated | relid=0 | w=10
  622. LANL -- r_associated #0: 10 / 0.909 -> en:mesothelioma, malignant, after asbestos exposure
    n1=LANL | n2=en:mesothelioma, malignant, after asbestos exposure | rel=r_associated | relid=0 | w=10
  623. LANL -- r_associated #0: 10 / 0.909 -> en:metabolic aspects
    n1=LANL | n2=en:metabolic aspects | rel=r_associated | relid=0 | w=10
  624. LANL -- r_associated #0: 10 / 0.909 -> en:metabolic syndrome
    n1=LANL | n2=en:metabolic syndrome | rel=r_associated | relid=0 | w=10
  625. LANL -- r_associated #0: 10 / 0.909 -> en:metachronous malignant neoplasm
    n1=LANL | n2=en:metachronous malignant neoplasm | rel=r_associated | relid=0 | w=10
  626. LANL -- r_associated #0: 10 / 0.909 -> en:metastatic angiosarcoma
    n1=LANL | n2=en:metastatic angiosarcoma | rel=r_associated | relid=0 | w=10
  627. LANL -- r_associated #0: 10 / 0.909 -> en:metastatic malignant neoplasm of unknown primary origin
    n1=LANL | n2=en:metastatic malignant neoplasm of unknown primary origin | rel=r_associated | relid=0 | w=10
  628. LANL -- r_associated #0: 10 / 0.909 -> en:metastatic neoplasm
    n1=LANL | n2=en:metastatic neoplasm | rel=r_associated | relid=0 | w=10
  629. LANL -- r_associated #0: 10 / 0.909 -> en:microbiological
    n1=LANL | n2=en:microbiological | rel=r_associated | relid=0 | w=10
  630. LANL -- r_associated #0: 10 / 0.909 -> en:minimal residual disease
    n1=LANL | n2=en:minimal residual disease | rel=r_associated | relid=0 | w=10
  631. LANL -- r_associated #0: 10 / 0.909 -> en:mir29b1 gene
    n1=LANL | n2=en:mir29b1 gene | rel=r_associated | relid=0 | w=10
  632. LANL -- r_associated #0: 10 / 0.909 -> en:mir29b1 wt allele
    n1=LANL | n2=en:mir29b1 wt allele | rel=r_associated | relid=0 | w=10
  633. LANL -- r_associated #0: 10 / 0.909 -> en:mir29b2 gene
    n1=LANL | n2=en:mir29b2 gene | rel=r_associated | relid=0 | w=10
  634. LANL -- r_associated #0: 10 / 0.909 -> en:mir29b2 wt allele
    n1=LANL | n2=en:mir29b2 wt allele | rel=r_associated | relid=0 | w=10
  635. LANL -- r_associated #0: 10 / 0.909 -> en:mir320a gene
    n1=LANL | n2=en:mir320a gene | rel=r_associated | relid=0 | w=10
  636. LANL -- r_associated #0: 10 / 0.909 -> en:mir320a wt allele
    n1=LANL | n2=en:mir320a wt allele | rel=r_associated | relid=0 | w=10
  637. LANL -- r_associated #0: 10 / 0.909 -> en:miscellaneous and site unspecified neoplasms benign
    n1=LANL | n2=en:miscellaneous and site unspecified neoplasms benign | rel=r_associated | relid=0 | w=10
  638. LANL -- r_associated #0: 10 / 0.909 -> en:miscellaneous and site unspecified neoplasms malignant and unspecified
    n1=LANL | n2=en:miscellaneous and site unspecified neoplasms malignant and unspecified | rel=r_associated | relid=0 | w=10
  639. LANL -- r_associated #0: 10 / 0.909 -> en:miscellaneous bone tumors
    n1=LANL | n2=en:miscellaneous bone tumors | rel=r_associated | relid=0 | w=10
  640. LANL -- r_associated #0: 10 / 0.909 -> en:miscellaneous mesenchymal tumors (all subtypes)
    n1=LANL | n2=en:miscellaneous mesenchymal tumors (all subtypes) | rel=r_associated | relid=0 | w=10
  641. LANL -- r_associated #0: 10 / 0.909 -> en:miscellaneous soft tissue tumors (all subtypes)
    n1=LANL | n2=en:miscellaneous soft tissue tumors (all subtypes) | rel=r_associated | relid=0 | w=10
  642. LANL -- r_associated #0: 10 / 0.909 -> en:miscellaneous tumors
    n1=LANL | n2=en:miscellaneous tumors | rel=r_associated | relid=0 | w=10
  643. LANL -- r_associated #0: 10 / 0.909 -> en:mitral valve prolapse
    n1=LANL | n2=en:mitral valve prolapse | rel=r_associated | relid=0 | w=10
  644. LANL -- r_associated #0: 10 / 0.909 -> en:mixed phenotype acute leukemia
    n1=LANL | n2=en:mixed phenotype acute leukemia | rel=r_associated | relid=0 | w=10
  645. LANL -- r_associated #0: 10 / 0.909 -> en:mixed phenotype acute leukemia with t(9;22)(q34;q11.2); bcr-abl1
    n1=LANL | n2=en:mixed phenotype acute leukemia with t(9;22)(q34;q11.2); bcr-abl1 | rel=r_associated | relid=0 | w=10
  646. LANL -- r_associated #0: 10 / 0.909 -> en:mixed phenotype acute leukemia with t(v;11q23); mll rearranged
    n1=LANL | n2=en:mixed phenotype acute leukemia with t(v;11q23); mll rearranged | rel=r_associated | relid=0 | w=10
  647. LANL -- r_associated #0: 10 / 0.909 -> en:mixed phenotype acute leukemia, b/myeloid, not otherwise specified
    n1=LANL | n2=en:mixed phenotype acute leukemia, b/myeloid, not otherwise specified | rel=r_associated | relid=0 | w=10
  648. LANL -- r_associated #0: 10 / 0.909 -> en:mixed phenotype acute leukemia, t/myeloid, not otherwise specified
    n1=LANL | n2=en:mixed phenotype acute leukemia, t/myeloid, not otherwise specified | rel=r_associated | relid=0 | w=10
  649. LANL -- r_associated #0: 10 / 0.909 -> en:mkl/myocardin-like protein 1
    n1=LANL | n2=en:mkl/myocardin-like protein 1 | rel=r_associated | relid=0 | w=10
  650. LANL -- r_associated #0: 10 / 0.909 -> en:mkl1 gene
    n1=LANL | n2=en:mkl1 gene | rel=r_associated | relid=0 | w=10
  651. LANL -- r_associated #0: 10 / 0.909 -> en:moderately differentiated malignant neoplasm
    n1=LANL | n2=en:moderately differentiated malignant neoplasm | rel=r_associated | relid=0 | w=10
  652. LANL -- r_associated #0: 10 / 0.909 -> en:monomorphic cells, medium-sized, with round nuclei, multiple nucleoli, and moderate amount of cytoplasm
    n1=LANL | n2=en:monomorphic cells, medium-sized, with round nuclei, multiple nucleoli, and moderate amount of cytoplasm | rel=r_associated | relid=0 | w=10
  653. LANL -- r_associated #0: 10 / 0.909 -> en:monosomy 7 of bone marrow
    n1=LANL | n2=en:monosomy 7 of bone marrow | rel=r_associated | relid=0 | w=10
  654. LANL -- r_associated #0: 10 / 0.909 -> en:morphology
    n1=LANL | n2=en:morphology | rel=r_associated | relid=0 | w=10
  655. LANL -- r_associated #0: 10 / 0.909 -> en:mouse leukemia
    n1=LANL | n2=en:mouse leukemia | rel=r_associated | relid=0 | w=10
  656. LANL -- r_associated #0: 10 / 0.909 -> en:mucoepidermoid tumor
    n1=LANL | n2=en:mucoepidermoid tumor | rel=r_associated | relid=0 | w=10
  657. LANL -- r_associated #0: 10 / 0.909 -> en:mucosal neuromas
    n1=LANL | n2=en:mucosal neuromas | rel=r_associated | relid=0 | w=10
  658. LANL -- r_associated #0: 10 / 0.909 -> en:multiple bilateral renal angiomyolipoma
    n1=LANL | n2=en:multiple bilateral renal angiomyolipoma | rel=r_associated | relid=0 | w=10
  659. LANL -- r_associated #0: 10 / 0.909 -> en:multiple giant cell granulomas (bones, joints, soft tissues)
    n1=LANL | n2=en:multiple giant cell granulomas (bones, joints, soft tissues) | rel=r_associated | relid=0 | w=10
  660. LANL -- r_associated #0: 10 / 0.909 -> en:multiple malignancy
    n1=LANL | n2=en:multiple malignancy | rel=r_associated | relid=0 | w=10
  661. LANL -- r_associated #0: 10 / 0.909 -> en:multiple schwannomas
    n1=LANL | n2=en:multiple schwannomas | rel=r_associated | relid=0 | w=10
  662. LANL -- r_associated #0: 10 / 0.909 -> en:multiple tumors
    n1=LANL | n2=en:multiple tumors | rel=r_associated | relid=0 | w=10
  663. LANL -- r_associated #0: 10 / 0.909 -> en:multiple tumors in 28% of patients
    n1=LANL | n2=en:multiple tumors in 28% of patients | rel=r_associated | relid=0 | w=10
  664. LANL -- r_associated #0: 10 / 0.909 -> en:multiple tumors in 74% of patients
    n1=LANL | n2=en:multiple tumors in 74% of patients | rel=r_associated | relid=0 | w=10
  665. LANL -- r_associated #0: 10 / 0.909 -> en:muscle tumors (all subtypes)
    n1=LANL | n2=en:muscle tumors (all subtypes) | rel=r_associated | relid=0 | w=10
  666. LANL -- r_associated #0: 10 / 0.909 -> en:myelodysplasia, immunodeficiency, facial dysmorphism, short stature, and psychomotor delay
    n1=LANL | n2=en:myelodysplasia, immunodeficiency, facial dysmorphism, short stature, and psychomotor delay | rel=r_associated | relid=0 | w=10
  667. LANL -- r_associated #0: 10 / 0.909 -> en:myelodysplastic syndrome
    n1=LANL | n2=en:myelodysplastic syndrome | rel=r_associated | relid=0 | w=10
  668. LANL -- r_associated #0: 10 / 0.909 -> en:myeloid leukemia
    n1=LANL | n2=en:myeloid leukemia | rel=r_associated | relid=0 | w=10
  669. LANL -- r_associated #0: 10 / 0.909 -> en:myeloid leukemia associated with down syndrome
    n1=LANL | n2=en:myeloid leukemia associated with down syndrome | rel=r_associated | relid=0 | w=10
  670. LANL -- r_associated #0: 10 / 0.909 -> en:myeloid leukemia in remission
    n1=LANL | n2=en:myeloid leukemia in remission | rel=r_associated | relid=0 | w=10
  671. LANL -- r_associated #0: 10 / 0.909 -> en:myeloid leukemia, unspecified, not having achieved remission
    n1=LANL | n2=en:myeloid leukemia, unspecified, not having achieved remission | rel=r_associated | relid=0 | w=10
  672. LANL -- r_associated #0: 10 / 0.909 -> en:myeloid sarcoma
    n1=LANL | n2=en:myeloid sarcoma | rel=r_associated | relid=0 | w=10
  673. LANL -- r_associated #0: 10 / 0.909 -> en:myelomonocytic leukemia
    n1=LANL | n2=en:myelomonocytic leukemia | rel=r_associated | relid=0 | w=10
  674. LANL -- r_associated #0: 10 / 0.909 -> en:myeloproliferative disease
    n1=LANL | n2=en:myeloproliferative disease | rel=r_associated | relid=0 | w=10
  675. LANL -- r_associated #0: 10 / 0.909 -> en:myeloproliferative neoplasm
    n1=LANL | n2=en:myeloproliferative neoplasm | rel=r_associated | relid=0 | w=10
  676. LANL -- r_associated #0: 10 / 0.909 -> en:myocardial infarction
    n1=LANL | n2=en:myocardial infarction | rel=r_associated | relid=0 | w=10
  677. LANL -- r_associated #0: 10 / 0.909 -> en:myocardial rhabdomyoma
    n1=LANL | n2=en:myocardial rhabdomyoma | rel=r_associated | relid=0 | w=10
  678. LANL -- r_associated #0: 10 / 0.909 -> en:myomatous neoplasm
    n1=LANL | n2=en:myomatous neoplasm | rel=r_associated | relid=0 | w=10
  679. LANL -- r_associated #0: 10 / 0.909 -> en:myosin-11
    n1=LANL | n2=en:myosin-11 | rel=r_associated | relid=0 | w=10
  680. LANL -- r_associated #0: 10 / 0.909 -> en:myxoid subcutaneous tumors
    n1=LANL | n2=en:myxoid subcutaneous tumors | rel=r_associated | relid=0 | w=10
  681. LANL -- r_associated #0: 10 / 0.909 -> en:myxoma
    n1=LANL | n2=en:myxoma | rel=r_associated | relid=0 | w=10
  682. LANL -- r_associated #0: 10 / 0.909 -> en:myxomatous neoplasm
    n1=LANL | n2=en:myxomatous neoplasm | rel=r_associated | relid=0 | w=10
  683. LANL -- r_associated #0: 10 / 0.909 -> en:ncit neoplasm core terminology
    n1=LANL | n2=en:ncit neoplasm core terminology | rel=r_associated | relid=0 | w=10
  684. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasm
    n1=LANL | n2=en:neoplasm | rel=r_associated | relid=0 | w=10
  685. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasm by morphology
    n1=LANL | n2=en:neoplasm by morphology | rel=r_associated | relid=0 | w=10
  686. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasm by site
    n1=LANL | n2=en:neoplasm by site | rel=r_associated | relid=0 | w=10
  687. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasm by special category
    n1=LANL | n2=en:neoplasm by special category | rel=r_associated | relid=0 | w=10
  688. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasm of perivascular myoid type - category
    n1=LANL | n2=en:neoplasm of perivascular myoid type - category | rel=r_associated | relid=0 | w=10
  689. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasm of uncertain behavior of endocrine glands and nervous system
    n1=LANL | n2=en:neoplasm of uncertain behavior of endocrine glands and nervous system | rel=r_associated | relid=0 | w=10
  690. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasm of uncertain behavior of other and unspecified sites and tissues
    n1=LANL | n2=en:neoplasm of uncertain behavior of other and unspecified sites and tissues | rel=r_associated | relid=0 | w=10
  691. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasm of uncertain behavior of other specified sites
    n1=LANL | n2=en:neoplasm of uncertain behavior of other specified sites | rel=r_associated | relid=0 | w=10
  692. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasm of uncertain behavior, site unspecified
    n1=LANL | n2=en:neoplasm of uncertain behavior, site unspecified | rel=r_associated | relid=0 | w=10
  693. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasm of uncertain malignant potential
    n1=LANL | n2=en:neoplasm of uncertain malignant potential | rel=r_associated | relid=0 | w=10
  694. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasm of unspecified nature of bone, soft tissue, and skin
    n1=LANL | n2=en:neoplasm of unspecified nature of bone, soft tissue, and skin | rel=r_associated | relid=0 | w=10
  695. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasm of unspecified nature of endocrine glands and other parts of nervous system
    n1=LANL | n2=en:neoplasm of unspecified nature of endocrine glands and other parts of nervous system | rel=r_associated | relid=0 | w=10
  696. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasm of unspecified nature of other genitourinary organs
    n1=LANL | n2=en:neoplasm of unspecified nature of other genitourinary organs | rel=r_associated | relid=0 | w=10
  697. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasm of unspecified nature of other specified sites
    n1=LANL | n2=en:neoplasm of unspecified nature of other specified sites | rel=r_associated | relid=0 | w=10
  698. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasm of unspecified nature of respiratory system
    n1=LANL | n2=en:neoplasm of unspecified nature of respiratory system | rel=r_associated | relid=0 | w=10
  699. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasm related morbidities
    n1=LANL | n2=en:neoplasm related morbidities | rel=r_associated | relid=0 | w=10
  700. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasm, uncertain whether benign or malignant
    n1=LANL | n2=en:neoplasm, uncertain whether benign or malignant | rel=r_associated | relid=0 | w=10
  701. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasm/cancer invasiveness
    n1=LANL | n2=en:neoplasm/cancer invasiveness | rel=r_associated | relid=0 | w=10
  702. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasm/cancer site
    n1=LANL | n2=en:neoplasm/cancer site | rel=r_associated | relid=0 | w=10
  703. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasm/cancer type
    n1=LANL | n2=en:neoplasm/cancer type | rel=r_associated | relid=0 | w=10
  704. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasms by histologic type
    n1=LANL | n2=en:neoplasms by histologic type | rel=r_associated | relid=0 | w=10
  705. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasms of histiocytes and accessory lymphoid cells
    n1=LANL | n2=en:neoplasms of histiocytes and accessory lymphoid cells | rel=r_associated | relid=0 | w=10
  706. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasms of uncertain or unknown behaviour
    n1=LANL | n2=en:neoplasms of uncertain or unknown behaviour | rel=r_associated | relid=0 | w=10
  707. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasms, adnexal and skin appendage
    n1=LANL | n2=en:neoplasms, adnexal and skin appendage | rel=r_associated | relid=0 | w=10
  708. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasms, connective tissue
    n1=LANL | n2=en:neoplasms, connective tissue | rel=r_associated | relid=0 | w=10
  709. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasms, cystic, mucinous, and serous
    n1=LANL | n2=en:neoplasms, cystic, mucinous, and serous | rel=r_associated | relid=0 | w=10
  710. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasms, experimental
    n1=LANL | n2=en:neoplasms, experimental | rel=r_associated | relid=0 | w=10
  711. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasms, hormone-dependent
    n1=LANL | n2=en:neoplasms, hormone-dependent | rel=r_associated | relid=0 | w=10
  712. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasms, multiple primary
    n1=LANL | n2=en:neoplasms, multiple primary | rel=r_associated | relid=0 | w=10
  713. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasms, post-traumatic
    n1=LANL | n2=en:neoplasms, post-traumatic | rel=r_associated | relid=0 | w=10
  714. LANL -- r_associated #0: 10 / 0.909 -> en:neoplasms, second primary
    n1=LANL | n2=en:neoplasms, second primary | rel=r_associated | relid=0 | w=10
  715. LANL -- r_associated #0: 10 / 0.909 -> en:neoplastic cell
    n1=LANL | n2=en:neoplastic cell | rel=r_associated | relid=0 | w=10
  716. LANL -- r_associated #0: 10 / 0.909 -> en:neoplastic hematopoietic and lymphoid cell
    n1=LANL | n2=en:neoplastic hematopoietic and lymphoid cell | rel=r_associated | relid=0 | w=10
  717. LANL -- r_associated #0: 10 / 0.909 -> en:neoplastic lymphoblast
    n1=LANL | n2=en:neoplastic lymphoblast | rel=r_associated | relid=0 | w=10
  718. LANL -- r_associated #0: 10 / 0.909 -> en:neoplastic myeloid cell
    n1=LANL | n2=en:neoplastic myeloid cell | rel=r_associated | relid=0 | w=10
  719. LANL -- r_associated #0: 10 / 0.909 -> en:neoplastic processes
    n1=LANL | n2=en:neoplastic processes | rel=r_associated | relid=0 | w=10
  720. LANL -- r_associated #0: 10 / 0.909 -> en:nerve sheath neoplasm
    n1=LANL | n2=en:nerve sheath neoplasm | rel=r_associated | relid=0 | w=10
  721. LANL -- r_associated #0: 10 / 0.909 -> en:nervous system neoplasm
    n1=LANL | n2=en:nervous system neoplasm | rel=r_associated | relid=0 | w=10
  722. LANL -- r_associated #0: 10 / 0.909 -> en:nervous system neoplasms malignant and unspecified nec
    n1=LANL | n2=en:nervous system neoplasms malignant and unspecified nec | rel=r_associated | relid=0 | w=10
  723. LANL -- r_associated #0: 10 / 0.909 -> en:nervous system tumor morphology
    n1=LANL | n2=en:nervous system tumor morphology | rel=r_associated | relid=0 | w=10
  724. LANL -- r_associated #0: 10 / 0.909 -> en:neural tissue tumors
    n1=LANL | n2=en:neural tissue tumors | rel=r_associated | relid=0 | w=10
  725. LANL -- r_associated #0: 10 / 0.909 -> en:neuroblastoma
    n1=LANL | n2=en:neuroblastoma | rel=r_associated | relid=0 | w=10
  726. LANL -- r_associated #0: 10 / 0.909 -> en:neuroblastoma (less common)
    n1=LANL | n2=en:neuroblastoma (less common) | rel=r_associated | relid=0 | w=10
  727. LANL -- r_associated #0: 10 / 0.909 -> en:neuroblastoma, arises anywhere along the sympathetic chain (including intracranially)
    n1=LANL | n2=en:neuroblastoma, arises anywhere along the sympathetic chain (including intracranially) | rel=r_associated | relid=0 | w=10
  728. LANL -- r_associated #0: 10 / 0.909 -> en:neuroendocrine neoplasm
    n1=LANL | n2=en:neuroendocrine neoplasm | rel=r_associated | relid=0 | w=10
  729. LANL -- r_associated #0: 10 / 0.909 -> en:neuroepitheliomatous neoplasm
    n1=LANL | n2=en:neuroepitheliomatous neoplasm | rel=r_associated | relid=0 | w=10
  730. LANL -- r_associated #0: 10 / 0.909 -> en:neurofibroma
    n1=LANL | n2=en:neurofibroma | rel=r_associated | relid=0 | w=10
  731. LANL -- r_associated #0: 10 / 0.909 -> en:neurofibromatosis
    n1=LANL | n2=en:neurofibromatosis | rel=r_associated | relid=0 | w=10
  732. LANL -- r_associated #0: 10 / 0.909 -> en:neuronal or mixed neuronal-glial neoplasm
    n1=LANL | n2=en:neuronal or mixed neuronal-glial neoplasm | rel=r_associated | relid=0 | w=10
  733. LANL -- r_associated #0: 10 / 0.909 -> en:neutrophilic leukemia
    n1=LANL | n2=en:neutrophilic leukemia | rel=r_associated | relid=0 | w=10
  734. LANL -- r_associated #0: 10 / 0.909 -> en:nevi and melanomas
    n1=LANL | n2=en:nevi and melanomas | rel=r_associated | relid=0 | w=10
  735. LANL -- r_associated #0: 10 / 0.909 -> en:nevus and/or melanoma
    n1=LANL | n2=en:nevus and/or melanoma | rel=r_associated | relid=0 | w=10
  736. LANL -- r_associated #0: 10 / 0.909 -> en:no cancer despite harboring complete deletions of the tp53 gene
    n1=LANL | n2=en:no cancer despite harboring complete deletions of the tp53 gene | rel=r_associated | relid=0 | w=10
  737. LANL -- r_associated #0: 10 / 0.909 -> en:no progression to cancer
    n1=LANL | n2=en:no progression to cancer | rel=r_associated | relid=0 | w=10
  738. LANL -- r_associated #0: 10 / 0.909 -> en:non-hematologic malignancy
    n1=LANL | n2=en:non-hematologic malignancy | rel=r_associated | relid=0 | w=10
  739. LANL -- r_associated #0: 10 / 0.909 -> en:non-hodgkin lymphoma
    n1=LANL | n2=en:non-hodgkin lymphoma | rel=r_associated | relid=0 | w=10
  740. LANL -- r_associated #0: 10 / 0.909 -> en:nonestrogen-dependent cancer
    n1=LANL | n2=en:nonestrogen-dependent cancer | rel=r_associated | relid=0 | w=10
  741. LANL -- r_associated #0: 10 / 0.909 -> en:nonmelanoma skin cancer (in some patients)
    n1=LANL | n2=en:nonmelanoma skin cancer (in some patients) | rel=r_associated | relid=0 | w=10
  742. LANL -- r_associated #0: 10 / 0.909 -> en:nonneoplastic disorders/lesions (all subtypes)
    n1=LANL | n2=en:nonneoplastic disorders/lesions (all subtypes) | rel=r_associated | relid=0 | w=10
  743. LANL -- r_associated #0: 10 / 0.909 -> en:nonseminoma (embryonal carcinoma, teratoma, choriocarcinoma, endodermal sinus tumor)
    n1=LANL | n2=en:nonseminoma (embryonal carcinoma, teratoma, choriocarcinoma, endodermal sinus tumor) | rel=r_associated | relid=0 | w=10
  744. LANL -- r_associated #0: 10 / 0.909 -> en:npm1 gene
    n1=LANL | n2=en:npm1 gene | rel=r_associated | relid=0 | w=10
  745. LANL -- r_associated #0: 10 / 0.909 -> en:npm1 wt allele
    n1=LANL | n2=en:npm1 wt allele | rel=r_associated | relid=0 | w=10
  746. LANL -- r_associated #0: 10 / 0.909 -> en:nucleoporin 98kd
    n1=LANL | n2=en:nucleoporin 98kd | rel=r_associated | relid=0 | w=10
  747. LANL -- r_associated #0: 10 / 0.909 -> en:nup98 gene
    n1=LANL | n2=en:nup98 gene | rel=r_associated | relid=0 | w=10
  748. LANL -- r_associated #0: 10 / 0.909 -> en:nup98 wt allele
    n1=LANL | n2=en:nup98 wt allele | rel=r_associated | relid=0 | w=10
  749. LANL -- r_associated #0: 10 / 0.909 -> en:nursing therapy
    n1=LANL | n2=en:nursing therapy | rel=r_associated | relid=0 | w=10
  750. LANL -- r_associated #0: 10 / 0.909 -> en:nutritional management
    n1=LANL | n2=en:nutritional management | rel=r_associated | relid=0 | w=10
  751. LANL -- r_associated #0: 10 / 0.909 -> en:odontogenic neoplasm
    n1=LANL | n2=en:odontogenic neoplasm | rel=r_associated | relid=0 | w=10
  752. LANL -- r_associated #0: 10 / 0.909 -> en:oligodendroglioma
    n1=LANL | n2=en:oligodendroglioma | rel=r_associated | relid=0 | w=10
  753. LANL -- r_associated #0: 10 / 0.909 -> en:oncocytic adenoma
    n1=LANL | n2=en:oncocytic adenoma | rel=r_associated | relid=0 | w=10
  754. LANL -- r_associated #0: 10 / 0.909 -> en:oncogene abl1
    n1=LANL | n2=en:oncogene abl1 | rel=r_associated | relid=0 | w=10
  755. LANL -- r_associated #0: 10 / 0.909 -> en:oncogene kit
    n1=LANL | n2=en:oncogene kit | rel=r_associated | relid=0 | w=10
  756. LANL -- r_associated #0: 10 / 0.909 -> en:optic glioma (19%)
    n1=LANL | n2=en:optic glioma (19%) | rel=r_associated | relid=0 | w=10
  757. LANL -- r_associated #0: 10 / 0.909 -> en:optic nerve glioma
    n1=LANL | n2=en:optic nerve glioma | rel=r_associated | relid=0 | w=10
  758. LANL -- r_associated #0: 10 / 0.909 -> en:oral cavity carcinoma
    n1=LANL | n2=en:oral cavity carcinoma | rel=r_associated | relid=0 | w=10
  759. LANL -- r_associated #0: 10 / 0.909 -> en:oral cavity neoplasm
    n1=LANL | n2=en:oral cavity neoplasm | rel=r_associated | relid=0 | w=10
  760. LANL -- r_associated #0: 10 / 0.909 -> en:oropharyngeal carcinoma
    n1=LANL | n2=en:oropharyngeal carcinoma | rel=r_associated | relid=0 | w=10
  761. LANL -- r_associated #0: 10 / 0.909 -> en:oropharyngeal squamous cell carcinoma
    n1=LANL | n2=en:oropharyngeal squamous cell carcinoma | rel=r_associated | relid=0 | w=10
  762. LANL -- r_associated #0: 10 / 0.909 -> en:osseous and chondromatous neoplasms
    n1=LANL | n2=en:osseous and chondromatous neoplasms | rel=r_associated | relid=0 | w=10
  763. LANL -- r_associated #0: 10 / 0.909 -> en:osseous and/or chondromatous neoplasm
    n1=LANL | n2=en:osseous and/or chondromatous neoplasm | rel=r_associated | relid=0 | w=10
  764. LANL -- r_associated #0: 10 / 0.909 -> en:osteogenic/miscellaneous bone tumors (all subtypes)
    n1=LANL | n2=en:osteogenic/miscellaneous bone tumors (all subtypes) | rel=r_associated | relid=0 | w=10
  765. LANL -- r_associated #0: 10 / 0.909 -> en:osteosarcoma
    n1=LANL | n2=en:osteosarcoma | rel=r_associated | relid=0 | w=10
  766. LANL -- r_associated #0: 10 / 0.909 -> en:osteosarcoma and meningioma especially
    n1=LANL | n2=en:osteosarcoma and meningioma especially | rel=r_associated | relid=0 | w=10
  767. LANL -- r_associated #0: 10 / 0.909 -> en:other hematologic disorders
    n1=LANL | n2=en:other hematologic disorders | rel=r_associated | relid=0 | w=10
  768. LANL -- r_associated #0: 10 / 0.909 -> en:other leukaemia of unspecified cell type
    n1=LANL | n2=en:other leukaemia of unspecified cell type | rel=r_associated | relid=0 | w=10
  769. LANL -- r_associated #0: 10 / 0.909 -> en:other leukemia
    n1=LANL | n2=en:other leukemia | rel=r_associated | relid=0 | w=10
  770. LANL -- r_associated #0: 10 / 0.909 -> en:other leukemia of unspecified cell type without mention of remission
    n1=LANL | n2=en:other leukemia of unspecified cell type without mention of remission | rel=r_associated | relid=0 | w=10
  771. LANL -- r_associated #0: 10 / 0.909 -> en:other myeloid leukaemia
    n1=LANL | n2=en:other myeloid leukaemia | rel=r_associated | relid=0 | w=10
  772. LANL -- r_associated #0: 10 / 0.909 -> en:other myeloid leukemia without mention of remission
    n1=LANL | n2=en:other myeloid leukemia without mention of remission | rel=r_associated | relid=0 | w=10
  773. LANL -- r_associated #0: 10 / 0.909 -> en:other specified leukemia (disorder)
    n1=LANL | n2=en:other specified leukemia (disorder) | rel=r_associated | relid=0 | w=10
  774. LANL -- r_associated #0: 10 / 0.909 -> en:other specified leukemia without mention of remission
    n1=LANL | n2=en:other specified leukemia without mention of remission | rel=r_associated | relid=0 | w=10
  775. LANL -- r_associated #0: 10 / 0.909 -> en:ovarian carcinoma
    n1=LANL | n2=en:ovarian carcinoma | rel=r_associated | relid=0 | w=10
  776. LANL -- r_associated #0: 10 / 0.909 -> en:ovarian cystadenoma
    n1=LANL | n2=en:ovarian cystadenoma | rel=r_associated | relid=0 | w=10
  777. LANL -- r_associated #0: 10 / 0.909 -> en:ovarian sex cord-stromal tumor
    n1=LANL | n2=en:ovarian sex cord-stromal tumor | rel=r_associated | relid=0 | w=10
  778. LANL -- r_associated #0: 10 / 0.909 -> en:pacemakers and implantable defibrillators
    n1=LANL | n2=en:pacemakers and implantable defibrillators | rel=r_associated | relid=0 | w=10
  779. LANL -- r_associated #0: 10 / 0.909 -> en:pancreatic adenocarcinoma
    n1=LANL | n2=en:pancreatic adenocarcinoma | rel=r_associated | relid=0 | w=10
  780. LANL -- r_associated #0: 10 / 0.909 -> en:pancreatic carcinoma
    n1=LANL | n2=en:pancreatic carcinoma | rel=r_associated | relid=0 | w=10
  781. LANL -- r_associated #0: 10 / 0.909 -> en:pancreatic squamous cell carcinoma
    n1=LANL | n2=en:pancreatic squamous cell carcinoma | rel=r_associated | relid=0 | w=10
  782. LANL -- r_associated #0: 10 / 0.909 -> en:papillary neoplasm
    n1=LANL | n2=en:papillary neoplasm | rel=r_associated | relid=0 | w=10
  783. LANL -- r_associated #0: 10 / 0.909 -> en:papillary renal cell carcinoma
    n1=LANL | n2=en:papillary renal cell carcinoma | rel=r_associated | relid=0 | w=10
  784. LANL -- r_associated #0: 10 / 0.909 -> en:papillary thyroid carcinoma (rare)
    n1=LANL | n2=en:papillary thyroid carcinoma (rare) | rel=r_associated | relid=0 | w=10
  785. LANL -- r_associated #0: 10 / 0.909 -> en:paraganglioma
    n1=LANL | n2=en:paraganglioma | rel=r_associated | relid=0 | w=10
  786. LANL -- r_associated #0: 10 / 0.909 -> en:paraganglioma and/or glomus tumor
    n1=LANL | n2=en:paraganglioma and/or glomus tumor | rel=r_associated | relid=0 | w=10
  787. LANL -- r_associated #0: 10 / 0.909 -> en:paraganglioma, catecholamine-secreting
    n1=LANL | n2=en:paraganglioma, catecholamine-secreting | rel=r_associated | relid=0 | w=10
  788. LANL -- r_associated #0: 10 / 0.909 -> en:paragangliomas, head and neck (31%)
    n1=LANL | n2=en:paragangliomas, head and neck (31%) | rel=r_associated | relid=0 | w=10
  789. LANL -- r_associated #0: 10 / 0.909 -> en:paragangliomas, head and neck (79%)
    n1=LANL | n2=en:paragangliomas, head and neck (79%) | rel=r_associated | relid=0 | w=10
  790. LANL -- r_associated #0: 10 / 0.909 -> en:paraneoplastic sps is associated with autoantibodies to amphiphysin (amph, 600418)
    n1=LANL | n2=en:paraneoplastic sps is associated with autoantibodies to amphiphysin (amph, 600418) | rel=r_associated | relid=0 | w=10
  791. LANL -- r_associated #0: 10 / 0.909 -> en:paraneoplastic sps is associated with breast cancer and other malignancies
    n1=LANL | n2=en:paraneoplastic sps is associated with breast cancer and other malignancies | rel=r_associated | relid=0 | w=10
  792. LANL -- r_associated #0: 10 / 0.909 -> en:paraneoplastic syndrome
    n1=LANL | n2=en:paraneoplastic syndrome | rel=r_associated | relid=0 | w=10
  793. LANL -- r_associated #0: 10 / 0.909 -> en:parasitology
    n1=LANL | n2=en:parasitology | rel=r_associated | relid=0 | w=10
  794. LANL -- r_associated #0: 10 / 0.909 -> en:parathyroid disease rare
    n1=LANL | n2=en:parathyroid disease rare | rel=r_associated | relid=0 | w=10
  795. LANL -- r_associated #0: 10 / 0.909 -> en:parathyroid gland adenoma
    n1=LANL | n2=en:parathyroid gland adenoma | rel=r_associated | relid=0 | w=10
  796. LANL -- r_associated #0: 10 / 0.909 -> en:parathyroid gland carcinoma
    n1=LANL | n2=en:parathyroid gland carcinoma | rel=r_associated | relid=0 | w=10
  797. LANL -- r_associated #0: 10 / 0.909 -> en:parotid gland adenoma and adenocarcinoma
    n1=LANL | n2=en:parotid gland adenoma and adenocarcinoma | rel=r_associated | relid=0 | w=10
  798. LANL -- r_associated #0: 10 / 0.909 -> en:parotid gland monomorphic adenoma
    n1=LANL | n2=en:parotid gland monomorphic adenoma | rel=r_associated | relid=0 | w=10
  799. LANL -- r_associated #0: 10 / 0.909 -> en:parotid oncocytomas
    n1=LANL | n2=en:parotid oncocytomas | rel=r_associated | relid=0 | w=10
  800. LANL -- r_associated #0: 10 / 0.909 -> en:pathological aspects
    n1=LANL | n2=en:pathological aspects | rel=r_associated | relid=0 | w=10
  801. LANL -- r_associated #0: 10 / 0.909 -> en:pediatric adverse events terminology
    n1=LANL | n2=en:pediatric adverse events terminology | rel=r_associated | relid=0 | w=10
  802. LANL -- r_associated #0: 10 / 0.909 -> en:pediatric terminology
    n1=LANL | n2=en:pediatric terminology | rel=r_associated | relid=0 | w=10
  803. LANL -- r_associated #0: 10 / 0.909 -> en:periampullary carcinoma nos
    n1=LANL | n2=en:periampullary carcinoma nos | rel=r_associated | relid=0 | w=10
  804. LANL -- r_associated #0: 10 / 0.909 -> en:periodontitis co-occurrent with leukemia
    n1=LANL | n2=en:periodontitis co-occurrent with leukemia | rel=r_associated | relid=0 | w=10
  805. LANL -- r_associated #0: 10 / 0.909 -> en:peripheral arterial disorder
    n1=LANL | n2=en:peripheral arterial disorder | rel=r_associated | relid=0 | w=10
  806. LANL -- r_associated #0: 10 / 0.909 -> en:pharmacotherapeutic
    n1=LANL | n2=en:pharmacotherapeutic | rel=r_associated | relid=0 | w=10
  807. LANL -- r_associated #0: 10 / 0.909 -> en:pheochromocytoma, adrenal (53%)
    n1=LANL | n2=en:pheochromocytoma, adrenal (53%) | rel=r_associated | relid=0 | w=10
  808. LANL -- r_associated #0: 10 / 0.909 -> en:pheochromocytoma, extraadrenal (21%)
    n1=LANL | n2=en:pheochromocytoma, extraadrenal (21%) | rel=r_associated | relid=0 | w=10
  809. LANL -- r_associated #0: 10 / 0.909 -> en:pheochromocytomas, adrenal (28%)
    n1=LANL | n2=en:pheochromocytomas, adrenal (28%) | rel=r_associated | relid=0 | w=10
  810. LANL -- r_associated #0: 10 / 0.909 -> en:pheochromocytomas, extraadrenal (48%)
    n1=LANL | n2=en:pheochromocytomas, extraadrenal (48%) | rel=r_associated | relid=0 | w=10
  811. LANL -- r_associated #0: 10 / 0.909 -> en:philadelphia chromosome positive, bcr-abl1 positive chronic myelogenous leukemia
    n1=LANL | n2=en:philadelphia chromosome positive, bcr-abl1 positive chronic myelogenous leukemia | rel=r_associated | relid=0 | w=10
  812. LANL -- r_associated #0: 10 / 0.909 -> en:philadelphia-negative myelogenous leukemia
    n1=LANL | n2=en:philadelphia-negative myelogenous leukemia | rel=r_associated | relid=0 | w=10
  813. LANL -- r_associated #0: 10 / 0.909 -> en:philadelphia-positive myelogenous leukemia
    n1=LANL | n2=en:philadelphia-positive myelogenous leukemia | rel=r_associated | relid=0 | w=10
  814. LANL -- r_associated #0: 10 / 0.909 -> en:phyllodes tumor
    n1=LANL | n2=en:phyllodes tumor | rel=r_associated | relid=0 | w=10
  815. LANL -- r_associated #0: 10 / 0.909 -> en:physiopathological
    n1=LANL | n2=en:physiopathological | rel=r_associated | relid=0 | w=10
  816. LANL -- r_associated #0: 10 / 0.909 -> en:pigmentation
    n1=LANL | n2=en:pigmentation | rel=r_associated | relid=0 | w=10
  817. LANL -- r_associated #0: 10 / 0.909 -> en:pilocytic astrocytoma
    n1=LANL | n2=en:pilocytic astrocytoma | rel=r_associated | relid=0 | w=10
  818. LANL -- r_associated #0: 10 / 0.909 -> en:pinealoma (trilateral retinoblastoma)
    n1=LANL | n2=en:pinealoma (trilateral retinoblastoma) | rel=r_associated | relid=0 | w=10
  819. LANL -- r_associated #0: 10 / 0.909 -> en:pituitary gland adenoma
    n1=LANL | n2=en:pituitary gland adenoma | rel=r_associated | relid=0 | w=10
  820. LANL -- r_associated #0: 10 / 0.909 -> en:pituitary gland neoplasm
    n1=LANL | n2=en:pituitary gland neoplasm | rel=r_associated | relid=0 | w=10
  821. LANL -- r_associated #0: 10 / 0.909 -> en:plant morphology
    n1=LANL | n2=en:plant morphology | rel=r_associated | relid=0 | w=10
  822. LANL -- r_associated #0: 10 / 0.909 -> en:plasma cell leukemia
    n1=LANL | n2=en:plasma cell leukemia | rel=r_associated | relid=0 | w=10
  823. LANL -- r_associated #0: 10 / 0.909 -> en:plasma cell myeloma
    n1=LANL | n2=en:plasma cell myeloma | rel=r_associated | relid=0 | w=10
  824. LANL -- r_associated #0: 10 / 0.909 -> en:plasma cell neoplasm
    n1=LANL | n2=en:plasma cell neoplasm | rel=r_associated | relid=0 | w=10
  825. LANL -- r_associated #0: 10 / 0.909 -> en:plasma cell neoplasms (all subtypes)
    n1=LANL | n2=en:plasma cell neoplasms (all subtypes) | rel=r_associated | relid=0 | w=10
  826. LANL -- r_associated #0: 10 / 0.909 -> en:plasmacytoma
    n1=LANL | n2=en:plasmacytoma | rel=r_associated | relid=0 | w=10
  827. LANL -- r_associated #0: 10 / 0.909 -> en:platelet disorder, familial, with associated myeloid malignancy
    n1=LANL | n2=en:platelet disorder, familial, with associated myeloid malignancy | rel=r_associated | relid=0 | w=10
  828. LANL -- r_associated #0: 10 / 0.909 -> en:poorly differentiated malignant neoplasm
    n1=LANL | n2=en:poorly differentiated malignant neoplasm | rel=r_associated | relid=0 | w=10
  829. LANL -- r_associated #0: 10 / 0.909 -> en:positive antinuclear antibody test
    n1=LANL | n2=en:positive antinuclear antibody test | rel=r_associated | relid=0 | w=10
  830. LANL -- r_associated #0: 10 / 0.909 -> en:possible increased risk of germ-cell tumors
    n1=LANL | n2=en:possible increased risk of germ-cell tumors | rel=r_associated | relid=0 | w=10
  831. LANL -- r_associated #0: 10 / 0.909 -> en:possibly increased risk for other cancers
    n1=LANL | n2=en:possibly increased risk for other cancers | rel=r_associated | relid=0 | w=10
  832. LANL -- r_associated #0: 10 / 0.909 -> en:possibly increased risk of cancer
    n1=LANL | n2=en:possibly increased risk of cancer | rel=r_associated | relid=0 | w=10
  833. LANL -- r_associated #0: 10 / 0.909 -> en:precancerous condition
    n1=LANL | n2=en:precancerous condition | rel=r_associated | relid=0 | w=10
  834. LANL -- r_associated #0: 10 / 0.909 -> en:precursor lymphoblastic leukemia/lymphoma (all subtypes)
    n1=LANL | n2=en:precursor lymphoblastic leukemia/lymphoma (all subtypes) | rel=r_associated | relid=0 | w=10
  835. LANL -- r_associated #0: 10 / 0.909 -> en:predisposition to uv-induced malignancies
    n1=LANL | n2=en:predisposition to uv-induced malignancies | rel=r_associated | relid=0 | w=10
  836. LANL -- r_associated #0: 10 / 0.909 -> en:pregnancy complications, neoplastic
    n1=LANL | n2=en:pregnancy complications, neoplastic | rel=r_associated | relid=0 | w=10
  837. LANL -- r_associated #0: 10 / 0.909 -> en:preneoplastic state
    n1=LANL | n2=en:preneoplastic state | rel=r_associated | relid=0 | w=10
  838. LANL -- r_associated #0: 10 / 0.909 -> en:primary adrenocortical nodular hyperplasia
    n1=LANL | n2=en:primary adrenocortical nodular hyperplasia | rel=r_associated | relid=0 | w=10
  839. LANL -- r_associated #0: 10 / 0.909 -> en:primary malignant germ cell neoplasm
    n1=LANL | n2=en:primary malignant germ cell neoplasm | rel=r_associated | relid=0 | w=10
  840. LANL -- r_associated #0: 10 / 0.909 -> en:primary malignant liver neoplasm
    n1=LANL | n2=en:primary malignant liver neoplasm | rel=r_associated | relid=0 | w=10
  841. LANL -- r_associated #0: 10 / 0.909 -> en:primary malignant neoplasm
    n1=LANL | n2=en:primary malignant neoplasm | rel=r_associated | relid=0 | w=10
  842. LANL -- r_associated #0: 10 / 0.909 -> en:prolactin-producing pituitary gland adenoma
    n1=LANL | n2=en:prolactin-producing pituitary gland adenoma | rel=r_associated | relid=0 | w=10
  843. LANL -- r_associated #0: 10 / 0.909 -> en:prolymphocytic leukemia
    n1=LANL | n2=en:prolymphocytic leukemia | rel=r_associated | relid=0 | w=10
  844. LANL -- r_associated #0: 10 / 0.909 -> en:propensity to tumor development
    n1=LANL | n2=en:propensity to tumor development | rel=r_associated | relid=0 | w=10
  845. LANL -- r_associated #0: 10 / 0.909 -> en:prostate carcinoma
    n1=LANL | n2=en:prostate carcinoma | rel=r_associated | relid=0 | w=10
  846. LANL -- r_associated #0: 10 / 0.909 -> en:prostate neoplasm
    n1=LANL | n2=en:prostate neoplasm | rel=r_associated | relid=0 | w=10
  847. LANL -- r_associated #0: 10 / 0.909 -> en:protein cbfa2t1
    n1=LANL | n2=en:protein cbfa2t1 | rel=r_associated | relid=0 | w=10
  848. LANL -- r_associated #0: 10 / 0.909 -> en:protein dek
    n1=LANL | n2=en:protein dek | rel=r_associated | relid=0 | w=10
  849. LANL -- r_associated #0: 10 / 0.909 -> en:protozoal cyst
    n1=LANL | n2=en:protozoal cyst | rel=r_associated | relid=0 | w=10
  850. LANL -- r_associated #0: 10 / 0.909 -> en:psammomatous melanotic schwannomas
    n1=LANL | n2=en:psammomatous melanotic schwannomas | rel=r_associated | relid=0 | w=10
  851. LANL -- r_associated #0: 10 / 0.909 -> en:psychological aspect of cancer
    n1=LANL | n2=en:psychological aspect of cancer | rel=r_associated | relid=0 | w=10
  852. LANL -- r_associated #0: 10 / 0.909 -> en:psychology qualifier
    n1=LANL | n2=en:psychology qualifier | rel=r_associated | relid=0 | w=10
  853. LANL -- r_associated #0: 10 / 0.909 -> en:pulmonary hypertension
    n1=LANL | n2=en:pulmonary hypertension | rel=r_associated | relid=0 | w=10
  854. LANL -- r_associated #0: 10 / 0.909 -> en:pura gene
    n1=LANL | n2=en:pura gene | rel=r_associated | relid=0 | w=10
  855. LANL -- r_associated #0: 10 / 0.909 -> en:pura wt allele
    n1=LANL | n2=en:pura wt allele | rel=r_associated | relid=0 | w=10
  856. LANL -- r_associated #0: 10 / 0.909 -> en:radiation therapy
    n1=LANL | n2=en:radiation therapy | rel=r_associated | relid=0 | w=10
  857. LANL -- r_associated #0: 10 / 0.909 -> en:radiation-related leukemia
    n1=LANL | n2=en:radiation-related leukemia | rel=r_associated | relid=0 | w=10
  858. LANL -- r_associated #0: 10 / 0.909 -> en:radiation-related malignant neoplasm
    n1=LANL | n2=en:radiation-related malignant neoplasm | rel=r_associated | relid=0 | w=10
  859. LANL -- r_associated #0: 10 / 0.909 -> en:radiation-related neoplasm
    n1=LANL | n2=en:radiation-related neoplasm | rel=r_associated | relid=0 | w=10
  860. LANL -- r_associated #0: 10 / 0.909 -> en:radiotherapeutic
    n1=LANL | n2=en:radiotherapeutic | rel=r_associated | relid=0 | w=10
  861. LANL -- r_associated #0: 10 / 0.909 -> en:rarely malignant
    n1=LANL | n2=en:rarely malignant | rel=r_associated | relid=0 | w=10
  862. LANL -- r_associated #0: 10 / 0.909 -> en:receptor-type tyrosine-protein kinase flt3
    n1=LANL | n2=en:receptor-type tyrosine-protein kinase flt3 | rel=r_associated | relid=0 | w=10
  863. LANL -- r_associated #0: 10 / 0.909 -> en:recurrent malignant neoplasm
    n1=LANL | n2=en:recurrent malignant neoplasm | rel=r_associated | relid=0 | w=10
  864. LANL -- r_associated #0: 10 / 0.909 -> en:refractory anemia with excess blasts in transformation
    n1=LANL | n2=en:refractory anemia with excess blasts in transformation | rel=r_associated | relid=0 | w=10
  865. LANL -- r_associated #0: 10 / 0.909 -> en:refractory malignant neoplasm
    n1=LANL | n2=en:refractory malignant neoplasm | rel=r_associated | relid=0 | w=10
  866. LANL -- r_associated #0: 10 / 0.909 -> en:rehabilitation aspects
    n1=LANL | n2=en:rehabilitation aspects | rel=r_associated | relid=0 | w=10
  867. LANL -- r_associated #0: 10 / 0.909 -> en:renal and urinary tract neoplasms benign
    n1=LANL | n2=en:renal and urinary tract neoplasms benign | rel=r_associated | relid=0 | w=10
  868. LANL -- r_associated #0: 10 / 0.909 -> en:renal and urinary tract neoplasms malignant and unspecified
    n1=LANL | n2=en:renal and urinary tract neoplasms malignant and unspecified | rel=r_associated | relid=0 | w=10
  869. LANL -- r_associated #0: 10 / 0.909 -> en:renal cell carcinoma
    n1=LANL | n2=en:renal cell carcinoma | rel=r_associated | relid=0 | w=10
  870. LANL -- r_associated #0: 10 / 0.909 -> en:renal cell carcinoma (less common)
    n1=LANL | n2=en:renal cell carcinoma (less common) | rel=r_associated | relid=0 | w=10
  871. LANL -- r_associated #0: 10 / 0.909 -> en:renal cell carcinoma, solitary papillary type 2 (about 20% of patients)
    n1=LANL | n2=en:renal cell carcinoma, solitary papillary type 2 (about 20% of patients) | rel=r_associated | relid=0 | w=10
  872. LANL -- r_associated #0: 10 / 0.909 -> en:renal cell carcinoma, usually clear cell type
    n1=LANL | n2=en:renal cell carcinoma, usually clear cell type | rel=r_associated | relid=0 | w=10
  873. LANL -- r_associated #0: 10 / 0.909 -> en:renal cortical adenoma
    n1=LANL | n2=en:renal cortical adenoma | rel=r_associated | relid=0 | w=10
  874. LANL -- r_associated #0: 10 / 0.909 -> en:reported colon and other abdominal cancer in relatives
    n1=LANL | n2=en:reported colon and other abdominal cancer in relatives | rel=r_associated | relid=0 | w=10
  875. LANL -- r_associated #0: 10 / 0.909 -> en:reproductive and genitourinary neoplasms gender unspecified nec
    n1=LANL | n2=en:reproductive and genitourinary neoplasms gender unspecified nec | rel=r_associated | relid=0 | w=10
  876. LANL -- r_associated #0: 10 / 0.909 -> en:reproductive neoplasms female malignant and unspecified
    n1=LANL | n2=en:reproductive neoplasms female malignant and unspecified | rel=r_associated | relid=0 | w=10
  877. LANL -- r_associated #0: 10 / 0.909 -> en:reproductive neoplasms male malignant and unspecified
    n1=LANL | n2=en:reproductive neoplasms male malignant and unspecified | rel=r_associated | relid=0 | w=10
  878. LANL -- r_associated #0: 10 / 0.909 -> en:respiratory and mediastinal neoplasms benign (excl mesotheliomas)
    n1=LANL | n2=en:respiratory and mediastinal neoplasms benign (excl mesotheliomas) | rel=r_associated | relid=0 | w=10
  879. LANL -- r_associated #0: 10 / 0.909 -> en:respiratory and mediastinal neoplasms malignant and unspecified
    n1=LANL | n2=en:respiratory and mediastinal neoplasms malignant and unspecified | rel=r_associated | relid=0 | w=10
  880. LANL -- r_associated #0: 10 / 0.909 -> en:retinoblastoma
    n1=LANL | n2=en:retinoblastoma | rel=r_associated | relid=0 | w=10
  881. LANL -- r_associated #0: 10 / 0.909 -> en:rh incompatibility
    n1=LANL | n2=en:rh incompatibility | rel=r_associated | relid=0 | w=10
  882. LANL -- r_associated #0: 10 / 0.909 -> en:rhabdoid tumor
    n1=LANL | n2=en:rhabdoid tumor | rel=r_associated | relid=0 | w=10
  883. LANL -- r_associated #0: 10 / 0.909 -> en:rhabdoid tumors, malignant (renal or extrarenal)
    n1=LANL | n2=en:rhabdoid tumors, malignant (renal or extrarenal) | rel=r_associated | relid=0 | w=10
  884. LANL -- r_associated #0: 10 / 0.909 -> en:rhabdomyosarcoma
    n1=LANL | n2=en:rhabdomyosarcoma | rel=r_associated | relid=0 | w=10
  885. LANL -- r_associated #0: 10 / 0.909 -> en:roentgenographic
    n1=LANL | n2=en:roentgenographic | rel=r_associated | relid=0 | w=10
  886. LANL -- r_associated #0: 10 / 0.909 -> en:sacrococcygeal teratoma
    n1=LANL | n2=en:sacrococcygeal teratoma | rel=r_associated | relid=0 | w=10
  887. LANL -- r_associated #0: 10 / 0.909 -> en:sarcoma
    n1=LANL | n2=en:sarcoma | rel=r_associated | relid=0 | w=10
  888. LANL -- r_associated #0: 10 / 0.909 -> en:schwannoma
    n1=LANL | n2=en:schwannoma | rel=r_associated | relid=0 | w=10
  889. LANL -- r_associated #0: 10 / 0.909 -> en:screening for prostate cancer
    n1=LANL | n2=en:screening for prostate cancer | rel=r_associated | relid=0 | w=10
  890. LANL -- r_associated #0: 10 / 0.909 -> en:sebaceous adenoma
    n1=LANL | n2=en:sebaceous adenoma | rel=r_associated | relid=0 | w=10
  891. LANL -- r_associated #0: 10 / 0.909 -> en:sebaceous carcinoma
    n1=LANL | n2=en:sebaceous carcinoma | rel=r_associated | relid=0 | w=10
  892. LANL -- r_associated #0: 10 / 0.909 -> en:sebaceous epithelioma
    n1=LANL | n2=en:sebaceous epithelioma | rel=r_associated | relid=0 | w=10
  893. LANL -- r_associated #0: 10 / 0.909 -> en:secondary acute myeloid leukemia
    n1=LANL | n2=en:secondary acute myeloid leukemia | rel=r_associated | relid=0 | w=10
  894. LANL -- r_associated #0: 10 / 0.909 -> en:secondary malignant neoplasm
    n1=LANL | n2=en:secondary malignant neoplasm | rel=r_associated | relid=0 | w=10
  895. LANL -- r_associated #0: 10 / 0.909 -> en:secondary neoplasm
    n1=LANL | n2=en:secondary neoplasm | rel=r_associated | relid=0 | w=10
  896. LANL -- r_associated #0: 10 / 0.909 -> en:secondary raynaud phenomenon
    n1=LANL | n2=en:secondary raynaud phenomenon | rel=r_associated | relid=0 | w=10
  897. LANL -- r_associated #0: 10 / 0.909 -> en:seminoma
    n1=LANL | n2=en:seminoma | rel=r_associated | relid=0 | w=10
  898. LANL -- r_associated #0: 10 / 0.909 -> en:sensitivity to genotoxic agents
    n1=LANL | n2=en:sensitivity to genotoxic agents | rel=r_associated | relid=0 | w=10
  899. LANL -- r_associated #0: 10 / 0.909 -> en:sertoli cell tumor
    n1=LANL | n2=en:sertoli cell tumor | rel=r_associated | relid=0 | w=10
  900. LANL -- r_associated #0: 10 / 0.909 -> en:sertoli-leydig cell ovarian tumors may occur
    n1=LANL | n2=en:sertoli-leydig cell ovarian tumors may occur | rel=r_associated | relid=0 | w=10
  901. LANL -- r_associated #0: 10 / 0.909 -> en:sex cord-stromal tumor
    n1=LANL | n2=en:sex cord-stromal tumor | rel=r_associated | relid=0 | w=10
  902. LANL -- r_associated #0: 10 / 0.909 -> en:shock
    n1=LANL | n2=en:shock | rel=r_associated | relid=0 | w=10
  903. LANL -- r_associated #0: 10 / 0.909 -> en:shwachman-diamond syndrome
    n1=LANL | n2=en:shwachman-diamond syndrome | rel=r_associated | relid=0 | w=10
  904. LANL -- r_associated #0: 10 / 0.909 -> en:sickle cell disease
    n1=LANL | n2=en:sickle cell disease | rel=r_associated | relid=0 | w=10
  905. LANL -- r_associated #0: 10 / 0.909 -> en:signet ring cell carcinoma
    n1=LANL | n2=en:signet ring cell carcinoma | rel=r_associated | relid=0 | w=10
  906. LANL -- r_associated #0: 10 / 0.909 -> en:sinonasal undifferentiated carcinoma
    n1=LANL | n2=en:sinonasal undifferentiated carcinoma | rel=r_associated | relid=0 | w=10
  907. LANL -- r_associated #0: 10 / 0.909 -> en:skeletal neoplasms benign
    n1=LANL | n2=en:skeletal neoplasms benign | rel=r_associated | relid=0 | w=10
  908. LANL -- r_associated #0: 10 / 0.909 -> en:skeletal neoplasms malignant and unspecified
    n1=LANL | n2=en:skeletal neoplasms malignant and unspecified | rel=r_associated | relid=0 | w=10
  909. LANL -- r_associated #0: 10 / 0.909 -> en:skin appendage tumors may show malignant transformation
    n1=LANL | n2=en:skin appendage tumors may show malignant transformation | rel=r_associated | relid=0 | w=10
  910. LANL -- r_associated #0: 10 / 0.909 -> en:skin basal cell carcinoma
    n1=LANL | n2=en:skin basal cell carcinoma | rel=r_associated | relid=0 | w=10
  911. LANL -- r_associated #0: 10 / 0.909 -> en:skin cancer susceptibility
    n1=LANL | n2=en:skin cancer susceptibility | rel=r_associated | relid=0 | w=10
  912. LANL -- r_associated #0: 10 / 0.909 -> en:skin carcinoma
    n1=LANL | n2=en:skin carcinoma | rel=r_associated | relid=0 | w=10
  913. LANL -- r_associated #0: 10 / 0.909 -> en:skin squamous cell carcinoma
    n1=LANL | n2=en:skin squamous cell carcinoma | rel=r_associated | relid=0 | w=10
  914. LANL -- r_associated #0: 10 / 0.909 -> en:small cell carcinoma of the ovary, hypercalcemic type
    n1=LANL | n2=en:small cell carcinoma of the ovary, hypercalcemic type | rel=r_associated | relid=0 | w=10
  915. LANL -- r_associated #0: 10 / 0.909 -> en:small intestinal carcinoma
    n1=LANL | n2=en:small intestinal carcinoma | rel=r_associated | relid=0 | w=10
  916. LANL -- r_associated #0: 10 / 0.909 -> en:small intestine carcinoid
    n1=LANL | n2=en:small intestine carcinoid | rel=r_associated | relid=0 | w=10
  917. LANL -- r_associated #0: 10 / 0.909 -> en:soft tissue neoplasms malignant and unspecified
    n1=LANL | n2=en:soft tissue neoplasms malignant and unspecified | rel=r_associated | relid=0 | w=10
  918. LANL -- r_associated #0: 10 / 0.909 -> en:soft tissue sarcoma
    n1=LANL | n2=en:soft tissue sarcoma | rel=r_associated | relid=0 | w=10
  919. LANL -- r_associated #0: 10 / 0.909 -> en:soft tissue tumor and/or sarcoma
    n1=LANL | n2=en:soft tissue tumor and/or sarcoma | rel=r_associated | relid=0 | w=10
  920. LANL -- r_associated #0: 10 / 0.909 -> en:solid growth pattern
    n1=LANL | n2=en:solid growth pattern | rel=r_associated | relid=0 | w=10
  921. LANL -- r_associated #0: 10 / 0.909 -> en:solid neoplasm
    n1=LANL | n2=en:solid neoplasm | rel=r_associated | relid=0 | w=10
  922. LANL -- r_associated #0: 10 / 0.909 -> en:somatostatin-producing neuroendocrine tumor
    n1=LANL | n2=en:somatostatin-producing neuroendocrine tumor | rel=r_associated | relid=0 | w=10
  923. LANL -- r_associated #0: 10 / 0.909 -> en:splenic manifestation of leukemia
    n1=LANL | n2=en:splenic manifestation of leukemia | rel=r_associated | relid=0 | w=10
  924. LANL -- r_associated #0: 10 / 0.909 -> en:squamous cell carcinoma
    n1=LANL | n2=en:squamous cell carcinoma | rel=r_associated | relid=0 | w=10
  925. LANL -- r_associated #0: 10 / 0.909 -> en:squamous cell carcinoma (1 patient)
    n1=LANL | n2=en:squamous cell carcinoma (1 patient) | rel=r_associated | relid=0 | w=10
  926. LANL -- r_associated #0: 10 / 0.909 -> en:squamous cell carcinoma (skin and tongue)
    n1=LANL | n2=en:squamous cell carcinoma (skin and tongue) | rel=r_associated | relid=0 | w=10
  927. LANL -- r_associated #0: 10 / 0.909 -> en:squamous cell carcinoma (skin or mucosa)
    n1=LANL | n2=en:squamous cell carcinoma (skin or mucosa) | rel=r_associated | relid=0 | w=10
  928. LANL -- r_associated #0: 10 / 0.909 -> en:squamous cell carcinoma in area of palmoplantar keratoderma (rare)
    n1=LANL | n2=en:squamous cell carcinoma in area of palmoplantar keratoderma (rare) | rel=r_associated | relid=0 | w=10
  929. LANL -- r_associated #0: 10 / 0.909 -> en:squamous cell neoplasm
    n1=LANL | n2=en:squamous cell neoplasm | rel=r_associated | relid=0 | w=10
  930. LANL -- r_associated #0: 10 / 0.909 -> en:squamous epitheliomas, multiple
    n1=LANL | n2=en:squamous epitheliomas, multiple | rel=r_associated | relid=0 | w=10
  931. LANL -- r_associated #0: 10 / 0.909 -> en:stage 0 cervical cancer ajcc v6
    n1=LANL | n2=en:stage 0 cervical cancer ajcc v6 | rel=r_associated | relid=0 | w=10
  932. LANL -- r_associated #0: 10 / 0.909 -> en:starry sky pattern
    n1=LANL | n2=en:starry sky pattern | rel=r_associated | relid=0 | w=10
  933. LANL -- r_associated #0: 10 / 0.909 -> en:statistical association of extensive metabolism (em, wildtype) and malignancy, especially smoking-induced lung cancer
    n1=LANL | n2=en:statistical association of extensive metabolism (em, wildtype) and malignancy, especially smoking-induced lung cancer | rel=r_associated | relid=0 | w=10
  934. LANL -- r_associated #0: 10 / 0.909 -> en:subacute leukemia
    n1=LANL | n2=en:subacute leukemia | rel=r_associated | relid=0 | w=10
  935. LANL -- r_associated #0: 10 / 0.909 -> en:subacute leukemia of unspecified cell type, without mention of remission
    n1=LANL | n2=en:subacute leukemia of unspecified cell type, without mention of remission | rel=r_associated | relid=0 | w=10
  936. LANL -- r_associated #0: 10 / 0.909 -> en:subacute myeloid leukemia without mention of remission
    n1=LANL | n2=en:subacute myeloid leukemia without mention of remission | rel=r_associated | relid=0 | w=10
  937. LANL -- r_associated #0: 10 / 0.909 -> en:subependymoma
    n1=LANL | n2=en:subependymoma | rel=r_associated | relid=0 | w=10
  938. LANL -- r_associated #0: 10 / 0.909 -> en:surgical aspects
    n1=LANL | n2=en:surgical aspects | rel=r_associated | relid=0 | w=10
  939. LANL -- r_associated #0: 10 / 0.909 -> en:susceptibility to malignant melanoma
    n1=LANL | n2=en:susceptibility to malignant melanoma | rel=r_associated | relid=0 | w=10
  940. LANL -- r_associated #0: 10 / 0.909 -> en:susceptibility to myelodysplasia
    n1=LANL | n2=en:susceptibility to myelodysplasia | rel=r_associated | relid=0 | w=10
  941. LANL -- r_associated #0: 10 / 0.909 -> en:susceptibility to myeloid leukemia
    n1=LANL | n2=en:susceptibility to myeloid leukemia | rel=r_associated | relid=0 | w=10
  942. LANL -- r_associated #0: 10 / 0.909 -> en:synovial neoplasm
    n1=LANL | n2=en:synovial neoplasm | rel=r_associated | relid=0 | w=10
  943. LANL -- r_associated #0: 10 / 0.909 -> en:synovial-like neoplasm
    n1=LANL | n2=en:synovial-like neoplasm | rel=r_associated | relid=0 | w=10
  944. LANL -- r_associated #0: 10 / 0.909 -> en:syringocystadenoma papilliferum
    n1=LANL | n2=en:syringocystadenoma papilliferum | rel=r_associated | relid=0 | w=10
  945. LANL -- r_associated #0: 10 / 0.909 -> en:t-cell chronic lymphocytic leukemia
    n1=LANL | n2=en:t-cell chronic lymphocytic leukemia | rel=r_associated | relid=0 | w=10
  946. LANL -- r_associated #0: 10 / 0.909 -> en:t-cell non-hodgkin lymphoma
    n1=LANL | n2=en:t-cell non-hodgkin lymphoma | rel=r_associated | relid=0 | w=10
  947. LANL -- r_associated #0: 10 / 0.909 -> en:tad regimen
    n1=LANL | n2=en:tad regimen | rel=r_associated | relid=0 | w=10
  948. LANL -- r_associated #0: 10 / 0.909 -> en:taxonomic
    n1=LANL | n2=en:taxonomic | rel=r_associated | relid=0 | w=10
  949. LANL -- r_associated #0: 10 / 0.909 -> en:temporal arteritis
    n1=LANL | n2=en:temporal arteritis | rel=r_associated | relid=0 | w=10
  950. LANL -- r_associated #0: 10 / 0.909 -> en:teratoid tumor, atypical
    n1=LANL | n2=en:teratoid tumor, atypical | rel=r_associated | relid=0 | w=10
  951. LANL -- r_associated #0: 10 / 0.909 -> en:testicular leukemia
    n1=LANL | n2=en:testicular leukemia | rel=r_associated | relid=0 | w=10
  952. LANL -- r_associated #0: 10 / 0.909 -> en:testicular sertoli cell tumor
    n1=LANL | n2=en:testicular sertoli cell tumor | rel=r_associated | relid=0 | w=10
  953. LANL -- r_associated #0: 10 / 0.909 -> en:testicular sertoli cell tumor, calcified
    n1=LANL | n2=en:testicular sertoli cell tumor, calcified | rel=r_associated | relid=0 | w=10
  954. LANL -- r_associated #0: 10 / 0.909 -> en:thalassemia
    n1=LANL | n2=en:thalassemia | rel=r_associated | relid=0 | w=10
  955. LANL -- r_associated #0: 10 / 0.909 -> en:therapeutic aspects
    n1=LANL | n2=en:therapeutic aspects | rel=r_associated | relid=0 | w=10
  956. LANL -- r_associated #0: 10 / 0.909 -> en:therapy-related acute myeloid leukemia
    n1=LANL | n2=en:therapy-related acute myeloid leukemia | rel=r_associated | relid=0 | w=10
  957. LANL -- r_associated #0: 10 / 0.909 -> en:therapy-related leukemia
    n1=LANL | n2=en:therapy-related leukemia | rel=r_associated | relid=0 | w=10
  958. LANL -- r_associated #0: 10 / 0.909 -> en:therapy-related malignant neoplasm
    n1=LANL | n2=en:therapy-related malignant neoplasm | rel=r_associated | relid=0 | w=10
  959. LANL -- r_associated #0: 10 / 0.909 -> en:therapy-related myeloid neoplasm
    n1=LANL | n2=en:therapy-related myeloid neoplasm | rel=r_associated | relid=0 | w=10
  960. LANL -- r_associated #0: 10 / 0.909 -> en:throat cancer
    n1=LANL | n2=en:throat cancer | rel=r_associated | relid=0 | w=10
  961. LANL -- r_associated #0: 10 / 0.909 -> en:thymoma
    n1=LANL | n2=en:thymoma | rel=r_associated | relid=0 | w=10
  962. LANL -- r_associated #0: 10 / 0.909 -> en:thymus epithelial neoplasm
    n1=LANL | n2=en:thymus epithelial neoplasm | rel=r_associated | relid=0 | w=10
  963. LANL -- r_associated #0: 10 / 0.909 -> en:thyroid cancer (follicular cell)
    n1=LANL | n2=en:thyroid cancer (follicular cell) | rel=r_associated | relid=0 | w=10
  964. LANL -- r_associated #0: 10 / 0.909 -> en:thyroid follicular cell tumor
    n1=LANL | n2=en:thyroid follicular cell tumor | rel=r_associated | relid=0 | w=10
  965. LANL -- r_associated #0: 10 / 0.909 -> en:thyroid gland carcinoma
    n1=LANL | n2=en:thyroid gland carcinoma | rel=r_associated | relid=0 | w=10
  966. LANL -- r_associated #0: 10 / 0.909 -> en:thyroid gland medullary carcinoma
    n1=LANL | n2=en:thyroid gland medullary carcinoma | rel=r_associated | relid=0 | w=10
  967. LANL -- r_associated #0: 10 / 0.909 -> en:thyroid gland neoplasm
    n1=LANL | n2=en:thyroid gland neoplasm | rel=r_associated | relid=0 | w=10
  968. LANL -- r_associated #0: 10 / 0.909 -> en:thyroid gland oncocytic adenoma
    n1=LANL | n2=en:thyroid gland oncocytic adenoma | rel=r_associated | relid=0 | w=10
  969. LANL -- r_associated #0: 10 / 0.909 -> en:thyroid gland oncocytic neoplasm
    n1=LANL | n2=en:thyroid gland oncocytic neoplasm | rel=r_associated | relid=0 | w=10
  970. LANL -- r_associated #0: 10 / 0.909 -> en:thyroid gland papillary carcinoma
    n1=LANL | n2=en:thyroid gland papillary carcinoma | rel=r_associated | relid=0 | w=10
  971. LANL -- r_associated #0: 10 / 0.909 -> en:transaminase cell carcinoma
    n1=LANL | n2=en:transaminase cell carcinoma | rel=r_associated | relid=0 | w=10
  972. LANL -- r_associated #0: 10 / 0.909 -> en:transient abnormal myelopoiesis
    n1=LANL | n2=en:transient abnormal myelopoiesis | rel=r_associated | relid=0 | w=10
  973. LANL -- r_associated #0: 10 / 0.909 -> en:transient ischemic attack
    n1=LANL | n2=en:transient ischemic attack | rel=r_associated | relid=0 | w=10
  974. LANL -- r_associated #0: 10 / 0.909 -> en:transitional cell papilloma and/or carcinoma
    n1=LANL | n2=en:transitional cell papilloma and/or carcinoma | rel=r_associated | relid=0 | w=10
  975. LANL -- r_associated #0: 10 / 0.909 -> en:trichoblastoma
    n1=LANL | n2=en:trichoblastoma | rel=r_associated | relid=0 | w=10
  976. LANL -- r_associated #0: 10 / 0.909 -> en:trichoepitheliomas may rarely show malignant transformation to basal cell carcinoma
    n1=LANL | n2=en:trichoepitheliomas may rarely show malignant transformation to basal cell carcinoma | rel=r_associated | relid=0 | w=10
  977. LANL -- r_associated #0: 10 / 0.909 -> en:triglycerides
    n1=LANL | n2=en:triglycerides | rel=r_associated | relid=0 | w=10
  978. LANL -- r_associated #0: 10 / 0.909 -> en:trophoblastic tumor
    n1=LANL | n2=en:trophoblastic tumor | rel=r_associated | relid=0 | w=10
  979. LANL -- r_associated #0: 10 / 0.909 -> en:tumor cells, benign
    n1=LANL | n2=en:tumor cells, benign | rel=r_associated | relid=0 | w=10
  980. LANL -- r_associated #0: 10 / 0.909 -> en:tumor in vein
    n1=LANL | n2=en:tumor in vein | rel=r_associated | relid=0 | w=10
  981. LANL -- r_associated #0: 10 / 0.909 -> en:tumor lysis syndrome adverse event
    n1=LANL | n2=en:tumor lysis syndrome adverse event | rel=r_associated | relid=0 | w=10
  982. LANL -- r_associated #0: 10 / 0.909 -> en:tumors and pregnancy
    n1=LANL | n2=en:tumors and pregnancy | rel=r_associated | relid=0 | w=10
  983. LANL -- r_associated #0: 10 / 0.909 -> en:tumors at multiple other sites including cns
    n1=LANL | n2=en:tumors at multiple other sites including cns | rel=r_associated | relid=0 | w=10
  984. LANL -- r_associated #0: 10 / 0.909 -> en:tumors of the sympathetic nervous system (5 to 10%)
    n1=LANL | n2=en:tumors of the sympathetic nervous system (5 to 10%) | rel=r_associated | relid=0 | w=10
  985. LANL -- r_associated #0: 10 / 0.909 -> en:undifferentiated and biphenotypic leukemia (all subtypes)
    n1=LANL | n2=en:undifferentiated and biphenotypic leukemia (all subtypes) | rel=r_associated | relid=0 | w=10
  986. LANL -- r_associated #0: 10 / 0.909 -> en:undifferentiated carcinoma
    n1=LANL | n2=en:undifferentiated carcinoma | rel=r_associated | relid=0 | w=10
  987. LANL -- r_associated #0: 10 / 0.909 -> en:undifferentiated malignant neoplasm
    n1=LANL | n2=en:undifferentiated malignant neoplasm | rel=r_associated | relid=0 | w=10
  988. LANL -- r_associated #0: 10 / 0.909 -> en:unilateral vestibular schwannoma
    n1=LANL | n2=en:unilateral vestibular schwannoma | rel=r_associated | relid=0 | w=10
  989. LANL -- r_associated #0: 10 / 0.909 -> en:unresectable malignant neoplasm
    n1=LANL | n2=en:unresectable malignant neoplasm | rel=r_associated | relid=0 | w=10
  990. LANL -- r_associated #0: 10 / 0.909 -> en:unspecified leukemia, in relapse
    n1=LANL | n2=en:unspecified leukemia, in relapse | rel=r_associated | relid=0 | w=10
  991. LANL -- r_associated #0: 10 / 0.909 -> en:unspecified leukemia, without mention of having achieved remission
    n1=LANL | n2=en:unspecified leukemia, without mention of having achieved remission | rel=r_associated | relid=0 | w=10
  992. LANL -- r_associated #0: 10 / 0.909 -> en:unspecified myeloid leukemia without mention of remission
    n1=LANL | n2=en:unspecified myeloid leukemia without mention of remission | rel=r_associated | relid=0 | w=10
  993. LANL -- r_associated #0: 10 / 0.909 -> en:unspecified myeloid leukemia, in relapse
    n1=LANL | n2=en:unspecified myeloid leukemia, in relapse | rel=r_associated | relid=0 | w=10
  994. LANL -- r_associated #0: 10 / 0.909 -> en:unspecified myeloid leukemia, without mention of having achieved remission
    n1=LANL | n2=en:unspecified myeloid leukemia, without mention of having achieved remission | rel=r_associated | relid=0 | w=10
  995. LANL -- r_associated #0: 10 / 0.909 -> en:use of ultrasonography
    n1=LANL | n2=en:use of ultrasonography | rel=r_associated | relid=0 | w=10
  996. LANL -- r_associated #0: 10 / 0.909 -> en:uterine leiomyosarcoma (less common)
    n1=LANL | n2=en:uterine leiomyosarcoma (less common) | rel=r_associated | relid=0 | w=10
  997. LANL -- r_associated #0: 10 / 0.909 -> en:uterine neoplasm
    n1=LANL | n2=en:uterine neoplasm | rel=r_associated | relid=0 | w=10
  998. LANL -- r_associated #0: 10 / 0.909 -> en:uveal melanoma
    n1=LANL | n2=en:uveal melanoma | rel=r_associated | relid=0 | w=10
  999. LANL -- r_associated #0: 10 / 0.909 -> en:vacuolization leukocyte
    n1=LANL | n2=en:vacuolization leukocyte | rel=r_associated | relid=0 | w=10
  1000. LANL -- r_associated #0: 10 / 0.909 -> en:vagus nerve paraganglioma
    n1=LANL | n2=en:vagus nerve paraganglioma | rel=r_associated | relid=0 | w=10
  1001. LANL -- r_associated #0: 10 / 0.909 -> en:valvular heart disorder
    n1=LANL | n2=en:valvular heart disorder | rel=r_associated | relid=0 | w=10
  1002. LANL -- r_associated #0: 10 / 0.909 -> en:varicose vein
    n1=LANL | n2=en:varicose vein | rel=r_associated | relid=0 | w=10
  1003. LANL -- r_associated #0: 10 / 0.909 -> en:vascular and perivascular tumors (all subtypes)
    n1=LANL | n2=en:vascular and perivascular tumors (all subtypes) | rel=r_associated | relid=0 | w=10
  1004. LANL -- r_associated #0: 10 / 0.909 -> en:vascular disorder
    n1=LANL | n2=en:vascular disorder | rel=r_associated | relid=0 | w=10
  1005. LANL -- r_associated #0: 10 / 0.909 -> en:vasculitis
    n1=LANL | n2=en:vasculitis | rel=r_associated | relid=0 | w=10
  1006. LANL -- r_associated #0: 10 / 0.909 -> en:vestibular schwannoma (over 90% of patients)
    n1=LANL | n2=en:vestibular schwannoma (over 90% of patients) | rel=r_associated | relid=0 | w=10
  1007. LANL -- r_associated #0: 10 / 0.909 -> en:veterinary aspects
    n1=LANL | n2=en:veterinary aspects | rel=r_associated | relid=0 | w=10
  1008. LANL -- r_associated #0: 10 / 0.909 -> en:vibrissae
    n1=LANL | n2=en:vibrissae | rel=r_associated | relid=0 | w=10
  1009. LANL -- r_associated #0: 10 / 0.909 -> en:viral leukemia
    n1=LANL | n2=en:viral leukemia | rel=r_associated | relid=0 | w=10
  1010. LANL -- r_associated #0: 10 / 0.909 -> en:viruses
    n1=LANL | n2=en:viruses | rel=r_associated | relid=0 | w=10
  1011. LANL -- r_associated #0: 10 / 0.909 -> en:wegener granulomatosis
    n1=LANL | n2=en:wegener granulomatosis | rel=r_associated | relid=0 | w=10
  1012. LANL -- r_associated #0: 10 / 0.909 -> en:well differentiated malignant neoplasm
    n1=LANL | n2=en:well differentiated malignant neoplasm | rel=r_associated | relid=0 | w=10
  1013. LANL -- r_associated #0: 10 / 0.909 -> en:white blood cell abnormality
    n1=LANL | n2=en:white blood cell abnormality | rel=r_associated | relid=0 | w=10
  1014. LANL -- r_associated #0: 10 / 0.909 -> en:x-linked dyskeratosis congenita
    n1=LANL | n2=en:x-linked dyskeratosis congenita | rel=r_associated | relid=0 | w=10
  1015. LANL -- r_associated #0: 10 / 0.909 -> en:yolk sac tumor
    n1=LANL | n2=en:yolk sac tumor | rel=r_associated | relid=0 | w=10
  1016. LANL -- r_associated #0: 10 / 0.909 -> érythroleucémie aigüe
    n1=LANL | n2=érythroleucémie aigüe | rel=r_associated | relid=0 | w=10
  1017. LANL -- r_associated #0: 10 / 0.909 -> fab m1
    n1=LANL | n2=fab m1 | rel=r_associated | relid=0 | w=10
  1018. LANL -- r_associated #0: 10 / 0.909 -> fab m2
    n1=LANL | n2=fab m2 | rel=r_associated | relid=0 | w=10
  1019. LANL -- r_associated #0: 10 / 0.909 -> fab m2, sai
    n1=LANL | n2=fab m2, sai | rel=r_associated | relid=0 | w=10
  1020. LANL -- r_associated #0: 10 / 0.909 -> fab mo
    n1=LANL | n2=fab mo | rel=r_associated | relid=0 | w=10
  1021. LANL -- r_associated #0: 10 / 0.909 -> granulocytes
    n1=LANL | n2=granulocytes | rel=r_associated | relid=0 | w=10
  1022. LANL -- r_associated #0: 10 / 0.909 -> la à granulocytes
    n1=LANL | n2=la à granulocytes | rel=r_associated | relid=0 | w=10
  1023. LANL -- r_associated #0: 10 / 0.909 -> LA à granulocytes
    n1=LANL | n2=LA à granulocytes | rel=r_associated | relid=0 | w=10
  1024. LANL -- r_associated #0: 10 / 0.909 -> Lam
    n1=LANL | n2=Lam | rel=r_associated | relid=0 | w=10
  1025. LANL -- r_associated #0: 10 / 0.909 -> lam
    n1=LANL | n2=lam | rel=r_associated | relid=0 | w=10
  1026. LANL -- r_associated #0: 10 / 0.909 -> LAM
    n1=LANL | n2=LAM | rel=r_associated | relid=0 | w=10
  1027. LANL -- r_associated #0: 10 / 0.909 -> lame
    n1=LANL | n2=lame | rel=r_associated | relid=0 | w=10
  1028. LANL -- r_associated #0: 10 / 0.909 -> leucémie
    n1=LANL | n2=leucémie | rel=r_associated | relid=0 | w=10
  1029. LANL -- r_associated #0: 10 / 0.909 -> leucémie aiguë
    n1=LANL | n2=leucémie aiguë | rel=r_associated | relid=0 | w=10
  1030. LANL -- r_associated #0: 10 / 0.909 -> leucémie aiguë myéloblastique
    n1=LANL | n2=leucémie aiguë myéloblastique | rel=r_associated | relid=0 | w=10
  1031. LANL -- r_associated #0: 10 / 0.909 -> leucémie aigüe myéloblastique
    n1=LANL | n2=leucémie aigüe myéloblastique | rel=r_associated | relid=0 | w=10
  1032. LANL -- r_associated #0: 10 / 0.909 -> leucémie aigüe myéloblastique : traitement personnes âgées
    n1=LANL | n2=leucémie aigüe myéloblastique : traitement personnes âgées | rel=r_associated | relid=0 | w=10
  1033. LANL -- r_associated #0: 10 / 0.909 -> leucémie aiguë myéloblastique m2
    n1=LANL | n2=leucémie aiguë myéloblastique m2 | rel=r_associated | relid=0 | w=10
  1034. LANL -- r_associated #0: 10 / 0.909 -> leucémie aigüe myéloblastique m2
    n1=LANL | n2=leucémie aigüe myéloblastique m2 | rel=r_associated | relid=0 | w=10
  1035. LANL -- r_associated #0: 10 / 0.909 -> leucémie aiguë myéloblastique type 1
    n1=LANL | n2=leucémie aiguë myéloblastique type 1 | rel=r_associated | relid=0 | w=10
  1036. LANL -- r_associated #0: 10 / 0.909 -> leucémie aigüe myéloblastique type 1
    n1=LANL | n2=leucémie aigüe myéloblastique type 1 | rel=r_associated | relid=0 | w=10
  1037. LANL -- r_associated #0: 10 / 0.909 -> leucémie aigüe myéloblastique type 2
    n1=LANL | n2=leucémie aigüe myéloblastique type 2 | rel=r_associated | relid=0 | w=10
  1038. LANL -- r_associated #0: 10 / 0.909 -> leucémie aiguë myéloblastique type 2
    n1=LANL | n2=leucémie aiguë myéloblastique type 2 | rel=r_associated | relid=0 | w=10
  1039. LANL -- r_associated #0: 10 / 0.909 -> leucémie aigüe myéloblastique type i
    n1=LANL | n2=leucémie aigüe myéloblastique type i | rel=r_associated | relid=0 | w=10
  1040. LANL -- r_associated #0: 10 / 0.909 -> leucémie aiguë myéloblastique type i
    n1=LANL | n2=leucémie aiguë myéloblastique type i | rel=r_associated | relid=0 | w=10
  1041. LANL -- r_associated #0: 10 / 0.909 -> leucémie aigüe myéloblastique type ii
    n1=LANL | n2=leucémie aigüe myéloblastique type ii | rel=r_associated | relid=0 | w=10
  1042. LANL -- r_associated #0: 10 / 0.909 -> leucémie aiguë myéloblastique type ii
    n1=LANL | n2=leucémie aiguë myéloblastique type ii | rel=r_associated | relid=0 | w=10
  1043. LANL -- r_associated #0: 10 / 0.909 -> leucémie aigüe myéloïde
    n1=LANL | n2=leucémie aigüe myéloïde | rel=r_associated | relid=0 | w=10
  1044. LANL -- r_associated #0: 10 / 0.909 -> leucémie aiguë myéloïde à différentiation minimale
    n1=LANL | n2=leucémie aiguë myéloïde à différentiation minimale | rel=r_associated | relid=0 | w=10
  1045. LANL -- r_associated #0: 10 / 0.909 -> leucémie aigüe myéloïde m2
    n1=LANL | n2=leucémie aigüe myéloïde m2 | rel=r_associated | relid=0 | w=10
  1046. LANL -- r_associated #0: 10 / 0.909 -> leucémie aiguë myéloïde m2
    n1=LANL | n2=leucémie aiguë myéloïde m2 | rel=r_associated | relid=0 | w=10
  1047. LANL -- r_associated #0: 10 / 0.909 -> leucémie aiguë myéloïde peu différenciée
    n1=LANL | n2=leucémie aiguë myéloïde peu différenciée | rel=r_associated | relid=0 | w=10
  1048. LANL -- r_associated #0: 10 / 0.909 -> leucémie aigüe non lymphoblastique
    n1=LANL | n2=leucémie aigüe non lymphoblastique | rel=r_associated | relid=0 | w=10
  1049. LANL -- r_associated #0: 10 / 0.909 -> leucémie aiguë non lymphocytaire
    n1=LANL | n2=leucémie aiguë non lymphocytaire | rel=r_associated | relid=0 | w=10
  1050. LANL -- r_associated #0: 10 / 0.909 -> leucémie granulocytaire aiguë
    n1=LANL | n2=leucémie granulocytaire aiguë | rel=r_associated | relid=0 | w=10
  1051. LANL -- r_associated #0: 10 / 0.909 -> leucémie myéloblastique aigüe
    n1=LANL | n2=leucémie myéloblastique aigüe | rel=r_associated | relid=0 | w=10
  1052. LANL -- r_associated #0: 10 / 0.909 -> leucémie myéloblastique aiguë
    n1=LANL | n2=leucémie myéloblastique aiguë | rel=r_associated | relid=0 | w=10
  1053. LANL -- r_associated #0: 10 / 0.909 -> leucémie myéloblastique aiguë type 1
    n1=LANL | n2=leucémie myéloblastique aiguë type 1 | rel=r_associated | relid=0 | w=10
  1054. LANL -- r_associated #0: 10 / 0.909 -> leucémie myéloblastique aigüe type 1
    n1=LANL | n2=leucémie myéloblastique aigüe type 1 | rel=r_associated | relid=0 | w=10
  1055. LANL -- r_associated #0: 10 / 0.909 -> leucémie myéloblastique aiguë type 2
    n1=LANL | n2=leucémie myéloblastique aiguë type 2 | rel=r_associated | relid=0 | w=10
  1056. LANL -- r_associated #0: 10 / 0.909 -> leucémie myéloblastique aigüe type 2
    n1=LANL | n2=leucémie myéloblastique aigüe type 2 | rel=r_associated | relid=0 | w=10
  1057. LANL -- r_associated #0: 10 / 0.909 -> leucémie myéloblastique aiguë type i
    n1=LANL | n2=leucémie myéloblastique aiguë type i | rel=r_associated | relid=0 | w=10
  1058. LANL -- r_associated #0: 10 / 0.909 -> leucémie myéloblastique aigüe type i
    n1=LANL | n2=leucémie myéloblastique aigüe type i | rel=r_associated | relid=0 | w=10
  1059. LANL -- r_associated #0: 10 / 0.909 -> leucémie myéloblastique aigüe type ii
    n1=LANL | n2=leucémie myéloblastique aigüe type ii | rel=r_associated | relid=0 | w=10
  1060. LANL -- r_associated #0: 10 / 0.909 -> leucémie myéloblastique aiguë type ii
    n1=LANL | n2=leucémie myéloblastique aiguë type ii | rel=r_associated | relid=0 | w=10
  1061. LANL -- r_associated #0: 10 / 0.909 -> leucémie myélogène aigüe
    n1=LANL | n2=leucémie myélogène aigüe | rel=r_associated | relid=0 | w=10
  1062. LANL -- r_associated #0: 10 / 0.909 -> leucémie myéloïde
    n1=LANL | n2=leucémie myéloïde | rel=r_associated | relid=0 | w=10
  1063. LANL -- r_associated #0: 10 / 0.909 -> leucémie myéloïde aigüe
    n1=LANL | n2=leucémie myéloïde aigüe | rel=r_associated | relid=0 | w=10
  1064. LANL -- r_associated #0: 10 / 0.909 -> leucémie myéloïde aiguë avec maturation
    n1=LANL | n2=leucémie myéloïde aiguë avec maturation | rel=r_associated | relid=0 | w=10
  1065. LANL -- r_associated #0: 10 / 0.909 -> leucémie myéloïde aiguë en rémission
    n1=LANL | n2=leucémie myéloïde aiguë en rémission | rel=r_associated | relid=0 | w=10
  1066. LANL -- r_associated #0: 10 / 0.909 -> leucémie myéloïde aiguë sans maturation
    n1=LANL | n2=leucémie myéloïde aiguë sans maturation | rel=r_associated | relid=0 | w=10
  1067. LANL -- r_associated #0: 10 / 0.909 -> leucémie myéloïde aiguë, différenciation minimale
    n1=LANL | n2=leucémie myéloïde aiguë, différenciation minimale | rel=r_associated | relid=0 | w=10
  1068. LANL -- r_associated #0: 10 / 0.909 -> leucémie myéloïde aiguë, sai (type fab ou oms non précisé) (voir aussi m-99303)
    n1=LANL | n2=leucémie myéloïde aiguë, sai (type fab ou oms non précisé) (voir aussi m-99303) | rel=r_associated | relid=0 | w=10
  1069. LANL -- r_associated #0: 10 / 0.909 -> leucémie non lymphoblastique aiguë
    n1=LANL | n2=leucémie non lymphoblastique aiguë | rel=r_associated | relid=0 | w=10
  1070. LANL -- r_associated #0: 10 / 0.909 -> leucémies
    n1=LANL | n2=leucémies | rel=r_associated | relid=0 | w=10
  1071. LANL -- r_associated #0: 10 / 0.909 -> myéloblastique
    n1=LANL | n2=myéloblastique | rel=r_associated | relid=0 | w=10
  1072. LANL -- r_associated #0: 10 / 0.909 -> myéloïde
    n1=LANL | n2=myéloïde | rel=r_associated | relid=0 | w=10
  1073. LANL -- r_associated #0: 10 / 0.909 -> myélose aiguë (type fab ou oms non précisé) (voir aussi m-99303)
    n1=LANL | n2=myélose aiguë (type fab ou oms non précisé) (voir aussi m-99303) | rel=r_associated | relid=0 | w=10
  1074. LANL -- r_associated #0: 10 / 0.909 -> NRAS gene
    n1=LANL | n2=NRAS gene | rel=r_associated | relid=0 | w=10
  1075. LANL -- r_associated #0: 10 / 0.909 -> oedème
    n1=LANL | n2=oedème | rel=r_associated | relid=0 | w=10
  1076. LANL -- r_associated #0: 10 / 0.909 -> poussée aiguë au cours d'une leucémie myéloïde chronique
    n1=LANL | n2=poussée aiguë au cours d'une leucémie myéloïde chronique | rel=r_associated | relid=0 | w=10
  1077. LANL -- r_associated #0: 10 / 0.909 -> venetoclax
    n1=LANL | n2=venetoclax | rel=r_associated | relid=0 | w=10
  1078. LANL -- r_associated #0: 5 / 0.455 -> en:acute myelocytic leukemia
    n1=LANL | n2=en:acute myelocytic leukemia | rel=r_associated | relid=0 | w=5
  1079. LANL -- r_associated #0: 5 / 0.455 -> en:leucemia
    n1=LANL | n2=en:leucemia | rel=r_associated | relid=0 | w=5
  1080. LANL -- r_associated #0: 5 / 0.455 -> en:leukaemia
    n1=LANL | n2=en:leukaemia | rel=r_associated | relid=0 | w=5
  1081. LANL -- r_associated #0: 5 / 0.455 -> en:leukocythemia
    n1=LANL | n2=en:leukocythemia | rel=r_associated | relid=0 | w=5
  1082. LANL -- r_associated #0: 5 / 0.455 -> LAM 3
    n1=LANL | n2=LAM 3 | rel=r_associated | relid=0 | w=5
  1083. LANL -- r_associated #0: 5 / 0.455 -> leucémie aiguë myéloblastique de type 3
    n1=LANL | n2=leucémie aiguë myéloblastique de type 3 | rel=r_associated | relid=0 | w=5
  1084. LANL -- r_associated #0: 5 / 0.455 -> LLC
    (médecine)
    n1=LANL | n2=LLC
    (médecine)
    | rel=r_associated | relid=0 | w=5
≈ 2 relations entrantes

  1. médecine --- r_associated #0: 25 --> LANL
    n1=médecine | n2=LANL | rel=r_associated | relid=0 | w=25
  2. physique nucléaire --- r_associated #0: 24 --> LANL
    n1=physique nucléaire | n2=LANL | rel=r_associated | relid=0 | w=24
Le service Rézo permet d'énumérer les relations existant pour un terme. Ce service est interrogeable par programme.
Projet JeuxDeMots - url: http://www.jeuxdemots.org
contact: mathieu.lafourcade@lirmm.fr